Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	105815	dendrimer or pamam or peg	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 14:44
S2	5010	sirna or rnai or dsrna	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 14:45
S3	8138	double adj stranded adj rna	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 14:45
S4	1231	S1 and S2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 14:45
S5	1231	S4 and S1	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 14:45
S6	63	delivery same oligonucleotide same dendrimer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 15:13
S7	574	delivery same dsrna or (double stranded rna) same dendrimer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 14:46
S8	81	agrawal and dendrimer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 15:13
S9	2198	agrawal.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 15:13
S10	4	S9 and dendrimer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 15:18
S11	414	ribozymes and dendrimer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 15:19
S12	15	delivery same ribozyme same dendrimer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/08 15:19

```
FILE 'EMBASE, BIOSIS, MEDLINE, SCISEARCH' ENTERED AT 09:09:21 ON 09 AUG
     2005
L1
          34391 S SIRNA OR DSRNA OR RNAI
L2
         258359 S OLIGONUCLEOTIDE OR ANTISENSE
L3
         41920 S DENDRIMER OR PAMAM OR (CARBOXYLIC ACID TERMINATED) OR DIAMINO
L4
         47891 S PEG
           207 S L3 AND L4
L5
L6
          89604 S L3 OR L4
            82 S L1 AND L6
L7
           1009 S L2 AND L6
L8
L9
             0 S L7 AND @PY<2002
L10
             31 S L7 AND PY<2002
            507 S L8 AND PY<2002
L11
            400 S L11 AND PY<2001
L12
L13
            71 S L2 AND PAMAM
L14
            39 S L13 AND PY<2002
L15
            21 DUP REM L10 (10 DUPLICATES REMOVED)
L16
            41 DUP REM L13 (30 DUPLICATES REMOVED)
```

L15 ANSWER 1 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

2001:508479 BIOSIS ACCESSION NUMBER: DOCUMENT NUMBER: PREV200100508479

TITLE: Eliciting antigen-specific egg-yolk IgY with naked DNA. AUTHOR(S): Romito, Marco [Reprint author]; Viljoen, Gerrit J.; Du

Plessis, Dion H.

Biotechnology Division, Onderstepoort Veterinary Institute CORPORATE SOURCE:

(OVI), Onderstepoort, 0110, South Africa

marco@moon.ovi.ac.za

SOURCE: Biotechniques, (September, 2001) Vol. 31, No. 3, pp.

670-675. print.

CODEN: BTNQDO. ISSN: 0736-6205.

DOCUMENT TYPE: Article LANGUAGE: English

ENTRY DATE: Entered STN: 31 Oct 2001

Last Updated on STN: 23 Feb 2002

ABSTRACT: Immunization with naked DNA was used to elicit chicken egg yolk antibodies (IqY). Layer hens were inoculated with plasmid DNA encoding the enhanced green fluorescent protein, the fusion protein of Newcastle disease virus, and VP2 of African horse sickness virus. IgY was extracted from egg yolks by polyethylene glycol precipitation. Specific antibodies were present in the yolks of eggs from hens immunized with each of the three different plasmids. This approach to raising polyclonal antibodies obviates the need to produce and purify large quantities of proteins for immunization and can potentially yield large amounts of diagnostically or therapeutically useful reagents.

CONCEPT CODE: Biochemistry studies - Nucleic acids, purines and

> pyrimidines 10062

Biochemistry studies - Proteins, peptides and amino acids

10064

Development and Embryology - General and descriptive

25502

Virology - Animal host viruses

INDEX TERMS: Major Concepts

Methods and Techniques

INDEX TERMS: Parts, Structures, & Systems of Organisms

egg yolk: embryonic structure, yolk

INDEX TERMS: Chemicals & Biochemicals

African horse sickness virus VP2: serotype 3; Newcastle

disease virus fusion protein; PEG 6000

polyethylene glycol: Merck; antigen-specific egg-yolk immunoglobulin Y: elicitation; diagnostically useful reagents; green fluorescent protein; naked DNA: Promega;

plasmid DNA: Promega; polyclonal antibodies;

therapeutically useful reagents

INDEX TERMS: Methods & Equipment

large quantity protein production: Molecular Biology Techniques and Chemical Characterization, production method; large quantity protein purification: Extraction, Isolation, Purification and Separation Techniques,

purification method; naked DNA immunization: Immunologic

Techniques, immunization method; plasmid DNA

inoculation: Immunologic Techniques, immunization method; polyclonal antibody raising: Immunologic Techniques, immunization method; polyethylene glycol precipitation: Extraction, Isolation, Purification and

Separation Techniques, extraction method

ORGANISM: Classifier

> Galliformes 85536

Super Taxa

Aves; Vertebrata; Chordata; Animalia

Organism Name

Amberlink hybrid chicken: Golden Jay, female Leghorn layer chicken: Avimune, Centurion, female

Animals, Birds, Chordates, Nonhuman Vertebrates,

Vertebrates

ORGANISM:

Classifier 03503 Paramyxoviridae

Super Taxa

Negative Sense ssRNA Viruses; Viruses; Microorganisms

Organism Name

Newcastle disease virus: strain-Onderstepoort

Taxa Notes

Microorganisms, Negative Sense Single-Stranded RNA

Viruses, Viruses

ORGANISM:

Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Organism Name

African horse sickness virus

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

L15 ANSWER 2 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

1999:210075 BIOSIS PREV199900210075

TITLE:

Comparative detection of enteric viruses in wastewaters, sediments and oysters by reverse transcription-PCR and cell

culture.

AUTHOR(S):

Green, David H.; Lewis, Gillian D. [Reprint author]

CORPORATE SOURCE:

Molecular Genetics and Microbiology, School of Biological Sciences, University of Auckland, PB 92019, Auckland, New

Zealand

SOURCE:

Water Research, (April, 1999) Vol. 33, No. 5, pp.

1195-1200. print.

CODEN: WATRAG. ISSN: 0043-1354.

DOCUMENT TYPE:

Article

LANGUAGE:

English

ENTRY DATE:

Entered STN: 26 May 1999

Last Updated on STN: 26 May 1999

ABSTRACT: The work presented here examines the utility of reverse transcription-PCR (RT-PCR) assays for monitoring enteric viruses contaminating wastewaters, sediments and shellfish. Sampling occurred over a 12 month period from and around a large cosmopolitan sewage treatment facility in Auckland, New Zealand. Viruses were concentrated using primary polyethylene glycol 6000 (***PEG*** 6000) precipitation and recently developed secondary concentration and purification techniques as preliminary steps to analysis by plaque assay or RT-PCR for enteroviruses, rotaviruses and hepatitis A virus (HAV). Enteroviruses were isolated by plaque assay from each of the different sample types at various points during the year. All three groups of viruses were detected by the PCR in different sample types and at various time points. The results demonstrated that RT-PCR was most useful when examining samples for viruses routinely difficult to identify, namely rotaviruses and HAV. CONCEPT CODE:

Public health - Sewage disposal and sanitary measures

37014

Ecology: environmental biology - General and methods

07502

Invertebrata: general and systematic - Mollusca

Virology - General and methods

INDEX TERMS:

Major Concepts

Marine Ecology (Ecology, Environmental Sciences);

Methods and Techniques; Waste Management (Sanitation)

INDEX TERMS:

Methods & Equipment

plaque assay: analytical method; RT-PCR [reverse transcriptase-polymerase chain reaction]: detection

method, polymerase chain reaction

GEOGRAPHICAL TERMS: Auckland (New Zealand, Australasian region)

ORGANISM:

Classifier

Pelecypoda 61500

Super Taxa

Mollusca; Invertebrata; Animalia

Organism Name oyster Taxa Notes

Animals, Invertebrates, Mollusks

ORGANISM:

Classifier

Picornaviridae 03603

Super Taxa

Positive Sense ssRNA Viruses; Viruses; Microorganisms

Organism Name enterovirus hepatitis A virus

Taxa Notes

Microorganisms, Positive Sense Single-Stranded RNA

Viruses, Viruses

ORGANISM:

Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Organism Name rotavirus Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

L15 ANSWER 3 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN ACCESSION NUMBER:

1997:456152 BIOSIS

DOCUMENT NUMBER:

PREV199799755355

TITLE:

Optimisation of the PEG reconcentration procedure for virus detection by cell culture or genomic

amplification.

AUTHOR(S):

Vilagines, P. [Reprint author]; Suarez, A.; Sarrette, B.

[Reprint author]; Vilagines, R. [Reprint author]

CORPORATE SOURCE:

Cent. Rech. Controle Eaux Paris, ave. Paul Vaillant

Couturier, 75014 Paris, France

SOURCE:

Water Science and Technology, (1997) Vol. 35, No. 11-12,

pp. 455-459.

CODEN: WSTED4. ISSN: 0273-1223.

DOCUMENT TYPE:

Article

LANGUAGE:

English

ENTRY DATE:

Entered STN: 27 Oct 1997

Last Updated on STN: 27 Oct 1997

ABSTRACT:A double reconcentration procedure was developed for virus detection in tapwater concentrates obtained by conventional adsorption-elution techniques suitable for cell inoculation as well as for genomic amplification. Using 7.5% 6000 and 2.5% NaCl, a 15 min contact time under agitation at room temperature followed by centrifugation (first step: 3,500 times g, 90min, 4 degree C; second step 10,000 times g, 20min, 4 degree C) were the conditions to obtain overall average virus recovery efficiencies of 71% for poliovirus from 900ml cluates and 88, 83 and 75% for poliovirus, coxsackie B2 and rotavirus respectively (400ml eluates). Direct extraction of viral RNA from the first pellet with Trizol was efficient for RT-PCR assays without any

further treatment Primer pairs were selected to amplify rotavirus group A and poliovirus in seeded tapwater concentrated by adsorption elution through glass wool. A positive signal was obtained for theoretic virus concentration of 1 PFU. Analysis of field samples (1001) by cell culture and genomic

amplification resulted in a higher sensitivity with the latter.

Biochemistry methods - Nucleic acids, purines and CONCEPT CODE:

> pyrimidines 10052

Genetics of bacteria and viruses

Microbiological apparatus, methods and media 32000

Virology - Animal host viruses 33506

Public health - Air, water and soil pollution Public health: microbiology - Public health microbiology

37400

INDEX TERMS: Major Concepts

Biochemistry and Molecular Biophysics; Genetics; Methods

and Techniques; Microbiology; Pollution Assessment

Control and Management

INDEX TERMS: Miscellaneous Descriptors

CELL CULTURE; COXSACKIE B2 VIRUS; DETECTION METHOD;

DRINKING WATER; EXTRACTION METHOD; GENOMIC AMPLIFICATION; METHODOLOGY; PATHOGEN; PEG

HYDROEXTRACTION; POLLUTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TAPWATER; VIRUS DETECTION

ORGANISM:

Classifier

Picornaviridae 03603

Super Taxa

Positive Sense ssRNA Viruses; Viruses; Microorganisms

Organism Name poliovirus Taxa Notes

Microorganisms, Positive Sense Single-Stranded RNA

Viruses, Viruses

ORGANISM:

Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Organism Name rotavirus Reoviridae Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

L15 ANSWER 4 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 1997:305124 BIOSIS DOCUMENT NUMBER: PREV199799612927

Development of double antibody sandwich competitive ELISA TITLE:

for measuring antibody against infectious bursal disease. Patnayak, D. P. [Reprint author]; Kalra, S. K. [Reprint

AUTHOR(S): author]; Kumar, Arvind [Reprint author]; Belwal, L. M.

Dep. Vet. Microbiol., CCS Haryana Agric. Univ., Hisar,

India

Indian Journal of Poultry Science, (1997) Vol. 32, No. 1, SOURCE:

pp. 53-58.

CODEN: IJPOAW. ISSN: 0019-5529.

DOCUMENT TYPE:

Article English

LANGUAGE:

CORPORATE SOURCE:

Entered STN: 26 Jul 1997 ENTRY DATE:

Last Updated on STN: 26 Jul 1997

ABSTRACT:A double antibody sandwich competitive ELISA for measuring anti- IBD antibody level in chickens was developed. Coating and tracing sera were raised in rabbits and guinea pigs, respectively using Georgia strain of IBD virus grown on chicken embryo fibroblast cell culture and purified as band on caesium

chloride-sucrose density gradient. Optimum dilutions of coating and tracing sera standardised were 1:1,000 and 1:800, respectively. The virus precipitated **PEG**-6000 was used as ELISA antigen and the virus concentration equivalent to log10-7.3 TCID-50 was found to be optimal in the test.

CONCEPT CODE:

Biochemistry studies - Proteins, peptides and amino acids

10064

Biochemistry studies - Carbohydrates 10068 Immunology - Bacterial, viral and fungal 34504 Medical and clinical microbiology - Virology

Veterinary science - Pathology 38004 Veterinary science - Microbiology

INDEX TERMS:

Major Concepts

Immune System (Chemical Coordination and Homeostasis);

Infection; Veterinary Medicine (Medical Sciences) Miscellaneous Descriptors

INDEX TERMS:

ANTI-INFECTIOUS BURSAL DISEASE ANTIBODIES; DOUBLE

ANTIBODY SANDWICH COMPETITIVE ELISA; HOST; IMMUNOLOGIC

METHOD; INFECTION; INFECTIOUS BURSAL DISEASE;

MEASUREMENT; MEASUREMENT METHOD; METHODOLOGY; PATHOGEN;

VETERINARY MEDICINE; VIRAL DISEASE

ORGANISM:

Classifier

Birnaviridae 03403

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Organism Name

infectious bursal disease virus

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

ORGANISM: Classifier

Galliformes 85536

Super Taxa

Aves; Vertebrata; Chordata; Animalia

Organism Name chicken Taxa Notes

Animals, Birds, Chordates, Nonhuman Vertebrates,

Vertebrates

L15 ANSWER 5 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

1997:365474 BIOSIS PREV199799657407

TITLE:

Seminested RT-PCR systems for small round structured viruses and detection of enteric viruses in seafood.

AUTHOR(S):

Hafliger, D.; Gilgen, M.; Luthy, J.; Hubner, P. [Reprint

CORPORATE SOURCE: Lab. Food Chemistry, Dep. Chemistry Biochemistry, Univ.

Berne, Freiestrasse 3, 3012 Berne, Switzerland

SOURCE:

International Journal of Food Microbiology, (1997) Vol. 37,

No. 1, pp. 27-36.

CODEN: IJFMDD. ISSN: 0168-1605.

DOCUMENT TYPE:

Article

LANGUAGE:

English

ENTRY DATE:

Entered STN: 25 Aug 1997

Last Updated on STN: 25 Aug 1997

ABSTRACT: Highly sensitive seminested RT-PCR systems for the specific detection of genotype I and II small round structured viruses (SRSVs) were developed based on the nucleic acid information deposited in the databanks. SRSVs could be detected in 10-7-fold dilutions of three different stool samples. In addition, a rapid and simple purification protocol for enteric viruses from seafood tissues was elaborated using poliovirus (PV) as model. The virus isolation and viral RNA purification include the following steps: elution of the viruses from the seafood tissue with glycine buffer, their concentration by

PEG -precipitation, lysis of viral particles with guanidine hydrochloride and viral RNA isolation using a silica based membrane. The detection limit was 3 to 30 TCID-50 of poliovirus in 1.25 g of seeded seafood tissues without marked food matrix differences, whereas SRSV viruses were 10and 100-fold better detected in mussels than in shrimps and oysters, respectively. The newly developed purification method, which was shown to remove potential RT-PCR inhibitors present in mussel tissue samples, was applied in a small market survey. 15 mussels, 15 oysters and 12 shrimps were examined for the presence of Hepatitis A virus (HAV), Enterovirus (EV), Rotavirus (RV) and SRSV using specific RT-PCR detection systems. The finding of three oyster samples positive for Rotavirus demonstrated the successful application of our method for the detection of enteric viruses in naturally contaminated seafood samples. The rapid isolation method might be suitable for application in routine testing laboratories and will help to improve public health controls for seafood.

CONCEPT CODE:

Comparative biochemistry 10010

Biochemistry methods - Nucleic acids, purines and

pyrimidines 10052

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biophysics - Molecular properties and macromolecules

10506

Food technology - Fish and other marine and freshwater

products 13522

Genetics of bacteria and viruses 31500 Virology - Animal host viruses 33506

Medical and clinical microbiology - Virology 36006 Public health - Public health laboratory methods 37006 Public health: microbiology - Public health microbiology

37400

Food microbiology - Food and beverage spoilage and

contamination 39002

INDEX TERMS:

Major Concepts

Biochemistry and Molecular Biophysics; Foods; Genetics; Infection; Microbiology; Public Health (Allied Medical

Sciences)

INDEX TERMS:

Chemicals & Biochemicals
GUANIDINE HYDROCHLORIDE

INDEX TERMS:

Miscellaneous Descriptors

ANALYTICAL METHOD; FOODS; GUANIDINE HYDROCHLORIDE; METHODOLOGY; MOLECULAR GENETICS; PUBLIC HEALTH; RNA; SEAFOOD; SEMINESTED REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION SYSTEMS; SEMINESTED RT-PCR SYSTEMS; VIRAL

SEAFOOD CONTAMINATION

ORGANISM:

Classifier

Malacostraca 75112

Super Taxa

Crustacea; Arthropoda; Invertebrata; Animalia

Organism Name shrimp Taxa Notes

Animals, Arthropods, Crustaceans, Invertebrates

ORGANISM:

Classifier

Pelecypoda 61500

Super Taxa

Mollusca; Invertebrata; Animalia

Organism Name mussels oysters Taxa Notes

Animals, Invertebrates, Mollusks

ORGANISM:

Classifier

Picornaviridae 03603

Super Taxa

Positive Sense ssRNA Viruses; Viruses; Microorganisms

Organism Name enterovirus

hepatitis A virus

poliovirus Taxa Notes

Microorganisms, Positive Sense Single-Stranded RNA

Viruses, Viruses

ORGANISM:

Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Organism Name rotavirus Reoviridae Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

REGISTRY NUMBER:

50-01-1 (GUANIDINE HYDROCHLORIDE)

L15 ANSWER 6 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

1999:302542 BIOSIS

PREV199900302542

TITLE:

Structural proteins of field isolates of infectious bursal

disease virus.

AUTHOR(S):

Vengadabady, N. [Reprint author]; Sulochana, S.

CORPORATE SOURCE:

Vaccine Research Center, Center for Animal Health Studies,

Madras-51, India

SOURCE:

Journal of Veterinary and Animal Sciences, (Dec., 1996)

Vol. 27, No. 2, pp. 106-110. print.

ISSN: 0971-0701.

DOCUMENT TYPE:

Article English

LANGUAGE: ENTRY DATE:

Entered STN: 12 Aug 1999

Last Updated on STN: 12 Aug 1999

. ABSTRACT: Four field isolates, two each from vaccinated and unvaccinated flocks and a vaccine strain of infectious bursal disease virus were concentrated and purified by initial PGE precipitation and subsequent differential centrifugation. The structural proteins of these isolates were resolved by SDS-PAGE using bovine serum albumin and chymotrypsin as molecular weight markers. All the four field isolates resolved nine polypeptides ranging between 32 kD to 86 kDm while the vaccine strain had 11 protein components the molecular of which ranged between 33 kD and 93 kD. The field isolates lacked the 93 kD, 80 kD and 43 kD proteins of the vaccine strain. The protein with mol. wt. of 52 kD was absent in the vaccine strain. A difference in the mol. wts. of proteins P6 and P12 of the field isolates and the vaccine strain was also detected.

CONCEPT CODE:

Medical and clinical microbiology - General and methods

36001

Biochemistry studies - General 10060 Immunology - General and methods 34502

INDEX TERMS:

Major Concepts

Biochemistry and Molecular Biophysics; Infection

INDEX TERMS:

Diseases

Gumboro disease: viral disease

INDEX TERMS:

Chemicals & Biochemicals

infectious bursal disease virus vaccine:

immunologic-drug; viral proteins

INDEX TERMS:

Methods & Equipment

differential centrifugation: purification method; polyacrylamide gel electrophoresis: analytical method ORGANISM:

Classifier

Birnaviridae 03403

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Organism Name

infectious bursal disease virus: pathogen

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

ORGANISM: Classifier

Galliformes 85536

Super Taxa

Aves; Vertebrata; Chordata; Animalia

Organism Name

chicken: chick, host

Taxa Notes

Animals, Birds, Chordates, Nonhuman Vertebrates,

Vertebrates

REGISTRY NUMBER:

9003-05-8 (POLYACRYLAMIDE)

L15 ANSWER 7 OF 21 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

DUPLICATE 1

ACCESSION NUMBER:

95004297 EMBASE

DOCUMENT NUMBER:

CORPORATE SOURCE:

1995004297

TITLE:

Double-stranded RNA mycoviruses in mycelium of Pleurotus

ostreatus.

AUTHOR:

Van Der Lende T.R.; Harmsen M.C.; Go S.J.; Wessel J.G.H. Department of Plant Biology, University of Groningen,

Kerklaan 30,9751 NN Haren, Netherlands

SOURCE:

FEMS Microbiology Letters, (1995) Vol. 125, No. 1, pp.

51-56.

ISSN: 0378-1097 CODEN: FMLED7

COUNTRY:

Netherlands
Journal; Article

DOCUMENT TYPE: FILE SEGMENT:

004 Microbiology

LANGUAGE:

English

SUMMARY LANGUAGE:

English Entered STN: 950125

ENTRY DATE:

Last Updated on STN: 950125

ABSTRACT: Mycelium of Pleurotus ostreatus var. florida with a decreased growth rate contained seven double-stranded RNA segments and isometrical virus particles with diameters of 24 and 30 nm. Mycelium with a normal growth rate lacked dsRNA. Protoclones from virus-containing mycelium contained one to seven of these dsRNA segments in varying concentrations. The exact correlation between slow growth and the presence of dsRNA molecules could not be established. Infection of virus-free protoplasts with ***PEG*** -precipitated virus particles resulted in mycelium that stably maintained the 2.4 kbp dsRNA.

CONTROLLED TERM:

Medical Descriptors:

*rna virus

*virus infection

article mycovirus nonhuman pleurotus

priority journal
Drug Descriptors:

*double stranded rna: EC, endogenous compound

L15 ANSWER 8 OF 21 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

DUPLICATE 2

ACCESSION NUMBER:

93313409 EMBASE

1993313409 DOCUMENT NUMBER:

Characterisation of isolates and strains of citrus tristeza TITLE:

> closterovirus using restriction analysis of the coat protein gene amplified by the polymerase chain reaction.

Gillings M.; Broadbent P.; Indsto J.; Lee R. AUTHOR:

Plant Pathology Branch, Biological/Chemical Research Inst., CORPORATE SOURCE:

NSW Agriculture, PMB 10, Rydalmere, NSW 2116, Australia Journal of Virological Methods, (1993) Vol. 44, No. 2-3,

SOURCE: pp. 305-317.

ISSN: 0166-0934 CODEN: JVMEDH

Netherlands COUNTRY: DOCUMENT TYPE: Journal; Article

004 Microbiology FILE SEGMENT:

> 005 General Pathology and Pathological Anatomy

029 Clinical Biochemistry 037 Drug Literature Index

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 931121

Last Updated on STN: 931121

ABSTRACT: Citrus Tristeza Virus (CTV) exists as a large number of distinct strains differing in biological properties and with different distributions in citrus producing countries. Strategies such as eradication or cross protection, aimed at controlling severe variants of the pathogen, require procedures to identify virus strains accurately and reliably. To fill the need for a rapid, reproducible assay, we have investigated the use of restriction analysis of the CTV coat protein gene amplified using the polymerase chain reaction (PCR). The primers 5' ATG GAC GAA ACA AAG 3' and 5' TCA ACG TGT GTT GAA TTT 3' amplified a DNA copy of the CTV coat protein gene (approx. 670 base pairs) when used in a reverse transcriptase PCR assay. Amplifications were carried out using dsRNA prepared from field and indicator plants, or from single-stranded RNA prepared from crude PEG precipitates of intact virions. All 51 CTV isolates tested produced an amplified product of the same size, regardless of country of origin or biological properties. Digestion of the amplified coat protein genes with the restriction enzymes Hinfl or Rsal revealed sequence variation in the PCR products. Hinfl provided the best discrimination between strains, defining seven Restriction Fragment Length Polymorphism (RFLP) groups, some of which circumscribed sets of isolates with similar biological properties. Limited analysis of field isolates using this method showed that individual trees could contain mixtures of CTV strains, as assessed by the recovery of several RFLP types from individual reactions. Single aphid transmissions of isolates usually, but not always, generated apparently pure single strains judged by the recovery of single RFLP groups.

CONTROLLED TERM: Medical Descriptors:

*plant virus

*virus characterization

*virus isolation

article

polymerase chain reaction

priority journal restriction site virus strain Drug Descriptors: oligonucleotide

L15 ANSWER 9 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

DUPLICATE 3

ACCESSION NUMBER: 1992:215902 BIOSIS

DOCUMENT NUMBER: PREV199293116127; BA93:116127

TITLE: ENCAPSIDATION OF THE LA FRANCE DISEASE-SPECIFIC DOUBLE-STRANDED RNAS IN 36-NM ISOMETRIC VIRUSLIKE

PARTICLES.

AUTHOR(S): GOODIN M M [Reprint author]; SCHLAGNHAUFER B; ROMAINE C P

CORPORATE SOURCE: DEP PLANT PATHOL, PA STATE UNIV, UNIVERSITY PARK, PA 16802,

USA

SOURCE: Phytopathology, (1992) Vol. 82, No. 3, pp. 285-290.

CODEN: PHYTAJ. ISSN: 0031-949X.

DOCUMENT TYPE:

Article

FILE SEGMENT:

BA

LANGUAGE:

ENGLISH

ENTRY DATE:

Entered STN: 4 May 1992

Last Updated on STN: 4 May 1992

ABSTRACT: We investigated the relationship between the conserved electrophoretic

pattern of nine double-stranded RNAs (dsRNAs) and the viruslike

particles (VLPs) associated with LaFrance disease of the button mushroom,
Agaricus bisporus. Using a purification procedure involving chloroform

extraction, PEG-NaCl precipitation, differential centrifugation, and equilibrium centrifugation in cesium-sulphate gradient, we have obtained preparations from diseased sporophores that were highly enriched in a 36-nm isometric VLP and contained minor amounts of both a 25-nm isometric VLP and 19-

+ 50-nm single-stranded RNA baciliform virus. Cesium-sulphate gradient fractions that contained these particles (average buoyant density = 1.25 g/cc)

also contained the nine disease-specific dsRNAs of 3.8-0.8 kb and three disease-associated polypeptides with molecular weights of 63, 66, and 129

K. Neither the VLPs, dsRNAs, nor the polypeptides were present in healthy sporophores analyzed under identical conditions. Our data suggest that

the nine dsRNAs implicated in the etiology of La France disease constitute the genome of a 36-nm isomertric virus.

CONCEPT CODE:

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biophysics - Molecular properties and macromolecules

10506

Genetics of bacteria and viruses 31500 Virology - Plant host viruses 33508 Horticulture - Vegetables 53008

Phytopathology - Diseases caused by viruses 54510

INDEX TERMS:

Major Concepts

Genetics; Horticulture (Agriculture); Infection;

Microbiology

INDEX TERMS:

Miscellaneous Descriptors

AGARICUS-BISPORUS FUNGUS VIRUS BACILLIFORM MICROORGANISM

MUSHROOM DIE-BACK ETIOLOGY PATHOGEN IDENTIFICATION

AGRICULTURE

ORGANISM:

Classifier

Viruses 03000

Super Taxa

Microorganisms

Taxa Notes

Microorganisms, Viruses

ORGANISM:

Classifier

Basidiomycetes 15300

Super Taxa

Fungi; Plantae

Taxa Notes

Fungi, Microorganisms, Nonvascular Plants, Plants

L15 ANSWER 10 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN DUPLICATE 4

ACCESSION NUMBER:

1991:322904 BIOSIS

DOCUMENT NUMBER:

PREV199192033419; BA92:33419

TITLE:

THE ULTRASTRUCTURE OF HYPHAL ANASTOMOSES BETWEEN VEGETATIVELY COMPATIBLE AND INCOMPATIBLE VIRULENT AND

HYPOVIRULENT STRAINS OF CRYPHONECTRIA-PARASITICA.

AUTHOR(S): NEWHOUSE J R [Reprint author]; MACDONALD W L

CORPORATE SOURCE: DEP PLANT PATHOL AGRIC MICROBIOL, 401 BROOKS HALL, PO BOX

6057, WEST VIGINIA UNIV, MORGANTOWN, W VA 26506-6057, USA

SOURCE: Canadian Journal of Botany, (1991) Vol. 69, No. 3, pp.

602-614.

CODEN: CJBOAW. ISSN: 0008-4026.

DOCUMENT TYPE:

Article

FILE SEGMENT:

BA

LANGUAGE:

ENGLISH

ENTRY DATE:

Entered STN: 15 Jul 1991

Last Updated on STN: 15 Jul 1991

ABSTRACT: European hypovirulent (dsRNA-containing) Cryphonectria parasitica strain Ep-50 was paired individually with West Virginia [USA] virulent (dsRNA-free) strains Ep-15-7-7 (vegetatively compatible) and Ep 7-5-1 (vegetatively incompatible) on cellophane membranes. hours after anastomoses formed, the strains were preserved using freeze-substitution and observed using transmission electron microscopy. Hyphal anastomoses betwen Ep-50 and Ep 15-7-7 showed complete cytoplasmic continuity, with microtubules and mitochondria extending through the fusion aperture. Spherical, membrane-bound virus-like particles, measuring 50-90 nm in diameter, were located in the Ep-50 hypha, the Ep 15-7-7 hypha, and the short anastomosis bridge between them. All anastomoses between the compatible strains involved a hyphal peg that grew toward a swelling that developed on the receiving hypha. Fusion took place between the swelling and the lateral wall of the peg. Anastomoses between the incompatible strains showed cellular collapse and cytoplasmic degeneration that extended away from the anastomosis area in hyphae of both strains. Because of this, vegetative incompatibility would seem to be a formidable barrier to hypovirulence conversion and biocontrol of C. parasitica.

CONCEPT CODE:

Cytology - Plant 02504

Genetics - Plant 03504

Ecology: environmental biology - Plant 07506

Virology - Plant host viruses 33508

Plant physiology - Growth, differentiation 51510

Plant physiology - Reproduction 51512

Horticulture - Temperate zone fruits and nuts 53002 Phytopathology - Diseases caused by fungi 54502

Phytopathology - Disease control 54516

INDEX TERMS:

Major Concepts

Cell Biology; Development; Ecology (Environmental Sciences); Genetics; Horticulture (Agriculture); Infection; Microbiology; Pest Assessment Control and

Management; Reproduction

INDEX TERMS:

Miscellaneous Descriptors

AMERICAN CHESTNUT BLIGHT VIRUS-LIKE PARTICLES HYPHAL

FUSION BIOLOGICAL CONTROL

ORGANISM:

Classifier

Ascomycetes 15100

Super Taxa

Fungi; Plantae

Taxa Notes

Fungi, Microorganisms, Nonvascular Plants, Plants

ORGANISM:

Classifier

Fagaceae 26070

Super Taxa

Dicotyledones; Angiospermae; Spermatophyta; Plantae

Taxa Notes

Angiosperms, Dicots, Plants, Spermatophytes, Vascular

Plants

STN

ACCESSION NUMBER: 1992:100851 BIOSIS

DOCUMENT NUMBER: PREV199293057401; BA93:57401

TITLE: STUDIES ON THE PURIFICATION AND PROPERTIES OF RICE BUNCHY

STUNT VIRUS.

AUTHOR(S): LIN Q [Reprint author]; XIE L; XIE L

CORPORATE SOURCE: LAB PLANT VIROL, FUJIAN AGRICULTURAL COLEGE, FUZHOU 350002

SOURCE: Scientia Agricultura Sinica, (1991) Vol. 24, No. 4, pp.

52-57.

CODEN: CKNYAR. ISSN: 0578-1752.

DOCUMENT TYPE: Article FILE SEGMENT: BA LANGUAGE: CHINESE

ENTRY DATE: Entered STN: 12 Feb 1992

Last Updated on STN: 12 Feb 1992

ABSTRACT: Purified preparation of rice bunchy stunt virus (RBSV) was obtained by using chloroform to clarify extracts, PEG to sediment virus particles and differential centrifugations and sucrose density gradient to concentrate virus particles. The preparation was examined with a UV spectrophotometer and showed a typical nucleoprotein spectrum with maximum absorption at 260nm and minimum at 240nm, A260/240 = 1.18 and A260/280 = 1.61. Plenty of virus particle's with their size of av. 60 (58.3-61.6)nm in diameter, could be observed under Hu 12 electron microscope when stained with PTA and showed icosahedronal structures with two layers of capsid protein units clearly. virus particles were serological trapped and decorated by Fujian antiserum againast RBSV in immunodiffusion and immunosorbent electron microscope tests. No special reaction was found between the antiserum against RBSV, RDV and RGDV. Nucleic acid was extracted from the virus preparation by means of phenol-methyl-phenol-SDS and showed a typical absorption spectrum of nucleic acid with maximum at 260nm and minimum at 228nm, A260/228 = 2.27, A260/280 =2.02. The nucleic acid was determined to be dsRNA based on its stability against RNase under various ionic intensities and reaction properties with methyl-resorcinol and diphenylamine. It occupied 17.5-20.1% of RBSV particles in accordance with its UV abosrption characteristics. Electrophoresis indicated that the total M Wt (+ 106) of the ds RNA was estimated to by 16.66, with segments of 2.70, 2.30, 1.90, 1.70, 1.68, 1.50 1.38, 1.20, 1.10, 0.60, 0.35 and 0.25. The dsRNA was infective when it was injected into Nephotettix cincticeps. These results suggest that RBSV is a new member of Phytoreovirus in the plant reovirus subgroup I. CONCEPT CODE:

Ecology: environmental biology - Plant 07506 Ecology: environmental biology - Animal 07508

Genetics of bacteria and viruses 31500 Virology - Plant host viruses 33508

Agronomy - Miscellaneous and mixed crops 52502 Phytopathology - Diseases caused by viruses 54510

Economic entomology - Field, flower and truck crops 60004 Invertebrata: comparative, experimental morphology,

Invertebrata: comparative, experimental morphology, physiology and pathology - Insecta: physiology 64076

INDEX TERMS: Major Concepts

Agronomy (Agriculture); Ecology (Environmental

Sciences); Economic Entomology; Genetics; Infection;

Microbiology

INDEX TERMS: Miscellaneous Descriptors

NEPHOTETTIX-CINCTICEPS APHID VECTOR PHYTOPATHOGEN

PHYTOREOVIRUS IDENTIFICATION INFECTIVITY VIRAL GENETICS

ORGANISM: Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

ORGANISM: Classifier

Homoptera 75324

Super Taxa

Insecta; Arthropoda; Invertebrata; Animalia

Taxa Notes

Animals, Arthropods, Insects, Invertebrates

L15 ANSWER 12 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 1990:331175 BIOSIS

DOCUMENT NUMBER: PREV199090039194; BA90:39194

TITLE: PARTIAL COMPLEMENTARY CLONING AND NUCLEOTIDE SEQUENCE OF

RICE DWARF VIRUS GENOME.

AUTHOR(S): GAO Q [Reprint author]; OU Y-X; LIU W; PAN N-S; CHEN Z-L

CORPORATE SOURCE: NATL LAB PLANT GENET ENG, PEKING UNIV, BEIJING 100871

SOURCE: Acta Botanica Sinica, (1990) Vol. 32, No. 1, pp. 13-18.

CODEN: CHWHAY. ISSN: 0577-7496.

DOCUMENT TYPE: Article

FILE SEGMENT: BA LANGUAGE: CHINESE

ENTRY DATE: Entered STN: 24 Jul 1990

Last Updated on STN: 24 Jul 1990

ABSTRACT: Rice dwarf virus (RDV) was isolated and purified from infected rice

leaves with chloroform extraction, PEG precipitation and sucrose

gradient centrifugation. Total RDV RNA genome was separated in the agarose gel and segments of RDV RNA genome were purified. The cDNAs of several segments were synthesized with oligo dT as primer. Through cDNA mapping, subcloning and sequencing, we have obtained partial DNA sequence of those segments. Here we report the cloning and partial DNA sequence of segment 8 from RDV RNA genome.

CONCEPT CODE:

Biochemistry methods - Nucleic acids, purines and

pyrimidines 10052

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biophysics - Molecular properties and macromolecules

10506

Genetics of bacteria and viruses 31500 Virology - Plant host viruses 33508

Agronomy - Sugar crops 52510

INDEX TERMS: Major Concepts

Agronomy (Agriculture); Biochemistry and Molecular

Biophysics; Genetics

INDEX TERMS: Miscellaneous Descriptors

DNA MAPPING MOLECULAR SEQUENCE DATA RNA SEQUENCE DNA

SEQUENCE

ORGANISM: Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

L15 ANSWER 13 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 1990:49657 BIOSIS

DOCUMENT NUMBER: PREV199089027021; BA89:27021

TITLE: INTESTINAL PERMEABILITY ASSESSED WITH POLYETHYLENE GLYCOLS

IN CHILDREN WITH DIARRHEA DUE TO ROTAVIRUS AND COMMON

BACTERIAL PATHOGENS IN A DEVELOPING COMMUNITY.

AUTHOR(S): JOHANSEN K [Reprint author]; STINTZING G; MAGNUSSON K E;

SUNDQVIST T; JALIL F; MURTAZA A; KHAN S R; LINDBLAD B S;

MOLLBY R; ET AL

CORPORATE SOURCE: ST GORAN'S CHILD HOSP, S-112 81 STOCKHOLM, SWED

SOURCE: Journal of Pediatric Gastroenterology and Nutrition, (1989)

Vol. 9, No. 3, pp. 307-313. CODEN: JPGND6. ISSN: 0277-2116.

DOCUMENT TYPE: FILE SEGMENT:

Article BA ENGLISH

LANGUAGE: ENTRY DATE:

Entered STN: 11 Jan 1990

Last Updated on STN: 11 Jan 1990

ABSTRACT:Intestinal permeability was assessed with different-sized polyethylene glycols (**PEG** 400 and **PEG** 1,000) in small children with acute diarrhea. All children with acute diarrhea absorbed and excreted less ***PEG*** of all molecular sizes into the urine when compared with healthy control children (p < 0.001). Children with acute rotavirus infection excreted

significantly less **PEG** of all sizes than children with Shigella, Salmonella, and enteropathogenic Escherichia coli (EPEC) infection (p < 0.001-0.01), suggesting a more severe mucosal lesion caused by rotavirus. In patients with severe malnutrition there was also a significant decrease in absorption of **PEGs** observed. In addition, malnourished patients with rotavirus diarrhea showed a pronounced decrease of **PEGs** in comparison with well-nourished patients. The ratio between the recovery of a large ***PEG*** molecule, 1,074 Da, and a small molecule, 370 Da, was utilized to assess the absorption of large molecules in relation to that of smaller ones. On applying this ratio, it was noted that the intestine in children with Shigella and EPEC infection was relatively more permeable to larger molecules than in healthy controls, while in rotavirus and Salmonella infection it was less permeable to larger molecules. In this study significant differences in the permeability characteristics were observed, suggesting etiology-specific effects on the mucosal barrier.

CONCEPT CODE:

Cytology - Human 02508

Biochemistry studies - General 10060 Biophysics - Membrane phenomena 10508

Pathology - Diagnostic 12504

Digestive system - General and methods 14001

Digestive system - Pathology 14006

Pediatrics - 25000

Virology - Animal host viruses 33506

Medical and clinical microbiology - General and methods

36001

Medical and clinical microbiology - Bacteriology 36002 Medical and clinical microbiology - Virology 36006

INDEX TERMS: Major Concepts

Cell Biology; Gastroenterology (Human Medicine, Medical

Sciences); Infection; Membranes (Cell Biology);

Pathology; Pediatrics (Human Medicine, Medical Sciences)

INDEX TERMS:

Miscellaneous Descriptors
SHIGELLA SALMONELLA ESCHERICHIA-COLI DIAGNOSIS

ORGANISM: Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

ORGANISM: Classifier

Enterobacteriaceae 06702

Super Taxa

Facultatively Anaerobic Gram-Negative Rods; Eubacteria;

Bacteria; Microorganisms

Taxa Notes

Bacteria, Eubacteria, Microorganisms

ORGANISM:

Classifier
Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Taxa Notes

Animals, Chordates, Humans, Mammals, Primates,

Vertebrates

25322-68-3D (POLYETHYLENE GLYCOLS) REGISTRY NUMBER:

L15 ANSWER 14 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

1987:168936 BIOSIS ACCESSION NUMBER:

DOCUMENT NUMBER:

PREV198783087377; BA83:87377

TITLE:

INTESTINAL PERMEABILITY IN SMALL CHILDREN DURING AND AFTER

ROTAVIRUS DIARRHEA ASSESSED WITH DIFFERENT SIZE

POLYETHYLENE GLYCOLS PEG 400 AND PEG

1000.

AUTHOR(S):

SOURCE:

STINTZING G [Reprint author]; JOHANSEN K; MAGNUSSON K E;

SVENSSON L; SUNDQVIST T

CORPORATE SOURCE:

ST GORAN'S CHILDREN'S HOSP, S-11281 STOCKHOLM, SWEDEN

Acta Paediatrica Scandinavica, (1986) Vol. 75, No. 6, pp.

1005-1009.

CODEN: APSVAM. ISSN: 0001-656X.

DOCUMENT TYPE:

Article BA

FILE SEGMENT: LANGUAGE: ENTRY DATE:

ENGLISH Entered STN: 11 Apr 1987

Last Updated on STN: 11 Apr 1987

ABSTRACT: The permeability properties of the small intestinal mucosa was investigated in nine previously healthy childen with acute diarrhea due to rotavirus. The investigation was performed after intake of a mixture in water of polyethyleneglycol molecules (PEG 400 and 1000) ranging from 282 to 1250 dalton in molecular weight. The 6-h urinary recovery of the was determined with high performance liquid chromatography and ***PEGs*** used to assess the permeability characteristics of the intestine. The patients served as their own controls and were investigated in the same manner after recovery 3-5 weeks later. A significantly lower urinary recovery of ***PEG*** was noted for all molecular sizes (326-1206 dalton) during acute diarrhea in comparison with the results obtained after recovery (p < 0.001-0.1). There was also a relatively lesser change in the urinary recovery of larger PEG molecules during infection, as reflected by a higher recovery ratio between 1074 and 370 dalton PEGs. The results indicate profound changes in the permeability characteristics of the intestine

during acute rotavirus diarrhea. CONCEPT CODE:

Biophysics - Molecular properties and macromolecules

10506

Biophysics - Membrane phenomena 10508

Digestive system - General and methods 14001

Digestive system - Physiology and biochemistry

Digestive system - Pathology 14006 15506 Urinary system - Pathology

Pediatrics -25000

Virology - Animal host viruses 33506

Medical and clinical microbiology - Virology 36006

INDEX TERMS: Major Concepts

Biochemistry and Molecular Biophysics; Digestive System (Ingestion and Assimilation); Gastroenterology (Human Medicine, Medical Sciences); Infection; Membranes (Cell Biology); Pediatrics (Human Medicine, Medical Sciences);

Urology (Human Medicine, Medical Sciences)

INDEX TERMS:

Miscellaneous Descriptors

CHROMATOGRAPHY

ORGANISM:

Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

ORGANISM:

Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Taxa Notes

Animals, Chordates, Humans, Mammals, Primates,

Vertebrates

REGISTRY NUMBER:

25322-68-3 (POLYETHYLENE GLYCOLS)

25322-68-3 (**PEG** 400) 25322-68-3 (**PEG** 1000)

L15 ANSWER 15 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER:

1984:352520 BIOSIS

DOCUMENT NUMBER:

PREV198478089000; BA78:89000

TITLE:

THE MESOPHASE STATE OF DOUBLE STRANDED RNA AND POLY RIBO NUCLEOTIDES IS CHARACTERISTIC OF HIGH OPTICAL ACTIVITY.

AUTHOR(S):

LORTKIPANIDZE G B [Reprint author]; EVDOKIMOV YU M; DEMBO A

T; BARSHAVSKII YA M

CORPORATE SOURCE:

INST MOL BIOL, ACAD SCI USSR, MOSCOW, USSR

SOURCE:

Molekulyarnaya Biologiya (Moscow), (1984) Vol. 18, No. 2,

pp. 466-473.

CODEN: MOBIBO. ISSN: 0026-8984.

DOCUMENT TYPE:

Article

FILE SEGMENT:

BA

LANGUAGE:

RUSSIAN

ABSTRACT:A small-angle reflection in X-ray diffraction and an intense band at Å .apprx. 270 nm in the CD [circular dichroism) spectrum are assigned to compact particles that arise when mixing water-salt solutions of PEG (polyethylene glycol) with water-salt solutions of double-stranded RNA (ds RNA) and those of poly(A) · poly(U), and poly(I) · poly(C). The discrepancy between the 35-40 Å small-angle reflection and the .apprx. 20 Å small-angle reflection typical of double-stranded polynucleotide crystals together with the presence of the intense band in the CD spectra suggest that the dsRNA molecules and the molecules of polyribonucleotides exist in a mesophase (liquid crystalline) state. The compact particles of dsRNA and those of polyribonucleotides have either a positive or a negative band of the CD spectrum depending on PEG concentration, ionic strength or solution temperature.

CONCEPT CODE:

Radiation biology - Radiation and isotope techniques

06504

Biochemistry methods - Nucleic acids, purines and

pyrimidines 10052

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biophysics - Methods and techniques 10504

Biophysics - Molecular properties and macromolecules

10506

INDEX TERMS:

Major Concepts

Biochemistry and Molecular Biophysics

INDEX TERMS:

Miscellaneous Descriptors

X-RAY DIFFRACTION CIRCULAR DICHROISM/

L15 ANSWER 16 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER:

1985:307317 BIOSIS

DOCUMENT NUMBER:

PREV198579087313; BA79:87313

TITLE:

ACUTE INFECTIONS WITH GIARDIA-LAMBLIA AND ROTAVIRUS DECREASE INTESTINAL PERMEABILITY TO LOW-MOLECULAR WEIGHT

POLYETHYLENE GLYCOLS PEG 400.

AUTHOR(S): SERRANDER R [Reprint author]; MAGNUSSON K-E; SUNDQVIST T

CORPORATE SOURCE: INFEKTIONSKLINIKEN, REGIONSJUKHUSET, S-58185 LINKOPING,

SWED

SOURCE: Scandinavian Journal of Infectious Diseases, (1984) Vol.

16, No. 4, pp. 339-344.

CODEN: SJIDB7. ISSN: 0036-5548.

DOCUMENT TYPE:

Article

FILE SEGMENT:

BA

LANGUAGE:

ENGLISH

ABSTRACT: The passive intestinal permeability of patients seeking care for acute diarrhea was investigated with a liquid meal containing differently sized, low

MW polyethylene glycols (PEG 400; MW 282-590). The subjects suffered

from acute infections caused either by G. lamblia or rotavirus. The patients were studied during infection and 3-4 wk later when they had recovered clinically. It was found that both giardia and rotavirus infections were associated with decreased 6 h urinary recovery of the **PEG** molecules,

particularly of the larger MW species. After the infection, the permeability

properties returned towards normal values. The results show that the

permeability and the absorptive capacity is altered in patients with acute G. lamblia and rotavirus infections which could be important in relation to

chronic infections and malnutrition attributed to these organisms.

CONCEPT CODE:

Biochemistry studies - General 10060 Digestive system - Pathology 14006 Blood - Other body fluids 15010 Virology - Animal host viruses 33506

Medical and clinical microbiology - General and methods

36001

Medical and clinical microbiology - Virology 36006

Parasitology - Medical 60504

Invertebrata: comparative, experimental morphology,

physiology and pathology - Protozoa 64002

INDEX TERMS:

Major Concepts

Gastroenterology (Human Medicine, Medical Sciences);

Infection; Parasitology

INDEX TERMS:

Miscellaneous Descriptors

HUMAN DIARRHEA

ORGANISM:

Classifier

Reoviridae 03402

Super Taxa

dsRNA Viruses; Viruses; Microorganisms

Taxa Notes

Double-Stranded RNA Viruses, Microorganisms, Viruses

ORGANISM:

Classifier

Flagellata 35200

Super Taxa

Protozoa; Invertebrata; Animalia

Taxa Notes

Animals, Invertebrates, Microorganisms, Protozoans

ORGANISM:

Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

DUPLICATE 5

Taxa Notes

Animals, Chordates, Humans, Mammals, Primates,

Vertebrates

REGISTRY NUMBER:

25322-68-3 (POLYETHYLENE GLYCOLS)

25322-68-3 (**PEG** 400)

L15 ANSWER 17 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

CONT.

ACCESSION NUMBER:

1983:290114 BIOSIS

DOCUMENT NUMBER:

PREV198376047606; BA76:47606

INHIBITION BY GLUCO CORTICO STEROID HORMONES OF INTERFERON TITLE:

AND PROSTAGLANDIN E INDUCTION BY POLY RIBO INOSINIC-ACID

POLY RIBO CYTIDYLIC-ACID.

ZOR U [Reprint author]; BEN-DORI R; MAOZ I; WALLACH D; AUTHOR(S):

GURARI-ROTMAN D

CORPORATE SOURCE:

DEP HORMONE RES, WEIZMANN INSTITUTE SCI, REHOVOT, ISRAEL Journal of General Virology, (1982) Vol. 63, No. 2, pp.

359-364.

CODEN: JGVIAY. ISSN: 0022-1317.

DOCUMENT TYPE:

SOURCE:

Article

FILE SEGMENT: ENGLISH LANGUAGE:

ABSTRACT: The relationship between induction of interferon (IFN) and prostaglandin E (PGE) production by poly (I·c) in cultured human foreskin fibroblasts (FS11) was examined. Hydrocortisone and

dexamethasone (2.5 + 10-7 M), which are known inhibitors of PGE synthesis, significantly decreased the induction of both IFN and PGE in IFN-pretreated (primed) cells. Desoxycorticosterone, progesterone and estradiol were devoid of this activity. Hydrocortisone also blocked the induction of IFN by double-stranded RNA (dsRNA), cycloheximide and actinomycin D in FS11 cells. Arachidonic acid overcame the inhibitory effect of hydrocortisone on PGE production, but failed to restore IFN production in the presence of the steroid. The prostaglandin synthetase inhibitors, indomethacin, aspirin and flufenamic acid, did not change IFN production by dsRNA in primed FS11 cells, although prostaglandin synthesis was abolished. Although the induction of IFN and PGE by poly(I·c) might be consequences of the same initial event in the cell, the accumulation of PGE does not seem to have a regulatory effect on the synthesis of IFN in this system.

CONCEPT CODE:

Cytology - Human 02508

Biochemistry methods - Proteins, peptides and amino acids

10054

Biochemistry methods - Lipids 10056

Biochemistry methods - Carbohydrates 10058

Biochemistry studies - General 10060

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biochemistry studies - Proteins, peptides and amino acids

Biochemistry studies - Lipids

Biochemistry studies - Sterols and steroids

Biochemistry studies - Carbohydrates

Metabolism - Carbohydrates 13004

Metabolism - Lipids 13006

Metabolism - Proteins, peptides and amino acids

Reproductive system - General and methods 16501

17004 Endocrine - Adrenals

Endocrine - Gonads and placenta 17006

Bones, joints, fasciae, connective and adipose tissue -

General and methods 18001

Pharmacology - Drug metabolism and metabolic stimulators

22003

Pharmacology - Endocrine system

Tissue culture, apparatus, methods and media Chemotherapy - General, methods and metabolism

Major Concepts INDEX TERMS:

Cell Biology; Metabolism; Pharmacology

Miscellaneous Descriptors INDEX TERMS:

> HUMAN FORE SKIN FIBROBLAST FS-11 CELLS HYDROCORTISONE DEXAMETHASONE DEOXY CORTICO STERONE PROGESTERONE ESTRADIOL CYCLO HEXIMIDE ACTINOMYCIN D METABOLIC-DRUG

INDOMETHACIN ASPIRIN FLUFENAMIC-ACID ENZYME

INHIBITOR-DRUG ARACHIDONIC-ACID DOUBLE STRANDED RNA

ORGANISM:

Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Animals, Chordates, Humans, Mammals, Primates,

Vertebrates

REGISTRY NUMBER:

50-23-7 (HYDROCORTISONE) 50-02-2 (DEXAMETHASONE)

64-85-7 (DEOXYCORTICOSTERONE)

57-83-0 (PROGESTERONE) 50-28-2 (ESTRADIOL) 66-81-9 (CYCLOHEXIMIDE) 50-76-0 (ACTINOMYCIN D) 53-86-1 (INDOMETHACIN) 50-78-2 (ASPIRIN)

530-78-9 (FLUFENAMIC-ACID) .506-32-1 (ARACHIDONIC-ACID)

L15 ANSWER 18 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

DUPLICATE 6

ACCESSION NUMBER:

1982:191368 BIOSIS

DOCUMENT NUMBER:

PREV198273051352; BA73:51352

TITLE:

COMPACT PARTICLES OF DOUBLE STRANDED POLY RIBO NUCLEOTIDES

1. THE CONDITIONS FOR FORMATION OF THE OPTICALLY ACTIVE

DOUBLE STRANDED RNA COMPACT PARTICLES.

AUTHOR(S):

LORTKIPANIDZE G B [Reprint author]; EVDOKIMOV YU M; KADYKOV

V A; VARSHAVSKII YA M

CORPORATE SOURCE:

INST MOL BIOL, ACAD SCI USSR, MOSCOW, USSR

SOURCE:

Molekulyarnaya Biologiya (Moscow), (1980) Vol. 14, No. 6,

pp. 1378-1386.

CODEN: MOBIBO. ISSN: 0026-8984.

DOCUMENT TYPE:

FILE SEGMENT:

RΑ

LANGUAGE:

RUSSIAN

Article

ABSTRACT: The conditions for formation of double-stranded RNA (dsRNA) compact particles in water-salt solutions containing polyethylene glycol (***PEG***) were determined. In solutions of mild ionic strength (.apprx. 0.3), compact particles of dsRNA are characterized by an intense positive CD[circular dichroism]-band (λ [eight wavelength] 270 nm), but in solutions of high ionic strength (1.0-1.5) the particles are characterized by intense positive or negative CD-bands (λ 270 nm). Heating of solutions of a high ionic strength containing compact particles with negative CD-bands is accompanied by a change in the sign of the CD-band. The same effect is observed when the ionic strength of the solutions is decreased. Melting of compact particles as revealed by the CD-method occurs prior to the melting of the secondary structure of dsRNA. The intense CD-bands reflect the ordered arrangement of the chromophores of polynucleotide chain in compact particles. The reasons for the change of the sign of the CD-bands are discussed.

CONCEPT CODE:

Biochemistry methods - Nucleic acids, purines and

pyrimidines 10052

Biochemistry studies - General

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biochemistry studies - Minerals Biophysics - Methods and techniques 10504

Biophysics - Molecular properties and macromolecules

10506

External effects - Temperature as a primary variable - hot

10618

Temperature - General measurement and methods 23001

INDEX TERMS: Major Concepts

Biochemistry and Molecular Biophysics

INDEX TERMS: Miscellaneous Descriptors

POLY ETHYLENE GLYCOL CIRCULAR DICHROISM WATER SALT

SOLUTION

REGISTRY NUMBER: 25322-68-3 (POLYETHYLENE GLYCOL)

L15 ANSWER 19 OF 21 MEDLINE on STN ACCESSION NUMBER: 78176823 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 651879

TITLE:

[Compact form of synthetic polynucleotides. Relationship

between secondary structure and circular dichroism

spectra].

Kompaktnaia forma sinteticheskikh polinukleotidov. Sviaz' sektrov krugovogo dikhroizma so vtorichnoi strukturoi. Piatigorskaia T L; Evdokimov Iu M; Varshavskii Ia M

AUTHOR: SOURCE:

Molekuliarnaia biologiia, (1978 Mar-Apr) 12 (2)

404-12.

Journal code: 0105454. ISSN: 0026-8984.

PUB. COUNTRY: USSR

DOCUMENT TYPE: Journa

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Russian

FILE SEGMENT: Pri

Priority Journals

ENTRY MONTH: 197807

ENTRY DATE:

Entered STN: 19900314

Last Updated on STN: 19900314 Entered Medline: 19780715

ABSTRACT:

The formation of compact particles from synthetic double- and triplestranded polynucleotides in water-salt solutions, containing poly(ethylene glycol) (***PEG***) has been investigated. CD spectra of compact particles are characterized by intense bands (positive or negative) in the region of 270 nm, compact particles being divided into two families--psi- and psi+--according to the CD band sign. The amplitude of the CD band at 270 nm increases with the increase of CPEG. Heating of a solution, containing compact particles, results in a disappearance of the CD band, the "melting" of compact particles as revealed by the CD method occuring prior to the melting of the secondary structure of the corresponding polynucleotide. It is concluded that intense CD bands, which are characteristic of the compact form of synthetic polynucleotides, arise (similar to the case of DNA or dsRNA) from regular arrangement of polynucleotide chains in compact particles. question, concerning the relation between parameters of the secondary structure of polynucleotides and their belonging either to psi- or to psi+ family is The factors, which could account for the appearance of intense bands in CD spectra of compact particles are also considered.

CONTROLLED TERM: Check Tags: Comparative Study

Circular Dichroism

Coliphages DNA, Bacterial DNA, Viral

English Abstract
Molecular Conformation

Nucleic Acid Conformation

Poly I-C

Polydeoxyribonucleotides

*Polynucleotides

CAS REGISTRY NO.:

24939-03-5 (Poly I-C)

CHEMICAL NAME:

0 (DNA, Bacterial); 0 (DNA, Viral); 0

(Polydeoxyribonucleotides); 0 (Polynucleotides)

L15 ANSWER 20 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN DUPLICATE 7

ACCESSION NUMBER:

1978:163084 BIOSIS

DOCUMENT NUMBER:

PREV197865050084; BA65:50084

TITLE:

DNA COMPACT FORM IN SOLUTION PART 12 FORMATION OF A COMPACT

FORM OF DOUBLE STRANDED POLY RIBO NUCLEOTIDES IN THE

PRESENCE OF POLY ETHYLENE GLYCOL.

AUTHOR(S):

EVDOKIMOV YU M [Reprint author]; PYATIGORSKAYA T L; KADYKOV V A; POLIVTSEV O F; DOSCOCIL J; KOUDELKA YA; VARSHAVSKII YA

CORPORATE SOURCE:

INST MOL BIOL, ACAD SCI USSR, MOSCOW, USSR

SOURCE:

Molekulyarnaya Biologiya (Moscow), (1977) Vol. 11, No. 4,

pp. 891-900.

CODEN: MOBIBO. ISSN: 0026-8984.

DOCUMENT TYPE:

Article

FILE SEGMENT: RUSSIAN LANGUAGE:

ABSTRACT: Double-stranded [ds] polyribonucleotides (a replicative form of phage f2 RNA and poly(A) \cdot poly(U), can adopt a compact form in solutions containing NaCl and poly(ethylene glycol) (PEG). EM observations show that dsRNA compact particles have the form of disks or doughnuts 200-400 Å in diameter. X-ray diffraction patterns from dense slurries of compact particles show a reflection at a spacing of 35 Å, ***dsRNA*** which is indicative of the existence of ordered regions in compact particles. The intense positive CD [circular dichroism] band, which is characteristic of and poly(a) · poly(U) compact particles, presumably results from the ordered regions in the particles. Heating of the solution leads to the disappearance of the intense positive CD band, probably as a result of the destruction of the ordered structure of compact particles. Heat or acid denatured dsRNA molecules as well as single-stranded molecules of ribosomal RNA also form large particles in PEG -containing solutions. However, X-ray diffraction patterns from these particles do not show the 35 Å reflection and the specific positive band is not present in the CD spectra, which indicates that such particles lack ordered internal structure. Similar mechanisms of compactization of double-stranded polynucleotides (DNA and RNA) may exist with compact particles divided into 2 families (Ψ + and Ψ -), differing by the secondary structure of double-stranded polynucleotides which form the particles.

CONCEPT CODE: Microscopy - Electron microscopy 01058

Radiation biology - Radiation and isotope techniques

06504

Biochemistry methods - Nucleic acids, purines and

pyrimidines 10052

Biochemistry studies - General

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Biophysics - Methods and techniques 10504

Biophysics - Molecular properties and macromolecules

10506

External effects - Temperature as a primary variable - hot

10618

Temperature - General measurement and methods 23001

Virology - Bacteriophage 33504

INDEX TERMS:

Major Concepts

Biochemistry and Molecular Biophysics; Microbiology

INDEX TERMS:

Miscellaneous Descriptors

BACTERIO PHAGE F-2 POLY ADENYLIC-ACID POLY URIDYLIC-ACID CIRCULAR DICHROISM X-RAY DIFFRACTION ELECTRON MICROSCOPY

ORGANISM:

Classifier

03000 Viruses

Super Taxa

Microorganisms

Taxa Notes

Microorganisms, Viruses

REGISTRY NUMBER: 25322-68-3 (POLYETHYLENE GLYCOL)

24936-38-7 (POLY ADENYLIC-ACID POLY URIDYLIC-ACID)

L15 ANSWER 21 OF 21 MEDLINE ON STN ACCESSION NUMBER: 76268953 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 8770

TITLE:

A compact form of double-stranded RNA in solutions

containing poly(ethyleneglycol).

AUTHOR:

Evdokimov Y M; Pyatigorskaya T L; Kadikov V A; Polyvtsev O

F; Doskocil J; Koudelka J; Varshavsky Y M

SOURCE:

Nucleic acids research, (1976 Jun) 3 (6) 1533-47.

Journal code: 0411011. ISSN: 0305-1048.

PUB. COUNTRY:

ENGLAND: United Kingdom

DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

197611

ENTRY DATE:

Entered STN: 19900313

Last Updated on STN: 19950206 Entered Medline: 19761101

ABSTRACT:

Molecules of single-stranded ribosomal RNA and double-stranded replicative form of phage f2 RNA (dsRNA) adopt a compact form in solutions, containing sufficiently high concentrations of salt (NaCl) and polymer (PEG). However, only in the cases of native dsRNA molecules the compact particles are characterized by a regular internal structure, which accounts for the appearance of an intense positive band in CD spectra. Heating or acidification of PEG-containing solutions of dsRNA leads to the disappearance of the intense positive CD band, which results from the "destruction" of the regular internal structure of compact particles. Comparison of properties of DNA and dsRNA compact particles formed in ***PEG*** -containing water-salt solutions suggests the existence of similar mechanisms of compactization of double-stranded polynucleotides.

CONTROLLED TERM: Circular Dichroism

Coliphages

Hydrogen-Ion Concentration Nucleic Acid Conformation Nucleic Acid Denaturation Osmolar Concentration *Polyethylene Glycols

*RNA, Ribosomal
*RNA, Viral
Sodium Chloride
Temperature

CAS REGISTRY NO.:

7647-14-5 (Sodium Chloride)

CHEMICAL NAME:

0 (Polyethylene Glycols); 0 (RNA, Ribosomal); 0 (RNA,

Viral)

=> d iall 116 1-41

L16 ANSWER 1 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2005:6

2005:629561 SCISEARCH

THE GENUINE ARTICLE: 934UN

TITLE:

Nanoparticle targeting of anticancer drug improves

therapeutic response in animal model of human epithelial

cancer

AUTHOR:

Kukowska-Latallo J F; Candido K A; Cao Z Y; Nigavekar S S; Majoros I J; Thomas T P; Balogh L P; Khan M K; Baker J R

(Reprint)

CORPORATE SOURCE: Univ Michigan, Hlth Syst, Ctr Biol Nanotechnol, 1150 W Med

> Ctr Dr, 9220 MSRB3, Ann Arbor, MI 48109 USA (Reprint); Univ Michigan, Hlth Syst, Ctr Biol Nanotechnol, Ann Arbor, MI 48109 USA; Univ Michigan, Hlth Syst, Dept Radiat Oncol,

Ann Arbor, MI 48109 USA

jbakerjr@umich.edu

COUNTRY OF AUTHOR:

USA

CANCER RESEARCH, (15 JUN 2005) Vol. 65, No. 12, pp. SOURCE:

5317-5324.

ISSN: 0008-5472.

AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PUBLISHER:

PHILADELPHIA, PA 19106-4404 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 36

Entered STN: 29 Jun 2005 ENTRY DATE:

Last Updated on STN: 29 Jun 2005

ABSTRACT:

Prior studies suggested that nanoparticle drug delivery might improve the therapeutic response to anticancer drugs and allow the simultaneous monitoring of drug uptake by tumors. We employed modified PAMAM dendritic polymers < 5 nm in diameter as carriers. Acetylated dendrimers were conjugated to folic acid as a targeting agent and then coupled to either methotrexate or tritium and either fluorescein or 6carboxytetramethylrhodamine. These conjugates were injected i.v. into immunodeficient mice bearing human KB tumors that overexpress the folic acid In contrast to nontargeted polymer, folate-conjugated nanoparticles concentrated in the tumor and liver tissue over 4 days after administration. The tumor tissue localization of the folate-targeted polymer could be attenuated by prior i.v. injection of free folic acid. Confocal microscopy confirmed the internalization of the drug conjugates into the tumor cells. Targeting methotrexate increased its antitumor activity and markedly decreased its toxicity, allowing therapeutic responses not possible with a free drug.

CATEGORY: ONCOLOGY

SUPPL. TERM PLUS:

FOLATE-BINDING PROTEIN; POSITIVE TUMOR-CELLS; IN-VITRO; KB CELLS; POLYAMIDOAMINE DENDRIMERS; STARBURST DENDRIMERS;

RECEPTOR; EFFICACY; DELIVERY; OLIGONUCLEOTIDES

	RECEPTOR; EFF	ICACY; I	DELIVERY; oligonucleoti i
REFERENCE(S):			
Referenced Author	Year VOL	ARN PO	G Referenced Work
(RAU)	(RPY) (RVL)) (RPG)	(RWK)
=======================================	===+ == ====+=====	=+======	+======================================
ANTONY A C	1985 260	14911	J BIOL CHEM
BELZ S	1998 265	157	ANAL BIOCHEM
BIELINSKA A	1996 24	2176	NUCLEIC ACIDS RES
CAMPBELL I G	1991 51	5329	CANCER RES
СНО В К	1997 8	338	BIOCONJUGATE CHEM
DAVIS T A	1999 17	1851	J CLIN ONCOL
DELONG R	1997 86	762	J PHARM SCI
GREEN M C	2000 26	1269	CANCER TREAT REV
GRIFFIN J L	2004 4	551	NAT REV CANCER
KRANZ D M	1995 92	9057	P NATL ACAD SCI USA
KRISHNA R	2000 11	265	EUR J PHARM SCI
KUKOWSKALATALLO J F	1996 93	4897	P NATL ACAD SCI USA
LEAMON C P	2004 56	1127	ADV DRUG DELIVER REV
LEAMON C P	1994 2	101	J DRUG TARGET
LEE R J	1995 1233	1134	BBA-BIOMEMBRANES
MAEDA H	2000 65	1271	J CONTROL RELEASE
MAJOROS I J	12003 136	15526	MACROMOLECULES
MALIK N	1999 10	1767	ANTI-CANCER DRUG
MALIK N	12000 65	133	J CONTROL RELEASE
MATHIAS C J	11998 39	1579	J NUCL MED
NELSON B C	2004 325	141	ANAL BIOCHEM

NIGAVEKAR S S	2004 21	476	PHARM RES
PARK J W	2002 8	11172	CLIN CANCER RES
QUINTANA A	2002 19	1310	PHARMACEUT RES
ROBERTS J C	1996 30	53	J BIOMED MATER RES
ROSS J F	1994 73	12432	CANCER
RUND L A	1999 83	141	INT J CANCER
SAPRA P	2002 62	7190	CANCER RES
THOMAS T P	2004 86	3959	BIOPHYS J
THOMAS T P	2005	1	IN PRESS J MED CHEM
TUREK J J	1993 106	423	J CELL SCI
WANG S	1995 92	3318	P NATL ACAD SCI USA
WEITMAN S D	1992 52	3396	CANCER RES
WEITMAN S D	1992 52	6708	CANCER RES
WIENER E C	1997 32	748	INVEST RADIOL
WILBUR D S	1998 9	813	BIOCONJUGATE CHEM

L16 ANSWER 2 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2005:369543 SCISEARCH

THE GENUINE ARTICLE: 911IU

TITLE: Fluorescent dendrimers with a peptide cathepsin B cleavage

site for drug delivery applications

AUTHOR: Fuchs S; Otto H (Reprint); Jehle S; Henklein P; Schluter A

D

CORPORATE SOURCE: Free Univ Berlin, Inst Chem Biochem, Thielallee 63,

D-14195 Berlin, Germany (Reprint); Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; Free Univ Berlin, Inst Chem Organ Chem, D-14195 Berlin, Germany; Humboldt Univ, Fak Med, Univ Klinikum Charite, D-10098 Berlin,

Germany

hotto@chemie.fu-berlin.de; peter.henklein@charite.de

COUNTRY OF AUTHOR: Germany

SOURCE: CHEMICAL COMMUNICATIONS, (2005) No. 14, pp. 1830-1832.

ISSN: 1359-7345.

PUBLISHER: ROYAL SOC CHEMISTRY, THOMAS GRAHAM HOUSE, SCIENCE PARK,

MILTON RD, CAMBRIDGE CB4 OWF, CAMBS, ENGLAND.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 35

ENTRY DATE: Entered STN: 14 Apr 2005

Last Updated on STN: 14 Apr 2005

ABSTRACT:

The synthesis of a multifunctionally equipped first generation (G1) dendrimer carrying a pentapeptide with a cathepsin B cleavage site, chelating ligands for Pt2+-complexation, and a dansyl fluorescence marker is described and an investigation of its cellular uptake as well as intracellular localization by confocal fluorescence microscopy reported.

CATEGORY: CHEMISTRY, MULTIDISCIPLINARY

SUPPL. TERM PLUS: IN-VITRO; CYSTEINE PROTEASES; ANTITUMOR-ACTIVITY;

PAMAM DENDRIMERS; HPMA COPOLYMERS; VIVO;

OLIGONUCLEOTIDES; DOXORUBICIN; SYSTEMS; DESIGN

REFERENCE(S):

Referenced Author (RAU)	(RPY) (RVL)) (RPG)	(RWK)
AULENTA F	2003 39		•
BAKER J R	2004 245	167	METHOD MOL BIOL
BARLOS K	1991 37	513	INT J PEPT PROT RES
BOAS U	2004 33	143	CHEM SOC REV
BRYANT L H	2001 7	47	FOCUS BIOTECHNOL
CARPINO L A	1993 34	17829	TETRAHEDRON LETT
CLONINGER M J	2002 6	1742	CURR OPIN CHEM BIOL

CRESPO L	2002 124	8876	J AM CHEM SOC
DEJESUS O L P	2002 13	453	BIOCONJUGATE CHEM
DELONG R	1997 86	1762	J PHARM SCI
DENNIG J	2003 228	1227	TOP CURR CHEM
DENNIG J	2002 90	1339	REV MOL BIOTECHNOL
ESFAND R	2001 6	427	DRUG DISCOV TODAY
FUCHS S	2004 5	1167	CHEM-EUR J
GIANASI E	1999 35	1994	EUR J CANCER
JULYAN P J	1999 57	281	J CONTROL RELEASE
KIM Y	1998 2	733	CURR OPIN CHEM BIOL
KITAGAWA K	2001 66	1	J ORG CHEM
KOBAYASHI H	2003 2	1	MOL IMAGING
KOJIMA C	2003 36	2183	MACROMOLECULES
KRAUSE W	2000 210	261	TOP CURR CHEM
LECAILLE F	2002 102	14459	CHEM REV
LIU M	1998 79	1269	POLYM MAT SCI ENG
MALIK N	1999 10	1767	ANTI-CANCER DRUG
MUSIL D	1991 10	2321	EMBO J
QINTANA A	2002 19	1310	PHARM RES
QUALMANN B	1996 35	909	ANGEW CHEM INT EDIT
SERGHERAERT C	1986	1061	J CHEM SOC P1
SHABAT D	2004 10	12626	CHEM-EUR J
SLOANE B F	1982 42	980	CANCER RES
STEVELMANS S	1996 118	7398	J AM CHEM SOC
STIBIRA S E	2002 41	1329	ANGEW CHEM INT EDIT
TURK V	2001 20	4629	EMBO J
ULBRICH K	2003 87	33	J CONTROL RELEASE
YOO H	2000 28	14225	NUCLEIC ACIDS RES

L16 ANSWER 3 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2005:179844 SCISEARCH

THE GENUINE ARTICLE: 893SM

TITLE: Versatile peptide dendrimers for nucleic acid delivery
AUTHOR: Bayele H K (Reprint); Sakthivel T; O'Donell M; Pasi K J;

Wilderspin A F; Lee C A; Toth I; Florence A T

CORPORATE SOURCE: Univ Coll London, Dept Biochem & Mol Biol, Royal Free

Campus, London NW3 2PF, England (Reprint); Univ London, Sch Pharm, London WC1N 1AX, England; Univ Coll London,

Dept Haematol, London NW3 2PF, England

h.bayele@rfc.ucl.ac.uk

COUNTRY OF AUTHOR: England

SOURCE: JOURNAL OF PHARMACEUTICAL SCIENCES, (FEB 2005) Vol. 94,

No. 2, pp. 446-457. ISSN: 0022-3549.

PUBLISHER: JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

47

ENTRY DATE:

Entered STN: 24 Feb 2005

Last Updated on STN: 24 Feb 2005

ABSTRACT:

Dendrimers are nonviral vectors that have attracted interest on account of a number of features. They are structurally versatile because their size, shape, and surface charge can be selectively altered. Here we examine the functions of a new family of composite dendrimers that were synthesized with lipidic amino acid cores. These dendrimers are bifunctional because they are characterized by positively charged (lysine) modules for interaction with nucleic acids and neutral lipidic moieties for membrane lipid-bilayer transit. We assessed their structure-function correlations by a combination of molecular and biophysical techniques. Our assessment revealed an unexpected pleitropy

of functions subserved by these vectors that included plasmid and ***oligonucleotide*** delivery. We also generated a firefly luciferase cell line in which we could modulate luciferase activity by RNA interference. We found that these vectors could also mediate RNA suppression of luciferase expression by delivering double-stranded luciferase transcripts generated in vitro. The structural uniqueness of these lipidic peptide dendrimers coupled with their ease and specificity of assembly and the versatility in their choice of cargo, puts them in a new category of macromolecule carriers. These vectors, therefore, have potential applications as epigenetic modifiers of gene function. (C) 2004 Wiley-Liss, Inc. and the American Pharmacists Association. CATEGORY: CHEMISTRY, MEDICINAL; CHEMISTRY, MULTIDISCIPLINARY;

CHEMISTRY, MEDICINAL; CHEMISTRY, MULITUISCIPT

PHARMACOLOGY & PHARMACY

SUPPLEMENTARY TERM: dendrimer; gene delivery; vector; transfection; lipidic

peptide; versatile

SUPPL. TERM PLUS: DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; GENE-TRANSFER;

ANTISENSE OLIGONUCLEOTIDES; EFFICIENT

TRANSFECTION; **PAMAM** DENDRIMERS; MESSENGER-RNA; PLASMID DNA; IN-VITRO; NUCLEOCYTOPLASMIC TRANSPORT

REFERENCE(S):

Referenced Author	Year	l VOL	ARN PG	Referenced Work
				(RWK)
BEHR J P BELTINGER C BERNSTEIN E BIELINSKA A	1989	186	6982	P NATL ACAD SCI USA
BELTINGER C				J CLIN INVEST
BERNSTEIN E	2001	409	363	NATURE
BIELINSKA A	1996	24	2176	NUCLEIC ACIDS RES
BLESSING T	1998	95	1427	P NATL ACAD SCI USA
BLOOMFIELD V A	1996	6	334	CURR OPIN STRUC BIOL BIOCHIM BIOPHYS ACTA
	1988	950	221	BIOCHIM BIOPHYS ACTA
BOUSSIF O	1995	192	7297	P NATL ACAD SCI USA
CAMPBELL M J	1995		1027	BIOTECHNIQUES
CHU C J .	1990	17	824	PHARMACEUT RES P NATL ACAD SCI USA
CLEVER J	1991	88	7333	P NATL ACAD SCI USA
COLIGE A DEAN N M EICHMAN J D	1993	32	7	BIOCHEMISTRY-US
DEAN N M	1994			J BIOL CHEM
EICHMAN J D	2002			DENDRIMERS OTHER DEN
ELBASHIR S M	2001	20	6877	EMBO J
ELBASHIR S M		411		NATURE
ELBASHIR S M	2001	15	•	GENE DEV
ESFAND R	2001	6	427	DRUG DISCOV TODAY
FIRE A			806	
FRITZ J D	1996	7		HUM GENE THER
				BIOCHEM BIOPH RES CO
GORLICH D			•	SCIENCE
GREBER U F	1998			SELF ASSEMBLING COMP
	1993			BIOCONJUGATE CHEM
KANEDA Y	1989	1243	•	SCIENCE
				HUM GENE THER
	1996			P NATL ACAD SCI USA
	1996			P NATL ACAD SCI USA
	1997	•	•	BIOTECHNIQUES
	1994			GENE THERAPEUTICS ME
OHNO M	1998	92	1327	CELL
	2002			P NATL ACAD SCI USA
				SCIENCE
	1994		647	BIOCONJUGATE CHEM
	1998	15	776	PHARMACEUT RES
	2001			GENE DEV
	1997	4	823	GENE THER
TARRASON G	1995	5	193	ANTISENSE RES DEV
	1990	129	138	ANTISENSE RES DEV ANGEW CHEM INT EDIT STP PHARMA SCI
TOTH I	1999	19	93	STP PHARMA SCI

TRUBETSKOY V S |1992 |1131 |311 |BIOCHIM BIOPHYS ACTA |1999 |13 |3191 |GENE DEV TUSCHL T |1993 |260 |1510 |SCIENCE WAGNER R W WAGNER E |1991 |88 |4255 | P NATL ACAD SCI USA WU G Y |1988 |27 |887 |BIOCHEMISTRY-US 12000 128 |4225 | NUCLEIC ACIDS RES YOO H ZAMORE P D |2000 |101 |25 ICELL

L16 ANSWER 4 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

DUPLICATE 1 on STN

ACCESSION NUMBER: 2005069953 EMBASE

Real-time detection and efficacy of antisense TITLE:

oligonucleotides delivered by PAMAM

dendrimers in living cells.

Maksimenko A.; Helin V.; Bertrand J.R.; Gottikh M.; Malvy AUTHOR:

CORPORATE SOURCE: A. Maksimenko, Bioalliance Pharma SA, 59, boulevard

M.-Valin, 75015 Paris, France.

andrei.maksimenko@bioalliancepharma.com

SOURCE:

Journal of Drug Delivery Science and Technology, (2005)

Vol. 15, No. 1, pp. 75-79.

Refs: 8

ISSN: 1157-1489 CODEN: JDDSAL

France COUNTRY:

DOCUMENT TYPE: Journal; Article 004 Microbiology Journal; Article FILE SEGMENT:

029 Clinical Biochemistry

LANGUAGE: English SUMMARY LANGUAGE: English

Entered STN: 20050224 ENTRY DATE:

Last Updated on STN: 20050224

ABSTRACT: The aim of the present investigation was to study the behavior of ***PAMAM*** dendrimer-nucleic acid complexes in vitro and living cells. We demonstrated the rapid and sensitive detection of mRNA in living cells using molecular beacon pair, one with a donor and the other with a quenching fluorophore that hybridises to adjacent regions on the same mRNA target, resulting in fluorescence resonance energy transfer (FRET). The molecular beacon was composed of a 13-nt loop structure containing the antisense sequence that can hybridise with the AUG translational start site of the Friend env gene. It was shown that SuperFect may stimulate the antisense ON-RNA hybridisation. The secondary structure of antisense ***oligonucleotide*** was optimized. An antisense sequence-specific inhibition of 75% was obtained for one reporter gene with a stem-loop ODN containing four phosphorothioate groups, two at each end.

Medical Descriptors: CONTROLLED TERM:

> *molecular beacon *gene delivery system

HeLa cell plasmid synthesis biotechnology

genetic transfection gene expression

flow cytometry enzyme assay

fluorescence resonance energy transfer

gene targeting

human human cell article

Drug Descriptors:

*dendrimer

*antisense oligonucleotide

*polymer messenger RNA

DNA

beta galactosidase

green fluorescent protein

CAS REGISTRY NO.: (DNA) 9007-49-2

L16 ANSWER 5 OF 41 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

DUPLICATE 2

ACCESSION NUMBER: 2005:176017 BIOSIS PREV200500173042 DOCUMENT NUMBER:

Synthesis and functional evaluation of DNA-assembled TITLE:

polyamidoamine dendrimer clusters for cancer cell-specific

targeting.

Choi, Youngseon; Thomas, Thommey; Kotlyar, Alina; Islam, AUTHOR(S):

Mohammad T.; Baker, James R. Jr. [Reprint Author]

CORPORATE SOURCE: Sch EngnDept Biochem Engn, Univ Michigan, Ann Arbor, MI,

48109, USA

jbakerjr@umich.edu

Chemistry & Biology (Cambridge), (January 2005) Vol. 12, SOURCE:

No. 1, pp. 35-43. print.

ISSN: 1074-5521.

· DOCUMENT TYPE:

Article LANGUAGE: English

ENTRY DATE:

Entered STN: 4 May 2005

Last Updated on STN: 4 May 2005

ABSTRACT: We sought to produce dendrimers conjugated to different biofunctional moieties (fluorescein (FITC) and folic acid (FA)), and then link them together using complementary DNA oligonucleotides to produce clustered

molecules that target cancer cells that overexpress the high-affinity folate

receptor. Amine-terminated, generation 5 polyamidoamine (G5 PAMAM)

dendrimers are first partially acetylated and then conjugated with FITC or FA, followed by the covalent attachment of complementary, 5'-phosphate-modified

34-base-long oligonucleotides. Hybridization of these

oligonucleotide conjugates led to the self-assembly of the FITC-and FA-conjugated dendrimers. In vitro studies of the DNA-linked dendrimer clusters indicated specific binding to KB cells expressing the folate receptor. Confocal microscopy also showed the internalization of the dendrimer cluster. These results demonstrate the ability to design and produce supramolecular arrays of dendrimers using oligonucleotide bridges. This will also allow for further development of DNA-linked dendrimer clusters as imaging agents and therapeutics.

CONCEPT CODE:

Biochemistry studies - General Biochemistry studies - Vitamins

Pathology - Diagnostic 12504 Pathology - Therapy 12512 Pharmacology - General 22002

Pharmacology - Clinical pharmacology 22005

Pharmacology - Blood and hematopoietic agents Neoplasms - Pathology, clinical aspects and systemic

24004 effects

Neoplasms - Therapeutic agents and therapy 24008

INDEX TERMS:

Major Concepts

Pharmacology; Tumor Biology

INDEX TERMS:

Diseases

cancer: neoplastic disease, drug therapy, therapy

Neoplasms (MeSH)

INDEX TERMS:

Chemicals & Biochemicals

amine-terminated, generated 5 polyamidoamine dendrimer:

antineoplastic-drug; complementary DNA

oligonucleotide; fluorescein: diagnostic-drug; folate receptor; folic acid: hematinic-drug,

hematologic-drug, vitamin-drug

INDEX TERMS:

Methods & Equipment

confocal microscopy: imaging and microscopy techniques,

laboratory techniques

ORGANISM:

Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

KB cell line (cell line)

Taxa Notes

Animals, Chordates, Humans, Mammals, Primates,

Vertebrates

REGISTRY NUMBER:

2321-07-5 (fluorescein) 59-30-3 (folic acid)

L16 ANSWER 6 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER:

2004:437828 SCISEARCH

THE GENUINE ARTICLE: 816YO

ים זיידי.

Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the

presence of polypropylenimine dendrimers

AUTHOR:

Santhakumaran L M; Thomas T; Thomas T J (Reprint)

CORPORATE SOURCE:

Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, 125 Paterson St, CAB 7090, New Brunswick, NJ 08903 USA (Reprint); Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA

COUNTRY OF AUTHOR:

SOURCE:

NUCLEIC ACIDS RESEARCH, (APR 2004) Vol. 32, No. 7, pp.

2102-2112.

ISSN: 0305-1048.

PUBLISHER:

OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP,

ENGLAND.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

47

ENTRY DATE:

Entered STN: 28 May 2004

Last Updated on STN: 28 May 2004

ABSTRACT:

We used polypropylenimine dendrimers for delivering a 31 nt triplex-forming ***oligonucleotide*** (ODN) in breast, prostate and ovarian cancer cell lines, using P-32-labeled ODN. Dendrimers enhanced the uptake of ODN by similar to14-fold in MDA-MB-231 breast cancer cells, compared with control ODN Dendrimers exerted their effect in a concentration- and molecular weight-dependent manner, with generation 4 (G-4) dendrimer having maximum efficacy: A similar increase in ODN uptake was found with MCF-7 and SK-BR-3 (breast), LNCaP (prostate) and SK-OV-3 (ovarian) cancer cells. The dendrimers had no significant effect on cell viability at concentrations at which maximum ODN uptake occurred. [H-3] Thymidine incorporation showed that complexing the ODN with G-4 significantly increased the growth-inhibitory effect of the ODN. Western blot analysis showed a significant 65% reduction of c-myc protein level in ODN-G-4 treated cells compared with that of ODN-treated/control cells. electrophoretic analysis showed that ODN remained intact in cells even after 48 h of treatment. The hydrodynamic radii of nanoparticles formed from ODN in the presence of the dendrimers were in the range of 130-280 nm, as determined by dynamic laser light scattering. Taken together, our results indicate that polypropylenimine dendrimers might be useful vehicles for delivering therapeutic oligonucleotides in cancer cells.

CATEGORY:

BIOCHEMISTRY & MOLECULAR BIOLOGY

SUPPL. TERM PLUS:

LASER-LIGHT SCATTERING; NONVIRAL GENE DELIVERY;

ANTISENSE OLIGONUCLEOTIDES; DNA

DELIVERY; IN-VITRO; TRANSFECTION EFFICIENCY; POTENTIAL

APPLICATIONS; POLYAMINE ANALOGS; PAMAM

DENDRIMERS; MOLECULAR-WEIGHT

REFERENCE(S):

REFERENCE(S):	l Vaan	LVOT	LADNI DC	Deferenced Work
Referenced Author			(RPG)	
(RAU)				•
BAF7A T				BIOCHEMISTRY-US
	1996	121	12176	NUCLEIC ACIDS RES
BUTELLA V	1997	123 18		HUM GENE THER
BOUSSIF O	1995	192		P NATL ACAD SCI USA
BRAASCH, D A				BIOCHEMISTRY-US
				PHARMACEUT RES
CHOI Y S				
COONEY M	11988	1241	1456	NANO LETT SCIENCE
	2002	19	1743	GENE THER
				ANGEW CHEM INT EDIT
	•	•	•	VIRUS RES
EVANS H M	12003	191	1075501	PHYS REV LETT
FILION M C	11998	1162	1159	INT J PHARM
				PHARMACEUT RES
	-		712	*
GODBEY W T	11999	145	1268	J BIOMED MATER RES
HAENSLER J	1993	14	1372	BIOCONJUGATE CHEM
HERMISTON T W	12002	19	11022	CANCER GENE THER
				BBA-PROTEIN STRUCT M
KIRCHEIS R	2001	•	•	ADV DRUG DELIVER REV
	•	•		CANCER RES
KOBAYASHI H	12003	12	11	MOL IMAGING
KOBAYASHI H KOPER G J M	11997	1119	 I 6512	J AM CHEM SOC
	•	•	•	ANNU REV PHARMACOL
		•		BIOCONJUGATE CHEM
LIU C M	12002	180	1620	
LIU G	2001	1276	13479	J MOL MED-JMM J BIOL CHEM
				J PHARM SCI
	-	•	•	J CONTROL RELEASE
NEWKOME G R	2001	İ	i	DENDRIMERS DENDRONS
NGUYEN T T	12002	189	018101	DENDRIMERS DENDRONS PHYS REV LETT J BIOMED MATER RES
ROBERTS J C	1996	I 30	I 53	J BIOMED MATER RES
SAMINATHAN M	12002	130	13722	NUCLEIC ACIDS RES
		•	•	J CLIN INVEST
	2000	•	•	INT J PHARM
	1997	14	823	GENE THER
	1995	i 7	123	GENE THER J BIOMAT SCI-POLYM E
	•			BIOCHEMISTRY-US
	1994	•		BREAST CANCER RES TR
				POLYM J
	•	•	•	BIOCHEMISTRY-US
		•		NUCLEIC ACIDS RES
		•	•	BIOCHEMISTRY-US
	12000	•	•	NUCLEIC ACIDS RES
	-	•	•	PHARMACEUT RES
		•	•	ADV DRUG DELIVER REV
	2002	•	•	BIOPHYS J
		,	, =	

L16 ANSWER 7 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2005:4089 SCISEARCH

THE GENUINE ARTICLE: 877PO

TITLE: Preparation of oligonucleotide arrays with

high-density DNA deposition and high hybridization

efficiency

AUTHOR: Park J W; Jung Y; Jung Y H; Seo J S; Lee Y (Reprint)

CORPORATE SOURCE: Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea (Reprint); Korea Adv Inst Sci & Technol, Ctr

Mol Design & Synth, Taejon 305701, South Korea; Macrogene Inc, Seoul 110061, South Korea; Seoul Natl Univ, Coll Med,

Dept Biochem & Mol Biol, Seoul 110744, South Korea

Younghoon.Lee@kaist.ac.kr

COUNTRY OF AUTHOR:

JTHOR: South Korea

SOURCE: BULLETIN OF THE KOREAN CHEMICAL SOCIETY, (20 NOV 2004)

Vol. 25, No. 11, pp. 1667-1670.

ISSN: 0253-2964.

PUBLISHER: KOREAN CHEMICAL SOC, 635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL

135-703, SOUTH KOREA.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

28

ENTRY DATE:

Entered STN: 13 Jan 2005

Last Updated on STN: 13 Jan 2005

ABSTRACT:

In DNA microarray produced by DNA-deposition technology, DNA-immobilization and -hybridization yields on a solid support are most important factors for its accuracy and sensitivity. We have developed a dendrimeric support using silylated aldehyde slides and polyamidoamine (PAMAM) dendrimers. ***oligonucleotide*** array was prepared through a crosslinking between the dendrimeric support and an oligonucleotide. Both DNA-immobilization and -hybridization yields on the solid support increased by the modification The increase of the immobilization and hybridization with the dendrimers. efficiency seems to result from a three-dimensional arrangement of the attached ***oligonucleotide.*** Therefore, our dendrimeric support may provide a simple and efficient solution to the preparation of DNA microarrays with high-density DNA-deposition and high hybridization efficiency.

CATEGORY: CHEMISTRY, MULTIDISCIPLINARY

SUPPLEMENTARY TERM: dendrimer; DNA chip; hybridization; immobilization;

oligonucleotide

SUPPL. TERM PLUS: DENDRIMER MONOLAYERS; IMMOBILIZATION; MICROARRAYS;

SUPPORTS; SURFACE; MICROCHIPS; ATTACHMENT; CHEMISTRY;

SEQUENCE; PROBE

REFERENCE(S):

	•	•	ARN PG (RPG)	Referenced Work (RWK)
				, , ,
AFANASSIEV V	2000		E66	NUCLEIC ACIDS RES
BEIER M	12000	128	E11	NUCLEIC ACIDS RES
BENTERS R	2002	130	e10	NUCLEIC ACIDS RES
BENTERS R	2001	2	686	CHEMBIOCHEM
BLIZNYUK V N	1998	139	15249	POLYMER
CHEN W	2000	116	115	LANGMUIR
CHRISEY L A	1996	24	3031	NUCLEIC ACIDS RES
GUO Z	1994	22	5456	NUCLEIC ACIDS RES
GUSCHIN D	1997	250	203	ANAL BIOCHEM
HACIA J G	1998	126	4975	NUCLEIC ACIDS RES
JANG N H	2002	123	1790	B KOR CHEM SOC
KIM S	1997	1407	353	FEBS LETT
KUMAR A	2000	128	E71	NUCLEIC ACIDS RES

LIPSHUTZ R J	1999 21	120	NAT GENET S
MANSFIELD M L	1996 37	3835	POLYMER
MATSON R S	1994 217	306	ANAL BIOCHEM
MATTHEWS O A	1997 23	1	PROG POLYM SCI
PROUDNIKOV D	1998 259	34	ANAL BIOCHEM
RAGHAVACHARI N	2003 312	101	ANAL BIOCHEM
REHMAN F N	1999 27	1649	NUCLEIC ACIDS RES
SABANAYAGAM C R	2000 28	E33	NUCLEIC ACIDS RES
SALO H	1999 10	815	BIOCONJUGATE CHEM
SAMBROOK J	1988	1	MOL CLONING LAB MANU
SHCHEPINOV M S	1997 25	1155	NUCLEIC ACIDS RES
SHCHEPINOV M S	1997 25	14447	NUCLEIC ACIDS RES
TOKUHISA H	1998 120	14492	J AM CHEM SOC
TOMALIA D A	1990 29	138	ANGEW CHEM INT EDIT
YOSHIOKA M	1991 566	361	J CHROMATOGR-BIOMED

L16 ANSWER 8 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2004:868459 SCISEARCH

THE GENUINE ARTICLE: 856NT

TITLE: Application of Starburst (TM) PAMAM dendrimers

as DNA carriers in vitro

AUTHOR: Guo C Y; Wang H (Reprint); Lin Y H; Cai Q L

CORPORATE SOURCE: Chinese Acad Med Sci, Inst Basic Med Sci, Dept Mol

Parasitol, Beijing 100005, Peoples R China (Reprint); Peking Union Med Coll, Beijing 100005, Peoples R China

hengwang@pumc.edu.cn

COUNTRY OF AUTHOR: Peoples R China

SOURCE: PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, (SEP 2004) Vol.

31, No. 9, pp. 804-811.

ISSN: 1000-3282.

PUBLISHER: SCIENCE CHINA PRESS, 16 DONGHUANGCHENGGEN NORTH ST,

BEIJING 100717, PEOPLES R CHINA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: Chinese

REFERENCE COUNT: 35

ENTRY DATE: Entered STN: 22 Oct 2004

Last Updated on STN: 22 Oct 2004

ABSTRACT:

Starburst(TM) PAMAM dendrimers are novel polymers with a molecular architecture characterized by regular, dentritic branching with radial Having high density of positive charges on their surfaces in symmetry. physiological condition because of the protonization of amino groups on the surfaces, and complexing with genetic materials on the basis of electrostatic interactions, those Starburst(TM) PAMAM dendrimers deliver genes into In order to characterize the potential effects of Starburst (TM) alive cells. ***PAMAM*** dendrimers as a carrier for DNA transfection, six different types generations of Starburst(TM) PAMAM dendrimers were investigated for their capabilities in binding DNA, and the effects on both DNA transfection and maintenance of cell viability was evaluated in vitro. The experiments demonstrated that it was the full generations but not the half generations of Starburst(TM) PAMAM dendrimer could transfect eukaryotic cells The dendrimer/DNA complexes were very steady, no dissociation of efficiently. the complexes was detectable in a large scope of pH (2 similar to 10). complexation of Starburst(TM) PAMAM dendrimer and DNA prevent the reaction that endonuclease dissociates the DNA. In a certain range of dendrimers to DNA charge ratios, the Starburst(TM) PAMAM dendrimer with higher generations showed much better transfection efficiency than those The transfection efficiency was also variable in with lower generations. different cell lines. Starburst (TM) PAMAM dendrimers complexing with DNA have no or very low cytotoxicity at the concentrations effective for DNA transfection (less than or equal to 1. $3 \times 10(-1)$ g/L).

cytotoxicity of Starburst(TM) **PAMAM** dendrimers without binding DNA could be detected at a lower concentration. The results demonstrated that Starburst(TM) **PAMAM** dendrimers, as a novel type of low toxicity, non-viral DNA delivery vehicle, had promising potential to mediate DNA transfection in vitro. It provide primary experimental basis for the application of the nanometer material-Starburst(TM) **PAMAM** dendrimers in vivo as DNA delivery carrier.

CATEGORY: BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS SUPPLEMENTARY TERM: DNA delivery; Starburst (TM) **PAMAM** dendrimers;

transfection; nonviral vectors

SUPPL. TERM PLUS: GENE DELIVERY; POLYAMIDOAMINE DENDRIMERS;

ANTISENSE OLIGODEOXYNUCLEOTIDES; DENDRITIC

MACROMOLECULES; EFFICIENT TRANSFER;

OLIGONUCLEOTIDES; TRANSFECTION; COMPLEXES;

POLYMERS; VACCINE

REFERENCE(S):

Referenced Author	Year	VOL	ARN PG	Referenced Work
(RAU)			(RPG)	·
BIELINSKA A U	1997			BBA-GENE STRUCT EXPR
BIELINSKA A U	1999	10	843	BIOCONJUGATE CHEM
BRAZEAU G A	1998	15	680	PHARMACEUT RES
BRODY S L	1994	716	90	ANN NY ACAD SCI
BRONTE V	2001	1	53	CURR GENE THER
DELONG R	1997	86	762	J PHARM SCI
DUNLAP D D	1997	25	3095	NUCLEIC ACIDS RES
EICHMAN J D	2000	3	232	PHARM SCI TECHNOL TO
ELSAYED M	2001		•	PHARMACEUT RES
FERKOL T	1993	92	2394	J CLIN INVEST
FISCHER D	1999	16	1272	PHARM RES
GAO X	1995	12	710	GENE THER
GAO X	1996	•		BIOCHEMISTRY-US
GODBEY W T	1999	196	•	P NATL ACAD SCI USA
HAWKER C J	1990	112	7638	J AM CHEM SOC
HELIN V	1999	18	1721	NUCLEOS NUCLEOT
HUGHES J A	1996	13	404	PHARMACEUT RES
KOWALCZYK D W	1999	55	751	CELL MOL LIFE SCI
KUKOWSKALATALLO J F	1999	264	253	BIOCHEM BIOPH RES CO
KUKOWSKALATALLO J F	1996	93	4897	P NATL ACAD SCI USA
LEWIS J G	1996	193	3176	P NATL ACAD SCI USA
LUNDSTROM K	2001	1	19	CURR GENE THER
	2001		832	PROG BIOCHEM BIOPHYS
	2002		•	J AM ACAD NURSE PRAC
QIN L H	1998	19	553	HUM GENE THER
RAJUR S B	1997	18	935	BIOCONJUGATE CHEM
ROBINSON H L	2002	12	239	NAT REV IMMUNOL
SHAH D S	2000	•	41	INT J PHARM
SINGH P	1994	40	1845	CLIN CHEM
TANG M X	1997	4	823	GENE THER
TOMALIA D A	1985	17	117	POLYM J
WANG K R	1998	1	1304	CELL BIOL
WOOLEY K L	1991	1113	14252	J AM CHEM SOC
YAMAMOTO S	12002		37	JPN J INFECT DIS
Y00 H	12000	28	14225	NUCLEIC ACIDS RES
				-

L16 ANSWER 9 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:238753 SCISEARCH

THE GENUINE ARTICLE: 780MA

TITLE: Current status of delivery systems to improve target

efficacy of oligonucleotides

AUTHOR: Shoji Y (Reprint); Nakashima H

CORPORATE SOURCE: St Marianna Univ, Sch Med, Dept Microbiol, Miyamae Ku,

2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan (Reprint);

St Marianna Univ, Sch Med, Dept Microbiol, Miyamae Ku,

Kawasaki, Kanagawa 2168511, Japan

COUNTRY OF AUTHOR:

Japan

SOURCE:

CURRENT PHARMACEUTICAL DESIGN, (2004) Vol. 10, No. 7, pp.

785-796.

ISSN: 1381-6128.

PUBLISHER:

BENTHAM SCIENCE PUBL LTD, PO BOX 1673, 1200 BR HILVERSUM,

NETHERLANDS.

DOCUMENT TYPE:

General Review; Journal

LANGUAGE:

English

REFERENCE COUNT:

120

ENTRY DATE:

Entered STN: 19 Mar 2004

Last Updated on STN: 19 Mar 2004

ABSTRACT:

The tragic failure of gene therapy resulted in rolling back the research of Because of the poor delivery of gene-based medicines, gene-based medicine. such as antisense oligonucleotides, ribozyme, triplex, or gene both in vitro and in vivo, further development of gene-based medicines as therapeutic agents have stagnated. Although the delivery system plays a critical role in the overall efficacy of oligonucleotides, inappropriate target selection, improper evaluation methods and misinterpretation of results often caused the pessimistic view. Still. the decoding of the whole human genome has rekindled the enthusiastic development of delivery. tools for gene-based medicine. We would like to focus on the newly developed delivery systems mainly for antisense There are two ways to improve ***oligonucleotides*** in this article. delivery efficacy of antisense oligonucleotides: One is the chemical modification of the antisense oligonucleotide The other way is by means of delivery vehicles, such as cationic liposomes, synthetic polymers, or non-viral vectors. We will review the current status of delivery vehicles both in vitro and in vivo. efficiency depends on the oligonucleotides' chemistry, length, size, net charge, cell/tissue type and administration route. It is difficult to deduce a common rule that affects delivery efficiency. Some cells like keratinocytes rapidly internalize oligonucleotides without a delivery system, which is contrary to common belief. Although we cannot extensively cover all reports, we will summarize several experiments with delivery system in vitro and in vivo. We will then address the possible factors promoting the efficient delivery of oligonucleotides.

CATEGORY: PHARMACOLOGY & PHARMACY

SUPPLEMENTARY TERM: oligonucleotides; delivery system; gene-based

medicine

SUPPL. TERM PLUS:

PHOSPHOROTHIOATE ANTISENSE

OLIGONUCLEOTIDES; MIXED-BACKBONE

OLIGONUCLEOTIDES; CELLULAR UPTAKE; IN-VIVO; C-MYC;

POLYALKYLCYANOACRYLATE NANOPARTICLES; TISSUE DISTRIBUTION;

PHYSICOCHEMICAL PROPERTIES; INTRACELLULAR DELIVERY;

PAMAM DENDRIMERS

REFERENCE(S):

Referenced Author (RAU)	(RPY) (RVL)	(RPG)	· · · · · · · · · · · · · · · · · · ·
AGRAWAL S	·	•	BIOCHEM PHARMACOL
AGRAWAL S	1997 94 2	2620 F	NATL ACAD SCI USA
AGRAWAL S	1995 287	7 - 10	CLIN PHARMACOKINET
AKHTAR S	1992 2 1	139 1	RENDS CELL BIOL
ALAHARI S K	1996 50 8	808 M	OL PHARMACOL
ANDERSON J M	1995 269 4	467 <i>P</i>	AM J PHYSIOL
ARIMA H	1997 86 4	438 5	PHARM SCI
ARORA V	2002 91 1	1009 3	PHARM SCI

BELTINGER C BENIMETSKAYA L	11995		1814 414	J CLIN INVEST NAT MED
BIELINSKA A	1997 1996		12176	NUCLEIC ACIDS RES
BOADO R J	11994		1406	BIOCONJUGATE CHEM
BOCHOT A	1998	İ	1089	P 2 WORLD APGI APV M
BOCHOT A	•	19	131	PROG RETIN EYE RES
BOCHOT A	1998	15	1364	PHARMACEUT RES
BOCHOT A	•	6	309	J DRUG TARGET
BOFFA L C	•	•	2258	CANCER RES
BOUSSIF O	•	-		P NATL ACAD SCI USA J INVEST DERMATOL
BRAND R M BRAND R M	12001	•	1	ANTISENSE NUCLEIC A
BUDKER V	•		176	J GENE MED
CHAVANY C	1994	•	1370	PHARMACEUT RES
CHAVANY C	1994			PHARMACEUT RES
CHAVANY C	1992			PHARMACEUT RES
CHOCHUNG Y S CROOKE S T	2002 1996		934 923	CURR OPIN INVEST DRU J PHARMACOL EXP THER
DANCEY J E			12259	CURR PHARM DESIGN
DEFIFE K M	2002			CURR OPIN DRUG DI DE
DELIE F	2001			INT J PHARM
DELONG R K	1999		•	NUCLEIC ACIDS RES
DELONG R	11997	•	1762	J PHARM SCI
DESMET M D	•		1189	OCUL IMMUNOL INFLAMM
DESMIDT P C DHEUR S	1991 1999			NUCLEIC ACIDS RES ANTISENSE NUCLEIC A
EDELMAN E R	11995			CIRC RES
ELIASSARI A	1994		325	COLLOID SURF A
EMILE C	1996		•	DRUG DELIV
FATTAL E	11998			J CONTROL RELEASE
FELGNER P L	•		•	NATURE
FERREIRO M G FRITZ H	2002 1997	-	755 272	PHARMACEUT RES J COLLOID INTERF SCI
GARCIACHAUMONT C	12000			PHARMACOL THERAPEUT
GEARY R S	2001	12	562	CURR OPIN INVEST NEW
GONZALEZ F M	12001		381	J CONTROL RELEASE
GOODCHILD J	1990		165	BIOCONJUGATE CHEM
GRAHAM M J HENRY K	1998 1987			J PHARMACOL EXP THER AM J OPHTHALMOL
HENRY S P	1997		•	ANTISENSE NUCLEIC A
	1996		•	PHARMACEUT RES
ISLAM A	2000		,	J DRUG TARGET
	1992			ANTISENSE RES DEV
JEONG J H	2003		•	BIOCONJUGATE CHEM
	1998 1999		•	J DRUG TARGET N-S ARCH PHARMACOL
KHAN A	12000		319	J DRUG TARGET
	11999			ACTA BIOCHIM POL
KRIEG A M	1995			NATURE
	1996			P NATL ACAD SCI USA
LAKTIONOV P P	1999		2315 99	NUCLEIC ACIDS RES
LAMBERT G LEWIS J G	2001 1996			ADV DRUG DELIVER REV P NATL ACAD SCI USA
LIEB L M	11997		-	J PHARM SCI
	1988			CURR TOP MICROBIOL
MAESAKI S	2002	-		CURR PHARM DESIGN
MANOHARAN M	2002		-	ANTISENSE NUCLEIC A
	1998 1996		•	NUCLEIC ACIDS RES J PHARMACOL EXP THER
	11996		-	PHARMACEUT RES
	11994	-	-	J INVEST DERMATOL
NIELSEN P E	11995	-	167	ANNU REV BIOPH BIOM
_				· ·
				,

```
|1993 |101 |727
NOONBERG S B
                                                           | J INVEST DERMATOL
                                                 | 727
| 261
| 915
| 503
| 288
                                |1999 |18
                                                           |CURR EYE RES
OGATA N
OLDENBURG K R
                              |1995 |84
                                                           IJ PHARM SCI
OPALINSKA J B
                               |2002 |1
                                                           INAT REV DRUG DISCOV
                               |2001 |3
                                                 1288
                                                           | CURR OPIN MOL THER
ORR R M
PANDOLFI D
                            | | 1999 | 18
                                                 |2051 |NUCLEOS NUCLEOT
PEIR P
                               |1999 |1418 |71 | |BIOCHIM BIOPHYS ACTA
                               |1983 |
                                                 |113
                                                           |TARGET DRUGS
PITHA J
PLENAT F
                              |1995 |147 |124 |AM J PATHOL
PUTNEY S D
                              |1999 |9
                                                 |451 |ANTISENSE NUCLEIC A
                              |1991 |1
RAHMAN M A
                                                 |319 |ANTISENSE RES DEV
RAOOF A A
                              |2002 |17
                                                 |131 | EUR J PHARM SCI
                              |2001 |53 |235 |ADV DRUG DELIVER REV
REDENTI E
REGNIER V
                              |1998 |15
                                                 |1596 | PHARMACEUT RES
RIFAI A
                               |1996 |149 |717 |AM J PATHOL
SARMIENTO U M
SCHWAB G
                               |1994 |4
                                                 199
                                                         ANTISENSE RES DEV
                                |1994 |91
                                                 |10460 | P NATL ACAD SCI USA
                             | 1994 | 5 | 55 | ANN ONCOL

| 2002 | 87 | 119 | BRIT J CANCER

| 1998 | 5 | 261 | J DRUG TARGET

| 1996 | 40 | 1670 | ANTIMICROB AGENTS CH
SCHWAB G
SHI W
SHOJI Y
SHOJI Y
SOMIA N
                            |2000 |1
|1993 |32
                                               |91 | NAT REV GENET
|4855 | BIOCHEMISTRY-US
STEIN C A
STEIN C A
STEWART A J
SUMMERTON J
TAKAKURA Y
TOJO K J
                              |1998 |8
                                               |129 |ANTISENSE NUCLEIC A
|1487 |MOL PHARMACOL
                              | 1996 | 50 | 1487 | MOL PHARMACOL | 1997 | 7 | 187 | ANTISENSE NUCLEIC A
                              |2002 |10
                                                 |99 |J DRUG TARGET
                            | 2002 | 10 | 99 | J DRUG TARGET | 1994 | 123 | 59 | MATH BIOSCI | 1999 | 32 | 51 | SYNAPSE | 2003 | 10 | 100 | GENE THER | 1994 | 1197 | 95 | BBA-REV BIOMEMBRANES | 1993 | 327 | 271 | FEBS LETT | 1998 | 87 | 387 | J PHARM SCI | 1999 | 96 | 13989 | P NATL ACAD SCI USA | 2001 | 1 | 177 | CURR CANC DRUG TARGE | 1998 | 9 | 749 | BIOCONJUGATE CHEM | 1999 | 1 | 458 | CURR OPIN MOL THER | 1996 | 24 | 655 | NUCLEIC ACIDS RES | 1998 | 290 | 119 | ARCH DERMATOL RES | 1989 | 86 | 6454 | P NATL ACAD SCI USA
TREMBLAY M
TURTURRO F
VLASSOV V V
VLASSOV V V
WALKER T L
WANG H
WANG H
WANG L X
WEBB M S
WEI Z P
WIGENS M
YAKUBOV L A
                              |1989 |86 |6454 |P NATL ACAD SCI USA
                             YANAGIHARA K
YAZAKI T
YOO H
ZAMECNIF P C
ZELPHATI O
ZELPHATI O
                              |1995 |212 |286 |BIOCHEM BIOPH RES CO
|1998 |8 |3269 |BIOORG MED CHEM LETT
ZEWERT T E
ZHOU W Q
ZHU X
                               |2002 |23
                                                 |2683 |BIOMATERIALS
ZON G
                               |1988 |5 |539
                                                           | PHARMACEUT RES
```

L16 ANSWER 10 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:482199 SCISEARCH

USA

THE GENUINE ARTICLE: 820SQ

TITLE: Designed dendrimer syntheses by self-assembly of

single-site, ssDNA functionalized dendrons

AUTHOR: DeMattei C R; Huang B H; Tomalia D A (Reprint)

deposition.

CORPORATE SOURCE: Cent Michigan Univ, Dendrit NanoTechnol Inc, 2625 Denison Dr, Mt Pleasant, MI 48858 USA (Reprint); Cent Michigan

Univ, Dendrit NanoTechnol Inc, Mt Pleasant, MI 48858 USA

COUNTRY OF AUTHOR:

SOURCE: NANO LETTERS, (MAY 2004) Vol. 4, No. 5, pp. 771-777.

ISSN: 1530-6984.

PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036

USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 57

ENTRY DATE: Entered STN: 11 Jun 2004

Last Updated on STN: 11 Jun 2004

ABSTRACT:

Single site, functionalized, single stranded (ssDNA) dendri-poly(amidoamine) (PAMAM) di-dendrons have been synthesized by covalently conjugating complementary 32 base pair oligonucleotides to single-site, thiol functionalized dendri-pamam di-dendrons possessing neutral or anionic surface groups. Combining these complementary (ss-DNA) functionalized ***PAMAM*** di-dendrons at appropriate assembly temperatures produced Watson-Crick base paired (dsDNA) cores, surrounded by four PAMAM These novel core-shell nanostructures represent a new class of precise monodisperse, linear-dendritic architectural copolymers. Using comparative gel electrophoresis, it was demonstrated that these self-assembled (di-dendron) dendrimers could be hemispherically differentiated as a function of surface chemistry as well as generational size. This new supramacromolecular approach offers a very facile and versatile strategy for the combinatorial design of size, shape, and surface substituents for both homogeneous and differentiated dendritic nanostructures.

CATEGORY: CHEMISTRY, MULTIDISCIPLINARY; MATERIALS SCIENCE,

MULTIDISCIPLINARY

SUPPL. TERM PLUS: DOUBLE-STRANDED DNA; IONIZATION MASS-SPECTROMETRY;

OLIGONUCLEOTIDE DENDRIMERS; POLYAMIDOAMINE

DENDRIMERS; DIRECTED SYNTHESIS; CHEMISTRY; POLYMERS;

SURFACE; SHAPE; MALDI

Referenced Author | Year | VOL | ARN PG | Referenced Work

(RAU)	(RPY)	(RVL)	(RPG)	•
	11996			NATURE
BROTHERS H M	1998	814	233	J CHROMATOGR A
CAO Y W	2001	123	7961	J AM CHEM SOC
CHOI Y S	2004	4	391	NANO LETT
CHOW H F	2003	159	3815	TETRAHEDRON
DUBIN P L	1993	635	51	J CHROMATOGR
DVORNIC P R	1995	98	403	MACROMOL SYMP
EICHMAN J D	2001	1	441	DENDRIMERS OTHER DEN
ESFAND R	2001	16	427	DRUG DISCOV TODAY
FRECHET J M J	2001			DENDRIMERS OTHER DEN
FRECHET J M J	1994	263	1710	SCIENCE
GOPIDAS K R	12003	125	6491	J AM CHEM SOC
GUO W H	12003	125	3901	J AM CHEM SOC
HECHT S	2001	40	174	ANGEW CHEM INT EDIT
HUDSON S D	1997	278	449	SCIENCE
HUMMELEN J C	1997	3	1489	CHEM-EUR J
KALLOS G J	1991	5	383	RAPID COMMUN MASS SP
KASAI S	2002	12	951	BIOORG MED CHEM LETT
KIRPEKAR F	1999	71	2334	ANAL CHEM
KUKOWSKALATALLO J F	1996	193	4897	P NATL ACAD SCI USA
LECCHI P	1995	16	972	J AM SOC MASS SPECTR
LI Z	2002	30	1558	NUCLEIC ACIDS RES
LITTLE D P	1997	169	323	INT J MASS SPECTROM
LIU L	12003	125	12110	J AM CHEM SOC
LOTHIANTOMALIA M K	1997	53	15495	TETRAHEDRON
LOWETH C J	1999	38	1808	ANGEW CHEM INT EDIT
MATTHEWS O A	1998	23	1	PROG POLYM SCI

```
MBINKYO J K N
                      |2001 |1
                                  1249
                                         ADV MATER
                      |1996 |382
                                  1607
                                         NATURE
MIRKIN C A
NEWKOME G R
                      |1996 |
                                         |DENDRITIC MOL
                                  1
NORDHOFF E
                      |1993 |21
                                  13347
                                         |NUCLEIC ACIDS RES
                      |1996 |118
                                  19855
                                         | J AM CHEM SOC
PERCEC V
PERCEC V
                      |1998 |391
                                  1161
                                         INATURE
SHCHEPINOV M S
                      |1999 |27
                                  |3035
                                         |NUCLEIC ACIDS RES
                      |1997 |25
                                  |4447 |NUCLEIC ACIDS RES
SHCHEPINOV M S
SINGH P
                      |2001 |
                                  |463
                                         | DENDRIMERS DENDRITIC
STORHOFF J J
                      11999 199
                                  |1849 | CHEM REV
                      |1989 |86
                                  |9084 | P NATL ACAD SCI USA
TAM J P
                      |2000 |289 |1757 |SCIENCE
TATON T A
TOMALIA D A
                      12003 1
                                         | HDB NANOSCIENCE ENG
                                  1
                      12003 159
                                  |3799 |TETRAHEDRON
TOMALIA D A
                      |1985 |17
TOMALIA D A
                                  1117
                                         | POLYM J
TOMALIA D A
                      |1993 |1
                                  |193
                                         |SUPRAMOL CHEM
                      |1996 |101
TOMALIA D A
                                  1243
                                         |MACROMOL SYMP
                      12002 | 40
TOMALIA D A
                                  |2719 |J POLYM SCI POL CHEM
                      12002 | 99
                                  |5081 | P NATL ACAD SCI USA
TOMALIA D A
TOMALIA D A
                      |1995 |272
                                  162
                                         |SCI AM
                      |1994 |6
                                  1529
                                         |ADV MATER
TOMALIA D A
                      [2000]
                                  1359
TOMALIA D A
                                         |SUPRAMOLECULAR POLYM
TOMALIA D A
                      |1990 |29
                                  1138
                                        |ANGEW CHEM INT EDIT
TURRO N J
                      |2001 |
                                  1309
                                         |DENDRIMERS OTHER DEN
WATKINS D M
                      |1997 |13
                                  |3136 |LANGMUIR
                                  |1536 |SCIENCE
WEI Y
                      |2002 |297
                      |2001 |40
                                  |1861 |ANGEW CHEM INT EDIT
WILLNER I
                      |1997 |97
ZENG F W
                                  |1681 | CHEM REV
                                  1239
ZHANG C
                      |2001 |
                                         | DENDRIMERS OTHER DEN
```

STN Patent No. (RPN)	Year Ref. (RPY)	Inventor/Assig (RIN)	nee Type 	Ref. Patent No. (RPN)
=======================================	= +==== +=====		=====+=====	+=========
US 6020457	2000 KLIMA	N L HZA	1	US 6020457

L16 ANSWER 11 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

ACCESSION NUMBER: 2004:285984 SCISEARCH

THE GENUINE ARTICLE: 803E0

TITLE: H-3 dendrimer nanoparticle organ/tumor distribution

AUTHOR: Nigavekar S S; Sung L Y; Llanes M; El-Jawahri A; Lawrence

T S; Becker C W; Balogh L; Khan M K (Reprint)

CORPORATE SOURCE: Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA

(Reprint); Univ Michigan, Michigan Mem Phoenix Project, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med,

Ctr Biol Nanotechnol, Ann Arbor, MI 48109 USA

COUNTRY OF AUTHOR: USA

SOURCE: PHARMACEUTICAL RESEARCH, (MAR 2004) Vol. 21, No. 3, pp.

476-483.

ISSN: 0724-8741.

PUBLISHER: KLUWER ACADEMIC/PLENUM PUBL, 233 SPRING ST, NEW YORK, NY

10013 USA.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

30

ENTRY DATE:

Entered STN: 2 Apr 2004

Last Updated on STN: 2 Apr 2004

ABSTRACT:

Purpose. To determine the in vivo biodistribution for differently charged poly(amidoamine) (PAMAM) dendrimers in B16 melanoma and DU145 human prostate cancer mouse tumor model systems.

Methods. Neutral (NSD) and positive surface charged (PSD) generation 5 (d

= 5 nm) **PAMAM** dendrimers were synthesized by using H-3-labeled acetic anhydride and tested in vivo. Dendrimer derivatives were injected intravenously, and their biodistribution was determined via liquid scintillation counting of tritium in tissue and excretory samples. Mice were also monitored for acute toxicity.

Results. Both PSD and NSD localized to major organs and tumor. Dendrimers cleared rapidly from blood, with deposition peaking at 1 h for most organs and stabilizing from 24 h to 7 days postinjection. Maximal excretion occurred via urine within 24 h postinjection. Neither dendrimer showed acute toxicity.

Conclusions. Changes in the net surface charge of polycationic ***PAMAMs*** modify their biodistribution. PSD deposition into tissues is higher than NSD, although the biodistribution trend is similar. Highest levels were found in lungs, liver, and kidney, followed by those in tumor, heart, pancreas, and spleen, while lowest levels were found in brain. These nanoparticles could have future utility as systemic biomedical delivery devices.

CATEGORY: CHEMISTRY, MULTIDISCIPLINARY; PHARMACOLOGY & PHARMACY

SUPPLEMENTARY TERM: biodistribution; melanoma; pamam dendrimers;

prostate cancer; tritiated nanoparticles

SUPPL. TERM PLUS: POLY (AMIDOAMINE) PAMAM DENDRIMERS; STARBURST

DENDRIMERS; ANTISENSE OLIGONUCLEOTIDES

; BIOLOGICAL EVALUATION; FOLATE RECEPTOR; CELLS; DELIVERY;

AGENTS; CANCER; NANOCOMPOSITES

REFERENCE(S):

Referenced Author Y	ear	VOL	ARN PG	Referenced Work
			(RPG)	
=======================================	•			
	2003			PHARMA CHEM
	· · · · ·			CHIM OGGI
				NUCLEIC ACIDS RES
	2002	-		J NANOPART RES
	L998	-		CANCER RES
, –	L997		•	EXS
DELONG R	L997			J PHARM SCI
EICHMAN J D 2	2000	3	232	PHARM SCI TECHNOL TO
	2001	18	23	PHARMACEUT RES
ESFAND R 2	2001	6	427	DRUG DISCOV TODAY
FOLKMAN J 1	L996		181	CANC MED
FOLKMAN J 1	L995	1	27	NAT MED
GRUNT T W 1	L986	2	575	SCANNING ELECTRON MI
HASHIZUME H 2	2000	156	1363	AM J PATHOL
JANSEN J F G A 1	L994	266	1226	SCIENCE
KOBAYASHI H 2	2001	12	100	BIOCONJUGATE CHEM
KUKOWSKALATALLO J F 1	L996	93	4897	P NATL ACAD SCI USA
MAJOROS I J 2	2003	36	5526	MACROMOLECULES
MALIK N 1	L999	10	767	ANTI-CANCER DRUG
OREILLY M S 1	L994	79	315	CELL
PETERSON J 2	2003	39	33	EUR POLYM J
QUINTANA A 2	2002	19	1310	PHARMACEUT RES
RADUCHEL B 1	1998	79	516	POLYM MAT SCI ENG
ROBERTS J C 1	1996	30	53	J BIOMED MATER RES
SHUKLA S 2	2003	14	158	BIOCONJUGATE CHEM
STEWART P A 1	1987	67	1697	J NEUROSURG
TOMALIA D A 1	1990 i	29	138	ANGEW CHEM INT EDIT
WILBUR D S 1	1998 j	9	813	BIOCONJUGATE CHEM
YOO H 1	1999 Î	16	1799	PHARMACEUT RES
ZHANG C X	2002	106	10316	J PHYS CHEM B

L16 ANSWER 12 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:284496 SCISEARCH

THE GENUINE ARTICLE: 802NQ

TITLE: DNA-directed synthesis of generation 7 and 5 PAMAM

dendrimer nanoclusters

AUTHOR: Choi Y S; Mecke A; Orr B G; Holl M M B; Baker J R

(Reprint)

CORPORATE SOURCE: Univ Michigan, Sch Engn, Dept Biomed Engn, Ann Arbor, MI

48109 USA (Reprint); Univ Michigan, Sch Literature Art & Sci, Dept Phys, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Literature Art & Sci, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ctr Biol

Nanotechnol, Ann Arbor, MI 48109 USA

COUNTRY OF AUTHOR: USA

SOURCE: NANO LETTERS, (MAR 2004) Vol. 4, No. 3, pp. 391-397.

ISSN: 1530-6984.

PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036

USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English REFERENCE COUNT: 28

ENTRY DATE: Entered STN: 2 Apr 2004

Last Updated on STN: 2 Apr 2004

ABSTRACT:

A novel nanostructure was constructed using two different generations of polyamidoamine (PAMAM) dendrimers and three sets of complementary ***oligonucleotides*** (34, 50, and 66 bases in length). ***oligonucleotides*** were covalently conjugated to partially acetylated generation 5 and 7 PAMAM dendrimers, and these conjugates were characterized by agarose gel electrophoresis. The agarose gel electrophoresis appearance of these covalently linked oligonucleotide dendrimers; was also compared to electrostatically bound oligonucleotide-dendrimer Equimolar amounts of the G5 and G7 conjugates were then hybridized together to allow for the DNA-directed sell-assembly of supramolecular Dynamic light scattering (DLS) analysis indicated that the overall size of the DNA-linked dendrimer clusters tended to increase according to the length of the oligonucleotide used ranging from 30 to 50 nm, which agreed with the diameter of dendrimer nanoclusters predicted by molecular The DNA-linked novel dendrimer nanoclusters were also examined with tapping-mode atomic force microscopy (AFM) to distinguish the DNA-linked structure from a nonlinked simple G7/G5 dendrimer mixture. AFM image analysis suggested that the distance between the DNA-linked dendrimers; was significantly larger than what was seen after simple mixing of G7/G5 The mixture showed a few dendrimers; physically in contact with dendrimers. an interdendrimer distance of 8-10 nm. The interdendrimer distance of the nanoclusters linked with the 50-base-long oligonucleotide pairs was measured to be 21 + /-2 nm, which is in agreement with the theoretical length of the oligonucleotides duplex. These results suggest that dendrimers can be self-assembled via complementary ***oligonucleotides*** to form supramolecular nanoclusters.

CATEGORY: CHEMISTRY, MULTIDISCIPLINARY; MATERIALS SCIENCE,

MULTIDISCIPLINARY

SUPPL. TERM PLUS: ATOMIC-FORCE MICROSCOPY; CORE-SHELL TECTO(DENDRIMERS);

SINGLE-STRANDED-DNA; POLY(AMIDOAMINE) DENDRIMERS; STARBURST DENDRIMERS; POLYAMIDOAMINE DENDRIMERS;

DRUG-DELIVERY; IN-VITRO; OLIGONUCLEOTIDES;

VISUALIZATION

(RAU)	(RPY)	(RVL)	(RPG)	
	-+=====	:+=====	+=====	+======================================
ALIVISATOS A P	1996	382	609	NATURE
BELL S A	12003	14	488	BIOCONJUGATE CHEM
BETLEY T A	12002	18	3127	LANGMUIR

```
BETLEY T A
                      |2001 |17
                                 |2768 |LANGMUIR
                      |1997 |1353 |180
                                        |BBA-GENE STRUCT EXPR
BIELINSKA A U
                                 |2176
                      |1996 |24
BIELINSKA A
                                        |NUCLEIC ACIDS RES
                      |1983 |11
                                  |6513 |NUCLEIC ACIDS RES
CHU B C F
                                 1762
                      |1997 |86
DELONG R
                                        | J PHARM SCI
                                1236
ELIZALDE O
                      |2000 |17
                                        | PART PART SYST CHAR
                      12001 |6
ESFAND R
                                 1427
                                        |DRUG DISCOV TODAY
                      |1998 |31
                                 |6259 |MACROMOLECULES
JACKSON C L
                      |1996 |93
                                 |4897 | P NATL ACAD SCI USA
KUKOWSKALATALLO J F
                      |2000 |16
                                 |5613 |LANGMUIR
MAJOROS I J
                     12003 | 36
                                 15526 IMACROMOLECULES
MIRKIN C A
                     |1996 |382 |607
                                        NATURE
OTTAVIANI M F
                     |2000 |33
                                 17842 | MACROMOLECULES
                     12002 | 6
PATRI A K
                                 |466 | CURR OPIN CHEM BIOL
QUINTANA A
                     |2002 |19
                                 |1310 | PHARMACEUT RES
RICHARDSON S C W
                     |2001 |2
                                 |1023 |BIOMACROMOLECULES
                      |1999 |99
                                 |1849 | CHEM REV
STORHOFF J J
                   11997 | 30
                                 |5763 |MACROMOLECULES
TINLAND B
                      |1990 |29
TOMALIA D A
                                 |138
                                        |ANGEW CHEM INT EDIT
                      |1996 |101
TOMALIA D A
                                 1243
                                        |MACROMOL SYMP
TOMALIA D A
                      |1994 |6
                                 1529
                                        | ADV MATER
                                 |1531 |ANGEW CHEM INT EDIT
TOMIOKA N
                      |1998 |37
TUNG C H
                     |2000 |11
                                 1605
                                        | BIOCONJUGATE CHEM
UPPULURI S
                     |2000 |12
                                 1796
                                        | ADV MATER
WAYBRIGHT S M
                     |2001 |123 |1828 |J AM CHEM SOC
```

L16 ANSWER 13 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:882632 SCISEARCH

THE GENUINE ARTICLE: 857QY

TITLE: A novel anionic dendrimer for improved cellular delivery

of antisense oligonucleotides

AUTHOR: Hussain M; Shchepinov M S; Sohail M; Benter I F; Hollins A

J; Southern E M; Akhtar S (Reprint)

CORPORATE SOURCE: Univ Wales Coll Cardiff, Welsh Sch Pharm, Ctr Genomebased

Therapeut, King Edward 7 Ave, Cardiff, S Glam, Wales (Reprint); Univ Wales Coll Cardiff, Welsh Sch Pharm, Ctr Genomebased Therapeut, Cardiff, S Glam, Wales; Aston Univ, Pharmaceut Sci Res Inst, Birmingham B4 7ET, W Midlands, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Kuwait Univ, Fac Med, Dept Pharmacol, Safat

13060, Kuwait

SaghirAtchtar@cardiff.ac.uk

COUNTRY OF AUTHOR:

Wales; England; Kuwait

SOURCE:

JOURNAL OF CONTROLLED RELEASE, (14 SEP 2004) Vol. 99, No.

1, pp. 139-155. ISSN: 0168-3659.

PUBLISHER:

ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,

NETHERLANDS.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

45

ENTRY DATE:

Entered STN: 29 Oct 2004

Last Updated on STN: 29 Oct 2004

ABSTRACT:

The optimal design of hybridisation-competent antisense

oligonucleotides (ODNs) coupled with an efficient delivery system
appear to be important prerequisites for the successful use of

antisense reagents for gene silencing. We selected an

antisense ODN complementary to an accessible region of the epidermal
growth factor receptor (EGFR) mRNA with the aid of an antisense

oligonucleotide scanning array. The scanning array comprised 2684

antisense ODN sequences targeting the first 120 nts in the coding The array-designed antisense ODN was region of EGFR mRNA. covalently conjugated to a novel anionic dendrimer using a pentaerythritolbased phosphoroamidite synthon via automated DNA synthesis and the ability of this conjugate to effectively deliver and down-regulate EGFR expression in cancer cells was evaluated. Each dendrimeric structure had nine ODN molecules covalently linked to a common centre at their 3' termini. This dendrimer conjugate was markedly more stable to serum nucleases compared to the free ODNs and the cellular uptake of ODN-dendrimer conjugates was up to 100-fold greater as compared to mannitol, a marker for fluid phase endocytosis, and up to 4-fold greater than naked ODN in cancer cells. ODN-dendrimer uptake was energy-dependent and mediated, at least in part, via binding to cell surface proteins; a process that was inhibited by self-competition and by competition with free ODN, salmon sperm DNA, heparin and dextran sulphate. Fluorescent microscopy studies showed a combination of punctate and more diffuse cytosolic distribution pattern for fluorescently labelled ODN-dendrimer conjugate in A431 cells implying internalization by endocytosis followed by release and sequestration of the conjugate into the cytosol. Little or no conjugate appeared to be present in the nuclei of A431 cells. In vitro RNase H-mediated cleavage assays confirmed that covalently conjugated antisense ODNs in the dendrimer conjugate were able to hybridize and cleave the array-defined hybridisation target site within the EGFR mRNA without the need for ODN dissociation from the conjugate. In cell culture, ODN-dendrimer conjugates were effective in inhibiting cancer cell growth that correlated with a marked knockdown in EGFR protein expression. These data highlight a novel anionic dendrimer delivery system for gene silencing oligonucleotides that improved their biological stability, cellular delivery and antisense activity in cultured cancer cells. (C) 2004 Elsevier B.V. All rights

CATEGORY: CHEMISTRY, MULTIDISCIPLINARY; PHARMACOLOGY & PHARMACY

SUPPLEMENTARY TERM: DNA array; dendrimer; antisense; EGFR; cellular

delivery; stability; gene silencing

SUPPL. TERM PLUS: GROWTH-FACTOR RECEPTOR; PAMAM DENDRIMERS;

PHOSPHOROTHIOATE OLIGONUCLEOTIDES; SCANNING ARRAYS; MESSENGER-RNA; IN-VITRO; COMPLEMENTARY OLIGONUCLEOTIDES; CELLS; REAGENTS; HYBRIDIZATION

REFERENCE(S):

Referenced Author (RAU)	(RPY) (RVL)	(RPG)	
			•
AKHTAR S	•		TRENDS CELL BIOL
AKHTAR S			NUCLEIC ACIDS RES
AKHTAR S			ANTISENSE NUCLEIC A
AKHTAR S			ADV DRUG DELIVER REV
AKHTAR S	•		J DRUG TARGET
ALAHARI S K			J PHARMACOL EXP THER
ALINO S F	1997 54	9	BIOCHEM PHARMACOL
BECK G F	1996 13	1028	PHARMACEUT RES
BIELINSKA A	1996 24	2176	NUCLEIC ACIDS RES
BOADO R J	1992 3	519	BIOCONJUGATE CHEM
BOHULA E A	2003 278	15991	J BIOL CHEM
COULSON J M	1996 50	314	MOL PHARMACOL
DAGLE J M	1991 1	11	ANTISENSE RES DEV
EICHMAN J D	2000 3	232	PHARM SCI TECHNOL TO
ESFAND R	2001 6	427	DRUG DISCOV TODAY
FELL P L	1997 7	319	ANTISENSE NUCLEIC A
HAENSLER J	1993 4	372	BIOCONJUGATE CHEM
HAWLEY P	1996 6	185	ANTISENSE NUCLEIC A
HO S P	1996 24	1901	NUCLEIC ACIDS RES
HOLLINS A J	2004 21	458	PHARM RES
HUGHES M D	[2001 6	303	DRUG DISCOV TODAY
JAASKELAINEN I	2002 2		MINI REV MED CHEM

JULIANO R L 2000 2 297 CURR OPIN MOL THER LEE R J 1997 14 173 CRIT REV THER DRUG MAIER M 1995 1 235 BIOMED PEPT PROTEINS MALIK N 2000 65 133 J CONTROL RELEASE MONIA B P 1996 2 668 NAT MED PETCH A K 2003 66 819 BIOCHEM PHARMACOL SHCHEPINOV M S 1999 27 3035 NUCLEIC ACIDS RES SHCHEPINOV M S 1997 25 4447 NUCLEIC ACIDS RES SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 77 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 29 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 44 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES ZHAO Q 1993 3 SANTISENSE RES DEV	JULIANO R L	1999 16	494	PHARMACEUT RES
MAIER M	JULIANO R L	2000 2	1297	CURR OPIN MOL THER
MALIK N 2000 65 133 J CONTROL RELEASE MONIA B P 1996 2 668 NAT MED PETCH A K 2003 66 819 BIOCHEM PHARMACOL SHCHEPINOV M S 1999 27 33035 NUCLEIC ACIDS RES SHCHEPINOV M S 1997 25 4447 NUCLEIC ACIDS RES SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 77 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 29 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 44 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	LEE R J	1997 14	173	CRIT REV THER DRUG
MONIA B P 1996 2 668 NAT MED PETCH A K 2003 66 819 BIOCHEM PHARMACOL SHCHEPINOV M S 1999 27 3035 NUCLEIC ACIDS RES SHCHEPINOV M S 1997 25 4447 NUCLEIC ACIDS RES SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 177 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 129 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 44 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	MAIER M	1995 1	1235	BIOMED PEPT PROTEINS
PETCH A K 2003 66 819 BIOCHEM PHARMACOL SHCHEPINOV M S 1999 27 3035 NUCLEIC ACIDS RES SHCHEPINOV M S 1997 25 4447 NUCLEIC ACIDS RES SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 177 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 129 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 144 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	MALIK N	2000 65	133	J CONTROL RELEASE
SHCHEPINOV M S 1999 27 3035 NUCLEIC ACIDS RES SHCHEPINOV M S 1997 25 4447 NUCLEIC ACIDS RES SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 77 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 129 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 15 646 RNA SOHAIL M 2000 144 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	MONIA B P	1996 2	1668	NAT MED
SHCHEPINOV M S 1997 25 4447 NUCLEIC ACIDS RES SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 77 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 129 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 15 646 RNA SOHAIL M 2000 144 123 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 138 CIBA F SYMP SOUTHERN E M 1994 22 11368 NUCLEIC ACIDS RES TANG M X 1997 4 1823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 166 16445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	PETCH A K	12003 66	819	BIOCHEM PHARMACOL
SHOJI Y 1996 40 1670 ANTIMICROB AGENTS CH SOHAIL M 2002 77 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 129 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 144 123 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SHCHEPINOV M S	1999 27	13035	NUCLEIC ACIDS RES
SOHAIL M 2002 77 43 ADV BIOCHEM ENG BIOT SOHAIL M 2001 29 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 44 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SHCHEPINOV M S	1997 25	14447	NUCLEIC ACIDS RES
SOHAIL M 2001 29 2041 NUCLEIC ACIDS RES SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 144 123 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 138 CIBA F SYMP SOUTHERN E M 1994 122 11368 NUCLEIC ACIDS RES TANG M X 1997 14 1823 IGENE THER TENASBROEK A L M A 2002 269 1583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 1991 PHARMACEUT RES YAKUBOV L A 1989 166 1799 PHARMACEUT RES	SHOJI Y	1996 40	1670	ANTIMICROB AGENTS CH
SOHAIL M 2001 170 181 METH MOL B SOHAIL M 1999 5 646 RNA SOHAIL M 2000 44 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOHAIL M	2002 77	43	ADV BIOCHEM ENG BIOT
SOHAIL M 1999 5 646 RNA SOHAIL M 2000 144 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 11368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOHAIL M	2001 29	2041	NUCLEIC ACIDS RES
SOHAIL M 2000 144 23 ADV DRUG DELIVER REV SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOHAIL M	2001 170	181	METH MOL B
SOUTHERN E M 1997 209 38 CIBA F SYMP SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOHAIL M	1999 5	646	RNA
SOUTHERN E M 1994 22 1368 NUCLEIC ACIDS RES TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOHAIL M	2000 44	123	ADV DRUG DELIVER REV
TANG M X 1997 4 823 GENE THER TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOUTHERN E M	1997 209	38	CIBA F SYMP
TENASBROEK A L M A 2002 269 583 EUR J BIOCHEM WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	SOUTHERN E M	1994 22	1368	NUCLEIC ACIDS RES
WIWATTANAPATAPEE R 2000 17 991 PHARMACEUT RES YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	TANG M X	1997 4	1823	GENE THER
YAKUBOV L A 1989 86 6445 P NATL ACAD SCI USA YOO H 1999 16 1799 PHARMACEUT RES	TENASBROEK A L M A	2002 269	583	EUR J BIOCHEM
YOO H 1999 16 1799 PHARMACEUT RES	WIWATTANAPATAPEE R	2000 17	1991	PHARMACEUT RES
	YAKUBOV L A	1989 86	16445	P NATL ACAD SCI USA
ZHAO Q 1993 3 53 ANTISENSE RES DEV	YOO H	1999 16	1799	PHARMACEUT RES
	ZHAO Q	1993 3	53 -	ANTISENSE RES DEV

L16 ANSWER 14 OF 41 MEDLINE on STN ACCESSION NUMBER: 2004122923 MEDLINE DOCUMENT NUMBER: PubMed ID: 15013240

TITLE: Hepatocyte targeting of 111In-labeled oligo-DNA with avidin

or avidin-dendrimer complex.

AUTHOR: Mamede Marcelo; Saga Tsuneo; Ishimori Takayoshi; Higashi

Tatsuya; Sato Noriko; Kobayashi Hisataka; Brechbiel Martin

W; Konishi Junji

CORPORATE SOURCE: Department of Nuclear Medicine and Diagnostic Imaging,

Graduate School of Medicine, Kyoto University, 54

Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

SOURCE: Journal of controlled release : official journal of the

Controlled Release Society, (2004 Feb 20) 95 (1) 133-41.

Journal code: 8607908. ISSN: 0168-3659.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200409

ENTRY DATE: Entered STN: 20040312

Last Updated on STN: 20040917 Entered Medline: 20040916

ABSTRACT:

To establish an effective nonviral gene transfer vector to hepatocytes, various oligo-carrier complexes were developed employing dendrimer (G4) and avidin-biotin systems (Av-bt), and their biodistribution were evaluated. In-111-labeled-oligo, without any carriers, showed low uptake in normal organs other than the kidney (21.48% ID/g at 15 min, 18.48% ID/g at 60 min). In contrast, 111In-oligo coupled with avidin through biotin (111In-oligo-bt-Av) showed very high accumulation in the liver (50.95% at 15 min, 47.88% at 60 min). 111In-oligo complexed with G4 showed high uptake in the kidney and spleen, but its hepatic uptake was relatively low (13.12% at 15 min, 10.67% at 60 min). When both G4 and Av-bt systems were employed, 111In-oligo/G4-bt-Av showed extremely high uptake in the lung (182.33% at 15 min, 125.54% at 60 min), probably due to the formation of large molecular weight complex and aggregates which are trapped in the lung, and its hepatic uptake was lower than 111In-oligo-bt-Average 111In-oligo-bt-Av, which exhibited the highest hepatic uptake in vivo, also showed high and rapid internalization into hepatocytes.

The avidin-biotin system seems to have potential as a carrier of oligo-DNA to the liver.

CONTROLLED TERM:

Check Tags: Female

Animals

*Avidin: CH, chemistry Chelating Agents

*DNA: AD, administration & dosage

DNA: PK, pharmacokinetics

Drug Carriers

*Gene Transfer Techniques
*Hepatocytes: ME, metabolism

Indium Radioisotopes: DU, diagnostic use

Mice

Mice, Inbred BALB C

*Oligonucleotides: AD, administration & dosage

Oligonucleotides: PK, pharmacokinetics

Oligonucleotides, Antisense: AD, administration &

dosage

Oligonucleotides, Antisense: PK, pharmacokinetics

Polyamines: CH, chemistry

Research Support, Non-U.S. Gov't

Tissue Distribution

CAS REGISTRY NO.:

CHEMICAL NAME:

1405-69-2 (Avidin); 9007-49-2 (DNA)

0 (Chelating Agents); 0 (Drug Carriers); 0 (Indium

Radioisotopes); 0 (Oligonucleotides); 0 (

Oligonucleotides, Antisense); 0 (PAMAM Starburst); 0 (Polyamines)

L16 ANSWER 15 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2004:118678 SCISEARCH

THE GENUINE ARTICLE: 767LQ

TITLE: Dendrimers in drug research
AUTHOR: Boas U (Reprint); Heegaard P M H

CORPORATE SOURCE: Danish Vet Inst, Dept Immunol & Biochem, Bulowsvej 27,

DK-1790 Copenhagen, Denmark (Reprint); Danish Vet Inst,

Dept Immunol & Biochem, DK-1790 Copenhagen, Denmark

COUNTRY OF AUTHOR:

SOURCE:

CHEMICAL SOCIETY REVIEWS, (10 JAN 2004) Vol. 33, No. 1,

pp. 43-63.

ISSN: 0306-0012.

133N: 0300-0012.

PUBLISHER: ROYAL SOC CHEMISTRY, THOMAS GRAHAM HOUSE, SCIENCE PARK,

MILTON RD, CAMBRIDGE CB4 OWF, CAMBS, ENGLAND.

DOCUMENT TYPE:

General Review; Journal

LANGUAGE:

English

REFERENCE COUNT:

158

ENTRY DATE:

Entered STN: 13 Feb 2004

Last Updated on STN: 13 Feb 2004

ABSTRACT:

Dendrimers are versatile, derivatisable, well-defined, compartmentalised chemical polymers with sizes and physicochemical properties resembling those of biomolecules e.g. proteins. The present critical review (citing 158 references) briefly describes dendrimer design, nomenclature and divergent/convergent dendrimer synthesis. The characteristic physicochemical features of dendrimers are highlighted, showing the effect of solvent pH and polarity on their spatial structure. The use of dendrimers in biological systems are reviewed, with emphasis on the biocompatibility of dendrimers, such as in vitro and in vivo cytotoxicity, as well as biopermeability, biostability The review deals with numerous applications of dendrimers and immunogenicity. as tools for efficient multivalent presentation of biological ligands in biospecific recognition, inhibition and targeting.

Dendrimers may be used as drugs for antibacterial and antiviral treatment

and have found use as antitumor agents. The review highlights the use of dendrimers as drug or gene delivery devices in e.g. anticancer therapy, and the design of different host-guest binding motifs directed towards medical applications is described.

Other specific examples are the use of dendrimers as 'glycocarriers' for the controlled multimeric presentation of biologically relevant carbohydrate moieties which are useful for targeting modified tissue in malignant diseases for diagnostic and therapeutic purposes. Finally, the use of specific types of dendrimers as scaffolds for presenting vaccine antigens, especially peptides, for use in vaccines is presented.

CATEGORY:

CHEMISTRY, MULTIDISCIPLINARY

SUPPL. TERM PLUS:

POLY(PROPYLENE IMINE) DENDRIMERS; NEUTRON-CAPTURE THERAPY;

POLY(AMIDOAMINE) PAMAM DENDRIMERS; POLYESTER

DENDRITIC SYSTEMS; ANTIBODY-BINDING PROPERTIES; SYNTHETIC

PEPTIDE VACCINE; GENE-TRANSFER AGENTS; IN-VITRO;

POLYAMIDOAMINE DENDRIMERS; ANTISENSE

OLIGONUCLEOTIDES

Referenced Author (RAU) Year VOL ARN PG Referenced Work (RAU) (RPG) (RPG) (RWK)	Referenced Author	lYear	l VOL	IARN PG	Referenced Work
ANDRE S 1999 9 1253 GLYCOBIOLOGY ANDREWS J M 1997 125 1082 INUCLEIC ACIDS RES ANDRE S 12001 2 822 CHEMBIOCHEM ASHWELL G 11974 41 199 ADV ENZYMOL AUTUMN K 12000 405 681 INATURE BAARS M W P L 12000 39 4262 ANGEW CHEM INT EDIT BAEK M G 12001 1257 CHEM COMMUN BAEK M G 12002 10 11 BLOGRAN MED CHEM BAENZIGER J U 1984 4 1271 PLASMA PROTEINS STRU BAENZIGER J U 1986 122 1611 CELL BALLAUFF M 12001 121 177 TOP CURR CHEM BALLOUFF M 12001 11 18 INANO LETTERS BARTH R F 1994 15 158 BLOCONJUGATE CHEM BARTH R F 1994 12 139 MOL CHEM NEUROPATHOL BATTAH S H 12001 12 1980 BLOCONJUGATE CHEM BAUSSANNE I 12000 14489 CHEM COMMUN BAY S 1997 49 620 J PEPT RES BEZOUSKA K 12002 90 1269 REV MOL BIOTECH BOAS U 12001 66 12136 J ORG CHEM BOAS U 12002 1 THERSIS U COPENHAGEN BOAS U 12004 124 12471 ANTIMICROB AGENTS CH BOURNE N 12006 14 12471 ANTIMICROB AGENTS CH BOYN W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 1155 SYNTHESIS-STUTTGART CHAI M H 12001 123 14670 J AM CHEM SOC CHEN C Z S 12000 12 1473 BLOMACROMOLECULES CHEN C Z S 12000 12 843 ADV MATER CHEN C Z S 12000 12 843 ADV MATER CORBELL J B 1200 15451 J PHAR HARMACOL DEBACKER S 1998 1002 15451 J PHAR HARMACOL DEBACKER S 1998 102 15451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT	(RAU)	(RPY)	(RVL)	(RPG)	(RWK)
ANDREWS J M					
ASHWELL G	ANDRE S	1999	19	1253	GLYCOBIOLOGY
ASHWELL G	ANDREWS J M	1997	25	1082	NUCLEIC ACIDS RES
ASHWELL G	ANDRE S	2001	2	822	CHEMBIOCHEM
AUTUMN K BAARS M W P L BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAEK M G BAENZIGER J U BAENZIGER J U BAENZIGER J U BAENZIGER J U BALAUFF M BALOGH L BALAUFF M BALOGH L BATTAH S F BATTAH S F BATTAH S F BAUSSANNE I BAUSSANNE I BAUSSANNE I BAUSSANNE I BAUSSANNE I BAUSSANNE I BAUSSANNE I BAOS U BAEK M G BAEK M G BAUS BEZOUSKA K BAUS BEZOUSKA K BAUS BEZOUSKA K BAUS BEZOUSKA K BAUS BEZOUSKA K BAUS BEZOUSKA K BAUS BEZOUSKA K BATTA B BEZOUS	ASHWELL G	1974	41	199	ADV ENZYMOL
BAEK M G 2001 257 CHEM COMMUN BAEK M G 2002 10 11 BIOORGAN MED CHEM BAENZIGER J U 11984 4 1271 PLASMA PROTEINS STRU BAENZIGER J U 11980 122 1177 TOP CURR CHEM BAENZIGER J U 11980 122 1177 TOP CURR CHEM BALLAUFF M 2001 212 1177 TOP CURR CHEM BALLAUFF M 12001 11 118 NANO LETTERS BARTH R F 11994 15 158 BIOCONJUGATE CHEM BARTH R F 11994 121 1139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 1980 BIOCONJUGATE CHEM BAUSSANNE I 12001 12 1980 BIOCONJUGATE CHEM BAUSSANNE I 12000 14489 CHEM COMMUN BAY S 11997 149 1620 13 PEPT RES BEZOUSKA K 12002 90 1269 REV MOL BIOTECH BILINSKA A 11996 124 22176 NUCLEIC ACIDS RES BOAS U 12001 166 12136 13 ORG CHEM BOAS U 12002 1 THESIS U COPENHAGEN BOAS U 12002 1 THESIS U COPENHAGEN BOSMAN A W 11999 199 11665 CHEM REV BOURNE N 12000 144 12471 ANTIMICROB AGENTS CH BOYD W C 11954 173 1226 13 IMMUNOL BRAZEAU G A 11998 115 680 PHARMACEUT RES BUHLEIER E 11978 1155 SYNTHESIS-STUTTGART CHAI M H 12001 123 14670 JAM CHEM SOC CHEN C Z S 12000 11 1473 BIOMACROMOLECULES CHEN C Z S 12000 12 843 JADV MATER CORBELL J B 12000 11 195 TETRAHEDRON-ASYMMETR DASS C R 12002 54 3 JADV MATER CORBELL J B 12000 11 195 TETRAHEDRON-ASYMMETR DASS C R 12002 154 3 JADV MATER CORBELL J B 12000 11 195 TETRAHEDRON-ASYMMETR DEBROANDERVANDENBERG 1993 322 11308 ANGEW CHEM INT EDIT DEFOORT J P 11992 140 1214 INT J PEPT PROT RES	AUTUMN K	12000	1405	1681	NATURE
BAENZIGER J U 1980 22 611 CELL BALLAUFF M 2001 212 177 TOP CURR CHEM BALOGH L 2001 1 18 NANO LETTERS BARTH R F 1994 5 58 BIOCONJUGATE CHEM BARTH R F 1994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 1980 BIOCONJUGATE CHEM BAUSSANNE I 2000 1489 CHEM COMMUN BAY S 11997 149 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 11996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 12002 1 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 11998 15 680 PHARMACEUT RES BUHLEIER E 11978 1155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 195 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 15451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BAARS M W P L	2000	39	14262	ANGEW CHEM INT EDIT
BAENZIGER J U 1980 22 6611 CELL BALLAUFF M 2001 212 177 TOP CURR CHEM BALOGH L 1201 1 18 NANO LETTERS BARTH R F 1994 15 158 BIOCONJUGATE CHEM BARTH R F 11994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 1489 CHEM COMMUN BAY S 11997 149 620 J PEPT RES BEZOUSKA K 12002 90 1269 REV MOL BIOTECH BOAS U 12001 66 2136 J ORG CHEM BOAS U 12002 3 1433 CHEMBIOCHEM BOAS U 12002 3 1433 CHEMBIOCHEM BOAS U 12002 1 THESIS U COPENHAGEN BOSMAN A W 11998 120 8547 J AM CHEM SOC BOSMAN A W 11999 199 11665 CHEM REV BOURNE N 12000 14 12471 ANTIMICROB AGENTS CH BOYD W C 11954 173 1226 J IMMUNOL BRAZEAU G A 11998 15 1680 PHARMACEUT RES BUHLEIER E 11978 1155 SYNTHESIS-STUTTGART CHAI M H 12001 123 14670 J AM CHEM SOC CHEN C Z S 12000 12 843 ADV MATER CHEN C Z S 12000 12 843 ADV MATER CORBELL J B 12000 14 173 BIOMACROMOLECULES CHEN C Z S 12002 1 BIOMATERIALS CORBELL J B 12000 11 195 TETRAHEDRON-ASYMMETR DASS C R 12002 54 3 J PHARM PHARMACOL DEBACKER S 11998 102 15451 J PHYSK CHEM INT EDIT DEFOORT J P 11992 140 1214 INT J PEPT PROT RES	BAEK M G	2001	1	1257	CHEM COMMUN
BAENZIGER J U 1980 22 611 CELL BALLAUFF M 2001 212 177 TOP CURR CHEM BALOGH L 2001 1 18 NANO LETTERS BARTH R F 1994 5 58 BIOCONJUGATE CHEM BARTH R F 1994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 1980 BIOCONJUGATE CHEM BAUSSANNE I 2000 1489 CHEM COMMUN BAY S 11997 149 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 11996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 12002 1 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 11998 15 680 PHARMACEUT RES BUHLEIER E 11978 1155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 195 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 15451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BAEK M G	2002	10	11	BIOORGAN MED CHEM
BAENZIGER J U 1980 22 6611 CELL BALLAUFF M 2001 212 177 TOP CURR CHEM BALOGH L 1201 1 18 NANO LETTERS BARTH R F 1994 15 158 BIOCONJUGATE CHEM BARTH R F 11994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 1489 CHEM COMMUN BAY S 11997 149 620 J PEPT RES BEZOUSKA K 12002 90 1269 REV MOL BIOTECH BOAS U 12001 66 2136 J ORG CHEM BOAS U 12002 3 1433 CHEMBIOCHEM BOAS U 12002 3 1433 CHEMBIOCHEM BOAS U 12002 1 THESIS U COPENHAGEN BOSMAN A W 11998 120 8547 J AM CHEM SOC BOSMAN A W 11999 199 11665 CHEM REV BOURNE N 12000 14 12471 ANTIMICROB AGENTS CH BOYD W C 11954 173 1226 J IMMUNOL BRAZEAU G A 11998 15 1680 PHARMACEUT RES BUHLEIER E 11978 1155 SYNTHESIS-STUTTGART CHAI M H 12001 123 14670 J AM CHEM SOC CHEN C Z S 12000 12 843 ADV MATER CHEN C Z S 12000 12 843 ADV MATER CORBELL J B 12000 14 173 BIOMACROMOLECULES CHEN C Z S 12002 1 BIOMATERIALS CORBELL J B 12000 11 195 TETRAHEDRON-ASYMMETR DASS C R 12002 54 3 J PHARM PHARMACOL DEBACKER S 11998 102 15451 J PHYSK CHEM INT EDIT DEFOORT J P 11992 140 1214 INT J PEPT PROT RES	BAENZIGER J U	1984	4	271	PLASMA PROTEINS STRU
BARTH R F 1994 5 58 BIOCONJUGATE CHEM BARTH R F 1994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 980 BIOCONJUGATE CHEM BAUSSANNE I 2000 14489 CHEM COMMUN BAY S 1997 49 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 199 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 173 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2000 14 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BAENZIGER J U	1980	122	611	CELL
BARTH R F 1994 5 58 BIOCONJUGATE CHEM BARTH R F 1994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 980 BIOCONJUGATE CHEM BAUSSANNE I 2000 14489 CHEM COMMUN BAY S 1997 49 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 199 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 173 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2000 14 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BALLAUFF M	2001	212	177	TOP CURR CHEM
BARTH R F 1994 5 58 BIOCONJUGATE CHEM BARTH R F 1994 21 139 MOL CHEM NEUROPATHOL BATTAH S H 2001 12 980 BIOCONJUGATE CHEM BAUSSANNE I 2000 14489 CHEM COMMUN BAY S 1997 49 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 199 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 173 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2000 14 473 BIOMACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BALOGH L	2001	1	18	NANO LETTERS
BAYS 1997 49 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BARTH R F	1994	5	58	BIOCONJUGATE CHEM
BAYS 1997 49 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BARTH R F	1994	21	139	MOL CHEM NEUROPATHOL
BAYS 1997 49 620 J PEPT RES BEZOUSKA K 2002 90 269 REV MOL BIOTECH BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BATTAH S H	2001	12	980	BIOCONJUGATE CHEM
BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BAUSSANNE I	12000		1489	CHEM COMMUN
BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BAY S	1997	149	620	J PEPT RES
BIELINSKA A 1996 24 2176 NUCLEIC ACIDS RES BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BEZOUSKA K	2002	190	269	REV MOL BIOTECH
BOAS U 2001 66 2136 J ORG CHEM BOAS U 2002 3 433 CHEMBIOCHEM BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 15 1680 PHARMACEUT RES BUHLEIER E 1978 1155 SYNTHESIS-STUTTGART CHAI M H 2001 123 14670 J AM CHEM SOC CHEN C Z S 2000 1 1473 BIOMACROMOLECULES CHEN W 2000 33 19169 MACROMOLECULES CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 195 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 11308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 1214 INT J PEPT PROT RES	BIELINSKA A	1996	24	2176	NUCLEIC ACIDS RES
BOAS U 2002 THESIS U COPENHAGEN BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 ITETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BOAS U	2001	66	2136	J ORG CHEM
BOSMAN A W 1998 120 8547 J AM CHEM SOC BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 1226 J IMMUNOL BRAZEAU G A 1998 15 1680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 14670 J AM CHEM SOC CHEN C Z S 2000 1 1473 BIOMACROMOLECULES CHEN W 2000 33 99169 MACROMOLECULES CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 195 ITETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BOAS U	2002	3	433	CHEMBIOCHEM
BOSMAN A W 1999 99 1665 CHEM REV BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 99169 MACROMOLECULES CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 195 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES					
BOURNE N 2000 44 2471 ANTIMICROB AGENTS CH BOYD W C 1954 73 226 J IMMUNOL BRAZEAU G A 1998 15 680 PHARMACEUT RES BUHLEIER E 1978 155 SYNTHESIS-STUTTGART CHAI M H 2001 123 4670 J AM CHEM SOC CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 99169 MACROMOLECULES CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	BOSMAN A W	1998	120	8547	J AM CHEM SOC
CHAI M H	BOSMAN A W '				
CHAI M H	BOURNE N	2000	44	2471	ANTIMICROB AGENTS CH
CHAI M H	BOYD W C	1954	173	1226	J IMMUNOL
CHAI M H	BRAZEAU G A	1998	15	1680	PHARMACEUT RES
CHEN C Z S 2000 1 473 BIOMACROMOLECULES CHEN W 2000 33 9169 MACROMOLECULES CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES					
CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	CHAI M H	2001	123	4670	J AM CHEM SOC
CHEN C Z S 2002 23 3359 BIOMATERIALS CHEN C Z S 2000 12 843 ADV MATER CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	CHEN C Z S				
CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES					
CORBELL J B 2000 11 95 TETRAHEDRON-ASYMMETR DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	CHEN C Z S	12002	23	3359	BIOMATERIALS
DASS C R 2002 54 3 J PHARM PHARMACOL DEBACKER S 1998 102 5451 J PHYS CHEM A DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES		12000	12	843	ADV MATER
DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES					
DEBRABANDERVANDENBERG 1993 32 1308 ANGEW CHEM INT EDIT DEFOORT J P 1992 40 214 INT J PEPT PROT RES	DASS C R	2002	54	3	J PHARM PHARMACOL
DEFOORT J P 1992 40 214 INT J PEPT PROT RES	DEBACKER S	1998	102	5451	J PHYS CHEM A
DEFOORT J P 1992 40 214 INT J PEPT PROT RES DEGENNES P G 1983 44 L351 J PHYS LETT	DEBRABANDERVANDENBERG	1993	32	1308	ANGEW CHEM INT EDIT
DEGENNES P G 1983 44 L351 J PHYS LETT	DEFOORT J P	1992	40	214	INT J PEPT PROT RES
	DEGENNES P G	1983	4 4	L351	J PHYS LETT
DEJESUS O L P 2002 13 453 BIOCONJUGATE CHEM	DEJESUS O L P	12002	13	1453	BIOCONJUGATE CHEM
DENNIG J 2002 90 339 REV MOL BIOTECHNOL	DENNIG J	12002	190	339	REV MOL BIOTECHNOL

DEOLIVEIRA E	2003	14	144	BIOCONJUGATE CHEM
DEVASAGAYAM T P	2002	140	680	INDIAN J EXP BIOL
	2001	176	1903	J CHEM TECHNOL BIOT
EHRLICH P H	1979	81	123	J THEOR BIOL
ELSAYED M	2002	•	-	J CONTROL RELEASE
ELSAYED M	2001	18	23	PHARMACEUT RES
ESFAND R	•	•		DRUG DISCOV TODAY
	•			ANGEW CHEM INT EDIT
	•	•		P INT S CONTR REL BI
	•	•		BIOMATERIALS
	•	•		J CONTROL RELEASE
•	•	•		BIOORGAN MED CHEM
	•		•	J CONTROL RELEASE
	•	•	•	ANTIVIR RES
	-	•	•	MACROMOLECULES
		•	•	ANAL BIOCHEM
	-	-	-	BIOCONJUGATE CHEM J CHEM SOC CHEM COMM
	1990 1993	•		J AM CHEM SOC
	1993 1993	•	•	J CHEM SOC P1
	-			J AM CHEM SOC
				SOLID PHASE SYNTHESI
	•	! !	•	BIOCONJUGATE TECHNIQ
	11996	•		PHARMACEUT RES
	•	•	•	BIOCONJUGATE CHEM
		•	•	EUR J PHARM SCI
		•	•	J CHEM SOC DALT 0821
	•	•	•	J AM CHEM SOC
		266		SCIENCE
JANSEN J F G		1	•	ABSTR PAP AM CHEM SO
JANSEN J F G A	1996	102	127	MACROMOL SYMP
JANSEN J F G A	1995	114	225	RECL TRAV CHIM PAY B
JEVPRASESPHANT R		•	263	INT J PHARM
KICHLER A	1998	6	201	J DRUG TARGET
		46	781	MAGNET RESON MED
	•	•	•	BIOCONJUGATE CHEM
	•	•	•	J INFECT DIS
	•	•	. – – –	EUR J PHARM BIOPHARM
	•		•	MACROMOLECULES
	•			BIOCHEMISTRY-US
	11975			BIOCH MOL BASIS CELL
	11990	•	•	MACROMOLECULES
	12002	•	•	TOP CURR CHEM J IMMUNOL
	2001 2000	•	•	J ORG CHEM
	11999		•	CHEM REV
	2000			J CONTROL RELEASE
	11999			ANTI-CANCER DRUG
	1998			ANGEW CHEM INT EDIT
	2002			J CONTROL RELEASE
	2001			TETRAHEDRON
	2002	-		J AM CHEM SOC
	1998			DEV BIOL STAND
	1999		•	VACCINE
MURAT M	1996			MACROMOLECULES
NAGAHORI N	2002	13	836	CHEMBIOCHEM
	2001		1481	J IMMUNOL
	2000			J INFECT DIS
NEWKOME G R	1991	130		ANGEW CHEM INT EDIT
NISHIYAMA N	2003	14	58	BIOCONJUGATE CHEM
NOURSE A	2000			BIOPOLYMERS
OTA S	12002	62	1471	CANCER RES

		-		BIOCONJUGATE CHEM
PATRI A K	2002	16	466	CURR OPIN CHEM BIOL
QUINTANA A	2002	119	1310	PHARMACEUT RES
RAJANANTHANAN P	1999	117	715	VACCINE
	2001		645	CHEM BIOL
		•	•	J AM CHEM SOC
		•		MACROMOLECULES
	•	•	1104	•
	•	•	•	MOL THER
	•		53	J BIOMED MATER RES
	2001		201	TOP CURR CHEM
ROESSLER B J	2001	1283	124	BIOCHEM BIOPH RES CO
ROY R	1996	16	692	CURR OPIN STRUC BIOL
ROY R	2001	123	1809	J AM CHEM SOC
ROY R	1999	138	369	ANGEW CHEM INT EDIT
	2002	-	291	REV MOL BIOTECH
	2002		195	REV MOL BIOTECHNOL
	2001	•		ARTERIOSCL THROM VAS
	2000	•		INT J PHARM
	•		158	BIOCONJUGATE CHEM
	•		•	CHEM COMMUN 1121
SMITH D K	1999	182	1225	HELV CHIM ACTA
STEPHAN H	1999		1875	CHEM COMMUN 0921
SUPATTAPONE S	1999	196	14529	P NATL ACAD SCI USA
TAJAROBI F	2001	1215	263	INT J PHARM
	•	•	5409	P NATL ACAD SCI USA
	*	•	703	BIOCONJUGATE CHEM
	11997	•	823	GENE THER
		•		POLYM J
	•	•	117	•
	-	•	1119	BIOORGAN MED CHEM
	•	•	3559	TETRAHEDRON
	•		231	REV MOL BIOTECHNOL
TWYMAN L J	11999	40	1743	TETRAHEDRON LETT
VANREGENMORTEL M H	11988		1	SYNTHETIC POLYPEPTID
VEPREK P	1999	5	203	J PEPT SCI
	12001	İ	4685	EUR J ORG CHEM DEC
	•	-	1567	CHEM REV
•	-		779	HELV CHIM ACTA
	•	•	12784	J IMMUNOL
	•	,	12/04	THESIS EINDHOVEN U T
	•		1 4 4 1	•
	•	•	441	ANNU REV BIOCHEM
	-	•	2635	BIOORG MED CHEM LETT
WITVROUW M	12000		1778	J MED CHEM
WITVROUW M	12000	58	1100	MOL PHARMACOL
WIWATTANAPATAPEE R	12000	17	991	PHARMACEUT RES
WOLLER E K	12002	4	17	ORG LETT
WOOLEY K L	1993	1115	11496	J AM CHEM SOC
YOO H			1799	I PHARMACEUT RES
YOO H	•	•	4225	NUCLEIC ACIDS RES
ZENG F W	•	197	1681	CHEM REV
				J CONTROL RELEASE
ZHUO R X	1999		249	
	2002		1399	NATURE
ZINSELMEYER B H	12002	119	1960	PHARMACEUT RES

STN Patent No. (RPN)	(RPY)	. Inventor/Assignee (RIN)		Ref. Patent No. (RPN)
US 0041859 US 5795582 US 4410688	2002 PRU 1998 WRI	SINER S B	1	US 0041859 US 005795582 US 4410688

L16 ANSWER 16 OF 41 MEDLINE on STN ACCESSION NUMBER: 2003511812 MEDLINE

DOCUMENT NUMBER: PubMed ID: 14588003

TITLE: Enzyme-amplified electrochemical detection of DNA using

electrocatalysis of ferrocenyl-tethered dendrimer.

AUTHOR: Kim Eunkyung; Kim Kyuwon; Yang Haesik; Kim Youn Tae; Kwak

Juhyoun

CORPORATE SOURCE: Department of Chemistry, Korea Advanced Institute of

Science and Technology (KAIST), Daejeon 305-701, Republic

of Korea.

SOURCE: Analytical chemistry, (2003 Nov 1) 75 (21) 5665-72.

Journal code: 0370536. ISSN: 0003-2700.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200406

ENTRY DATE: Entered STN: 20031101

Last Updated on STN: 20040609 Entered Medline: 20040608

ABSTRACT:

We have developed a sandwich-type enzyme-linked DNA sensor as a new electrochemical method to detect DNA hybridization. A partially ferrocenyl-tethered poly(amidoamine) dendrimer (Fc-D) was used as an electrocatalyst to enhance the electronic signals of DNA detection as well as a building block to immobilize capture probes. Fc-D was immobilized on a carboxylic acid-terminated self-assembled monolayer (SAM) by covalent coupling of unreacted amine in Fc-D to the acid. Thiolated capture probe was attached to the remaining amine groups of Fc-D on the SAM via a bifunctional linker. The target DNA was hybridized with the capture probe, and an extension in the DNA of the target was then hybridized with a biotinylated detection probe. Avidin-conjugated alkaline phosphatase was bound to the detection probe and allowed to generate the electroactive label, p-aminophenol, from p-aminophenyl phosphate enzymatically. p-Aminophenol diffuses into the Fc-D layer and is then electrocatalytically oxidized by the electronic mediation of the immobilized Fc-D, which leads to a great enhancement in signal. Consequently, the amount of hybridized target can be estimated using the intensity of electrocatalytic current. This DNA sensor exhibits a detection limit of 20 fmol. Our method was also successfully applied to the sequence-selective discrimination between perfectly matched and single-base mismatched target oligonucleotides.

CONTROLLED TERM: Alkaline Pho

Alkaline Phosphatase: ME, metabolism

Aminophenols: CH, chemistry Aminophenols: ME, metabolism Aniline Compounds: ME, metabolism

Avidin: CH, chemistry

Biosensing Techniques: IS, instrumentation

*Biosensing Techniques: MT, methods

Biotinylation: MT, methods

Calibration Catalysis

Cross-Linking Reagents: CH, chemistry

*DNA: AN, analysis

DNA Probes: CS, chemical synthesis

Electrochemistry Enzyme Stability

*Ferrous Compounds: CH, chemistry

Gold: CH, chemistry

*Nucleic Acid Hybridization: MT, methods
Organophosphorus Compounds: ME, metabolism

Oxidation-Reduction

Polyamines: CH, chemistry

Research Support, Non-U.S. Gov't

Sensitivity and Specificity

Spectroscopy, Fourier Transform Infrared

CAS REGISTRY NO.: 102-54-5 (ferrocene); 123-30-8 (4-aminophenol); 1405-69-2

(Avidin); 72962-65-3 (4-aminophenylphosphate); 7440-57-5

(Gold); 9007-49-2 (DNA)

CHEMICAL NAME:

0 (Aminophenols); 0 (Aniline Compounds); 0 (Cross-Linking

Reagents); 0 (DNA Probes); 0 (Ferrous Compounds); 0

(Organophosphorus Compounds); 0 (PAMAM

Starburst); 0 (Polyamines); EC 3.1.3.1 (Alkaline

Phosphatase)

L16 ANSWER 17 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2003:856012 SCISEARCH

THE GENUINE ARTICLE: 725NB

TITLE:

Radiolabeling of avidin with very high specific activity

for internal radiation therapy of intraperitoneally

disseminated tumors

AUTHOR:

Mamede M; Saga T (Reprint); Kobayashi H; Ishimori T;

Higashi T; Sato N; Brechbiel M W; Konishi J

CORPORATE SOURCE:

Kyoto Univ, Grad Sch Med, Dept Nucl Med & Diagnost Imaging, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan (Reprint); Kyoto Univ, Grad Sch Med, Dept Nucl Med & Diagnost Imaging, Sakyo Ku, Kyoto 6068507, Japan; NCI,

NIH, Bethesda, MD 20892 USA

COUNTRY OF AUTHOR:

Japan; USA

SOURCE:

CLINICAL CANCER RESEARCH, (1 SEP 2003) Vol. 9, No. 10,

Part 1, pp. 3756-3762.

ISSN: 1078-0432.

PUBLISHER:

AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR,

PHILADELPHIA, PA 19106-4404 USA.

DOCUMENT TYPE:

Article; Journal English

LANGUAGE:
REFERENCE COUNT:

43

ENTRY DATE:

Entered STN: 17 Oct 2003

Last Updated on STN: 17 Oct 2003

ABSTRACT:

Purpose: For the effective internal radiation therapy of i.p. disseminated tumors, we developed avidin (Av)-dendrimer-chelate complex, which can be labeled with indium-111, emitting Auger and conversion electrons, with very high specific activity, and we studied its internalization, biodistribution, and therapeutic effect in nude mice with i.p. tumors.

Experimental Design: Generation 4 dendrimer (G4) was biotinylated and conjugated with 52 1B4M chelates. In-111-G4-bt was mixed with Av to form In-111-G4-Av complex. In-111-G4-Av was incubated with ovarian cancer cells (SHIN-3), and the rate of internalization of the radiolabel into SHIN-3 cells was followed. In-111-G4-Av was i.p. injected into nude mice that had i.p. disseminated SHIN-3 tumors, and the biodistribution was determined. Nude mice bearing i.p. disseminated tumors received i.p. injection of In-111-G4-Av (9.25 or 18.5 MBq x 2, with a 1-week interval) and were followed for the formation of malignant ascites.

Results: Av could be labeled with In-111 with specific activity as high as 37 GBq/mg. More than 75% of the radioactivity was internalized 24 It after binding to cancer cells. In-111-G4-Av accumulated rapidly and highly in the i.p. tumors (128.20% injected dose/gram of tissue at 2 h, 114.91% injected dose/gram of tissue at 24 h for unsaturated compound) with high tumor:background ratios. Treatment with a high dose of In-111-G4-bt-Av was tolerable and showed dose-dependent therapeutic effect.

Conclusions: G4-Av complex, which could be labeled with In-111 with very high specific activity and showed efficient internalization into cancer cells and high accumulation to i.p. tumors, appears to be suitable for the internal radiation therapy of i.p. disseminated tumors using metallic radionuclides emitting Auger and conversion electrons.

CATEGORY:

ONCOLOGY

SUPPL. TERM PLUS: ELECTRON-EMITTING RADIONUCLIDES; NEUTRON-CAPTURE THERAPY;

GROUP NO 6; MONOCLONAL-ANTIBODY; AUGER-ELECTRON;

ANTISENSE OLIGONUCLEOTIDES; STARBURST

DENDRIMERS; PAMAM DENDRIMERS; CELLS-INVITRO;

COLON-CANCER

REFERENCE(S):

Referenced Author	lYear	I VOI.	IARN PG	Referenced Work
(RAU)	I (RPV)	(BVT.)	I (RPG)	(RWK)
(1010)				
BARTH R F BEHR T M BEHR T M BIELINSKA A CHINOL M CHU C S DAYA D DELONG R FRECHET J M J GABIUS H J GREEN N M GRIFFITHS G L HILLER Y	12000	127	1753	MOL CHEM NEUROPATHOL EUR J NUCL MED
BEHR T M	11998	176	1738	ITNT I CANCER
BIFITNSKA A	11996	124	12176	INICIFIC ACIDS RES
CHINOL M	11998	178	1189	IRDIT I CANCED
CHI C S	11000	154	1333	LORGIET CYMECOL SIDV
DAVA D	11991	18	1277	ISEMIN DIACH DATHOL
DEIONG P	11007	186	1762	LI DUADM SCI
FDECHET IM I	11001	1263	102 1710	ISCIENCE
CARTIC U T	11006	1203	1572	LANDICANCED DEC
CDEEN N M	11075	130	105	LADY DOOMETH CHEM
CDIEFIRUS C I	11000	43 01	1005	LADV PROTEIN CHEM
GRIEFILD G L	11007	1010 101	303 1 <i>6</i> 7	INI U CANCER
HILLER Y	11987	248.	110/	BIOCHEM J MED PHYS MED PHYS
HOWELL R W	11992	119	13/1	MED PHYS
HOWELL R W HUMM J L HYAMS D M KOBAYASHI H KOBAYASHI H KOBAYASHI H KOBAYASHI H KOBAYASHI H	11994	Z I	11901	MED PHYS
HYAMS D M	1987	122	1333	ARCH SURG-CHICAGO
KOBAYASHI H	12001	112	587	BIOCONJUGATE CHEM
KOBAYASHI H	12001	114	705	J MAGN RESON IMAGING
KOBAYASHI H	11994	135	1677	J MAGN RESON IMAGING J NUCL MED EUR J NUCL MED
KOBAYASHI H	12000	127	1334	EUR J NUCL MED
KOBAYASHI H KUKOWSKALATALLO J F LOTAN R MCLEAN J R N MCLEAN J R	1999	110	103	BIOCONJUGATE CHEM
KUKOWSKALATALLO J F	1996	193	4897	P NATL ACAD SCI USA
LOTAN R	1988	551	385	ANN NY ACAD SCI
MCLEAN J R N	1989	167	661	BIOCHEM CELL BIOL
MCLEAN J R MEREDITH R F MONSIGNY M MUTO M G PAGANELLI G	1989	119	205	RADIAT RES
MEREDITH R F	1995	36	2229	J NUCL MED ANN NY ACAD SCI
MONSIGNY M	1988	551	399	ANN NY ACAD SCI
MUTO M G	1992	45	265	GYNECOL ONCOL
PAGANELLI G	1994	35	1970	J NUCL MED
PAGANELLI G	1991	51	5960	GYNECOL ONCOL J NUCL MED CANCER RES
PAGANELLI G PAGANELLI G RAZ A	1987	39	353	INT J CANCER CLIN CANCER RES
ROSENBLUM M G	1999	5	953	CLIN CANCER RES
SAGA T	1999	35	1281	EUR J CANCER RADIAT RES CLIN CANCER RES
SAHU S K SATO N	1995	141	193	RADIAT RES
SATO N	2001	7	3606	CLIN CANCER RES
SUGARBAKER P H	2001	31	573	JPN J CLIN ONCOL ANGEW CHEM INT EDIT
TOMALTA D A	1990	29	138	ANGEW CHEM INT EDIT
TOWNSEND R	1981	194	209	BIOCHEM J
WU C C	1994	4	449	BIOORG MED CHEM LETT
YAO Z S	1999	140	479	BIOCHEM J BIOORG MED CHEM LETT J NUCL MED
YAO Z S	11998	190	125	IJ NATL CANCER I
YOO H	11999	116	 I 1799	J NATL CANCER I PHARMACEUT RES
ZHANG M L	11997	124	161	PHARMACEUT RES NUCL MED BIOL
	,,		,	, 1100 0100

L16 ANSWER 18 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:529929 SCISEARCH

THE GENUINE ARTICLE: 691XV

TITLE: The potential of antisense as a CNS therapeutic

AUTHOR: Godfray J (Reprint); Estibeiro P

CORPORATE SOURCE: ExpressOn Biosyst Ltd, Roslin BioCtr, Logan Bldg, Roslin

EH25 9TT, Midlothian, Scotland (Reprint); ExpressOn

Biosyst Ltd, Roslin BioCtr, Roslin EH25 9TT, Midlothian,

Scotland

COUNTRY OF AUTHOR: Scotland

SOURCE: EXPERT OPINION ON THERAPEUTIC TARGETS, (JUN 2003) Vol. 7,

No. 3, pp. 363-376.

ISSN: 1472-8222.

PUBLISHER: ASHLEY PUBLICATIONS LTD, UNITEC HOUSE, 3RD FL, 2 ALBERT

PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND.

DOCUMENT TYPE: General Review; Journal

LANGUAGE: English

REFERENCE COUNT: 78

ENTRY DATE: Entered STN: 13 Jul 2003

Last Updated on STN: 13 Jul 2003

ABSTRACT:

Antisense offers a precise and specific means of knocking down expression of a target gene, and is a major focus of research in neuroscience It has application as a tool in gene function and target and other areas. validation studies and is emerging as a therapeutic technology in its own right. it has become increasingly obvious, however, that there are a number of hurdles to overcome before antisense can be used effectively in the CNS, most notably finding suitable nucleic acid chemistries and an effective delivery vehicle to transport antisense oligonucleotides (AS-ODNs) across the blood-brain barrier (BBB) to their site of action. Despite these problems, a number of potential applications of AS-ODNs in CN5 therapeutics have been validated in vitro and, in some cases, in vivo. the authors outline available nucleic acid chemistries and review progress in the development of non-invasive delivery vehicles that may be applicable to CNS Further to this, they discuss a number of experimental applications of AS-ODNs to CNS research and speculate on the development of ***antisense*** techniques to treat CNS disease.

CATEGORY: PHARMACOLOGY & PHARMACY

SUPPLEMENTARY TERM: antisense; brain; CNS; delivery; fianctional

genomics; oligonucleotide (ODN); target

validation; therapeutic

SUPPL. TERM PLUS: BLOOD-BRAIN-BARRIER; RNA SECONDARY STRUCTURE; LOCKED

NUCLEIC-ACIDS; GENE-EXPRESSION; OLIGONUCLEOTIDE

ARRAYS; DRUG-DELIVERY; IN-VITRO; MORPHINE-TOLERANCE;

PAMAM DENDRIMERS; DOWN-REGULATION

REFERENCE(5):	17 1 7707	I INDU DOL DOSONO DE MINORIO
Referenced Author	•	L ARN PG Referenced Work
(RAU)	(RPY) (RV)	
		==+====+==============================
ARNER S	1988 33	11
BAKHSHI S	1995 26	133 J NEURO-ONCOL
BANKS W A	2001 297	1113 J PHARMACOL EXP THER
BELTINGER C	1995 95	1814 J CLIN INVEST
BIELINSKA A	1996 24	2176 NUCLEIC ACIDS RES
BOHN L M	2000 408	720 NATURE
BRAASCH D A	2002 41	4503 BIOCHEMISTRY-US
CHIANG M Y	1991 266	18162 J BIOL CHEM
CLARK C L	1997 25	4098 NUCLEIC ACIDS RES
CLEEK R L	1997 35	525 J BIOMED MATER RES
CROOKE S T	1999 1489	9 31 BBA-GENE STRUCT EXPR
DELONG R	1997 86	762 J PHARM SCI
DING Y	2001 29	1034 NUCLEIC ACIDS RES
DOVE A	2002 20	121 NAT BIOTECHNOL
EPA W R	2000 10	469 ANTISENSE NUCLEIC A
ESTIBEIRO P	2001 24	S56 TRENDS NEUROSCI S
FISHER R S	2002 16	579 CNS DRUGS
FRANTSEVA M V	2002 22	453 J CEREBR BLOOD F MET
FRIEDMAN K J	1999 274	36193 J BIOL CHEM
GEARY R S	2001 296	890 J PHARMACOL EXP THER
GROOTHUIS D R	2000 2	45 NEURO-ONCOLOGY

GUM R J	2003	52	21	DIABETES
HALFORD J C G	2001	12	353	CURR DRUG TARGETS
HANNON G J	2002	418	1244	NATURE
	12002	1297	1609	SCIENCE
HUGHES M D	12001	•	•	DRUG DISCOV TODAY
JAIN K K	2001	•		PHARMACOGENOMICS
	-	•		PEPTIDES
	2001	•		
	12000	•	319	J DRUG TARGET
	12000			ANTISENSE NUCLEIC A
	12002		-	ANTISENSE NUCLEIC A
	2002	•	•	P NATL ACAD SCI USA
KURRECK J	12002	130	1911	NUCLEIC ACIDS RES
LAKKARAJU A	2001	1276	132000	J BIOL CHEM
LEARY D	2000	21	112	AM BOOK REV
MACDONALD T J	2001	121	3785	ANTICANCER RES
MANOHARAN M	2002			ANTISENSE NUCLEIC A
	2002		-	IJ MOL NEUROSCI
	12001	•	•	BRAIN RES
	2001			CURR CANC DRUG TARGE
	2001	11507	1176	BIOCHIM BIOPHYS ACTA
MERCATANTE D R				•
MILLER G	12002	•	•	SCIENCE
	11997		•	NAT BIOTECHNOL
MIR K U	1999	•	•	NAT BIOTECHNOL
MORITA K	2002	•		BIOORG MED CHEM LETT
MUKAI S	12000		•	CANCER RES
NORMANDSDIQUI N	1998	163	163	INT J PHARM
PAGE D	1		1	UNPUB RECENT RES DEV
PARDRIDGE W M	2001	16	11	DRUG DISCOV TODAY
PARDRIDGE W M	12001	187	97	JPN J PHARMACOL
PARDRIDGE W M	2002	1		NAT REV DRUG DISCOV
PARDRIDGE W M	2002	•		DRUG DISCOV TODAY
PRZEWLOCKA B	12002			NEUROSCI LETT
READ T A	12002	•	•	CURR PHARM BIOTECHNO
ROBINSON E S J	11997		•	IJ PSYCHOPHARMACOL
ROH H	12000		-	CANCER RES
	12000			•
SAZANI P				NUCLEIC ACIDS RES
SHCHEPINOV M S	1997		•	NUCLEIC ACIDS RES
SHI N Y	12000	•		IP NATL ACAD SCI USA
SHI N Y	12000	•		P NATL ACAD SCI USA
SHOICHET M S	12000		•	ADV DRUG DELIVER REV
SKUTELLA T	1994	14	579	CELL MOL NEUROBIOL
SLAUGENHAUPT S A	2001	68	598	AM J HUM GENET
SUMMERTON J	1997	7	187	ANTISENSE NUCLEIC A
SUN H B	2002	104	246	MOL BRAIN RES
TANAKA S	12002	50	965	RINSHO BYORI
TOULME J J	2001	119	17	NAT BIOTECHNOL
TYLER B M	1999	196		P NATL ACAD SCI USA
VANHUIJSDUIJNEN R H	2002			DRUG DISCOV TODAY
VICKERS T A	2000			NUCLEIC ACIDS RES
WAHLESTEDT C	12000			P NATL ACAD SCI USA
	12002			IANN NY ACAD SCI
WAKUTANI Y	•	•		
YAZAKI T	11996		•	MOL PHARMACOL
YOO H	12000		•	NUCLEIC ACIDS RES
YUE S	2001		•	ZHONGHUA YI XUE ZA Z
ZHANG Y	12002			J GENE MED
	12002	•		MOL THER
ZINKER B A	12002	199	11357	P NATL ACAD SCI USA

L16 ANSWER 19 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:266191 SCISEARCH

THE GENUINE ARTICLE: 780QG

TITLE: Water-soluble polycationic dendrimers with a

phosphoramidothioate backbone: Preliminary studies of

cytotoxicity and oligonucleotide/plasmid

delivery in human cell culture

AUTHOR: Maszewska M; Leclaire J; Cieslak M; Nawrot B; Okruszek A

(Reprint); Caminade A M; Majoral J P

CORPORATE SOURCE: Polish Acad Sci, Ctr Mol & Macromol Studies, Dept Bioorgan

Chem, Sienkiewicza 112, PL-90363 Lodz, Poland (Reprint); Polish Acad Sci, Ctr Mol & Macromol Studies, Dept Bioorgan Chem, PL-90363 Lodz, Poland; CNRS, Chim Coordinat Lab,

F-31077 Toulouse 4, France

COUNTRY OF AUTHOR: Poland; France

SOURCE: OLIGONUCLEOTIDES, (2003) Vol. 13, No. 4, pp. 193-205.

ISSN: 1545-4576.

PUBLISHER: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY

10538 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 28

ENTRY DATE: Entered STN: 26 Mar 2004

Last Updated on STN: 26 Mar 2004

ABSTRACT:

A series of water-soluble polycationic dendrimers with a phosphoramidothioate backbone (P-dendrimers) was studied in human cell culture. Preliminary studies have shown that P-dendrimers of series 1 and 2, possessing N,N-diethyl-ethylenediamine hydrochloride functions at the surface, show rather moderate cytotoxicity toward HeLa, HEK 293, and HUVEC cells in a standard MTT assay in serum-containing medium, generally lower than lipofectin. The experiments of cellular uptake have shown the necessity for the presence of serum for transfection with P-dendrimers of series 1 and 2. These compounds efficiently delivered fluorescein-labeled oligodeoxyribonucleotide into HeLa cells in serum-containing medium, but they failed to do so in HUVEC cell culture. The dendrimers were found to be successful mediators of transfection of the HeLa cells with a DNA plasmid containing the functional gene of enhanced green fluorescent protein (EGFP).

CATEGORY: BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOTECHNOLOGY & APPLIED

MICROBIOLOGY

SUPPL. TERM PLUS: PHOSPHORUS-CONTAINING DENDRIMERS; ANTISENSE

OLIGONUCLEOTIDES; PAMAM DENDRIMERS;

POLYAMIDOAMINE DENDRIMERS; STARBURST DENDRIMERS;

SURFACE-CHEMISTRY; GENE-TRANSFER; COMPLEXES; EXPRESSION;

GROWTH

	Year	•	•	Referenced Work
(RAU)			(RPG) 	· · ·
AGRAWAL S		т===== 16	172	MOL MED TODAY
ALAHARI S K	,	1286		J PHARMACOL EXP THER
AXEL D I	•	137	·	IJ VASC RES
BIELINSKA A			,	NUCLEIC ACIDS RES
BOUSSIF O		13		IGENE THER
CIESLAK M	12002	277		J BIOL CHEM
DASS C R	2002	154	13	J PHARM PHARMACOL
DELONG R	1997	86	762	J PHARM SCI
GALLIOT C	1997	277	1981	SCIENCE
GLEAVES C A	11990	128	171	J VIROL METHODS
HAENSLER J	11993	4	372	BIOCONJUGATE CHEM
HANSEN M B	1989	119	1203	J IMMUNOL METHODS
HELIN V	1999	58	95	BIOCHEM PHARMACOL
JAFFE E A	1973	152	2745	J CLIN INVEST
KOLTOVER I	1998	281	78	SCIENCE
KUKOWSKALATALLO J F	1996	93	4897	P NATL ACAD SCI USA

LAUNAY N	1994 33	1589	ANGEW CHEM INT EDIT
LOUP C	1999 5	3644	CHEM-EUR J
POXON S W	1996 3	1255	DRUG DELIV
RAJUR S B	1997 8	1935	BIOCONJUGATE CHEM
SATO N	2001 7	3606	CLIN CANCER RES
SLANY M	1995 117	19764	J AM CHEM SOC
TANG M X	1996 7	1703	BIOCONJUGATE CHEM
TOMALIA D A	1990 29	138	ANGEW CHEM INT EDIT
WAGNER R W	1994 372	333	NATURE
WANG Y O	2000 2	1602	MOL THER
YOO H	1999 16	1799	PHARMACEUT: RES
YOO H	2000 28	14225	NUCLEIC ACIDS RES

L16 ANSWER 20 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

DUPLICATE 3 on STN

2004087708 EMBASE ACCESSION NUMBER:

Interactions between PAMAM dendrimers and bovine TITLE:

serum albumin.

AUTHOR: Klajnert B.; Stanislawska L.; Bryszewska M.; Palecz B. CORPORATE SOURCE: M. Bryszewska, Department of General Biophysics, Univ. of

Lodz, ul. Banacha 12/16, Lodz 90-237, Poland.

marbrys@biol.uni.lodz.pl

Biochimica et Biophysica Acta - Proteins and Proteomics, SOURCE:

(30 May 2003) Vol. 1648, No. 1-2, pp. 115-126.

Refs: 34

ISSN: 1570-9639 CODEN: BBAPBW

COUNTRY: Netherlands DOCUMENT TYPE: Journal; Article

Clinical Biochemistry FILE SEGMENT: 029

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20040311

Last Updated on STN: 20040311

ABSTRACT: Dendrimers are a new class of polymeric materials. They are globular, highly branched, monodisperse macromolecules. Due to their structure, dendrimers promise to be new, effective biomedical materials as ***oligonucleotide*** transfection agents and drug carriers. More information about biological properties of dendrimers is crucial for further investigation of dendrimers in therapeutic applications. In this study the mechanism of interactions between polyamidoamine (PAMAM) dendrimers and bovine serum albumin (BSA) was examined. PAMAM dendrimers are based on an ethylenediamine core and branched units are constructed from both methyl acrylate and ethylenediamine. We used three types of PAMAM dendrimers with different surface groups (-COOH, -NH(2), -OH). As BSA contains two tryptophan residues we were able to evaluate dendrimers influence on protein molecular conformation by measuring the changes in the fluorescence of BSA in the presence of dendrimers. Additionally experiments with a fluorescent probe 1-anilinonaphthalene-8-sulfonic acid (ANS) were carried out. The differential scanning calorimetry (DSC) was chosen to investigate impact on protein thermal stability upon the dendrimers. Our experiments showed that the extent of the interactions between BSA and dendrimers strongly depends on their surface groups and is the biggest for amino-terminated dendrimers. . COPYRGT. 2003 Elsevier Science B.V. All rights reserved.

CONTROLLED TERM: Medical Descriptors:

> *molecular dynamics molecular interaction molecular mechanics albumin blood level

cattle

experimental test intermethod comparison surface property protein analysis fluorescence conformation

differential scanning calorimetry

thermostability

nonhuman

controlled study

article

priority journal
Drug Descriptors:

*polyamide
*amine
*albumin
*dendrimer
ethylenediamine

acrylic acid methyl ester

tryptophan fluorescent dye

8 anilino 1 naphthalenesulfonic acid

CAS REGISTRY NO.: (polyamide) 63428-83-1; (ethylenediamine) 107-15-3;

(acrylic acid methyl ester) 96-33-3; (tryptophan)

6912-86-3, 73-22-3; (8 anilino 1 naphthalenesulfonic acid)

82-76-8

L16 ANSWER 21 OF 41 MEDLINE on STN ACCESSION NUMBER: 2003372862 MEDLINE DOCUMENT NUMBER: PubMed ID: 12907739

TITLE: Impact of surface chemistry and blocking strategies on DNA

microarrays.

AUTHOR: Taylor Scott; Smith Stephanie; Windle Brad; Guiseppi-Elie

Anthony

CORPORATE SOURCE: Center for Bioelectronics, Biosensors and Biochips (C3B),

Virginia Commonwealth University, PO Box 843038, 601 West

Main Street, Richmond, VA 23284-3038, USA.

SOURCE: Nucleic acids research, (2003 Aug 15) 31 (16) e87.

Journal code: 0411011. ISSN: 1362-4962.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200401

ENTRY DATE: Entered STN: 20030809

Last Updated on STN: 20040130 Entered Medline: 20040129

ABSTRACT:

The surfaces and immobilization chemistries of DNA microarrays are the foundation for high quality gene expression data. Four surface modification chemistries, poly-L-lysine (PLL), 3-glycidoxypropyltrimethoxysilane (GPS), DAB-AM-poly(propyleminime hexadecaamine) dendrimer (DAB) and 3-aminopropyltrimethoxysilane (APS), were evaluated using cDNA and ***oligonucleotide*** sub-arrays. Two un-silanized glass surfaces, RCA-cleaned and immersed in Tris-EDTA buffer were also studied. DNA on amine-modified surfaces was fixed by UV (90 mJ/cm(2)), while DNA on GPS-modified surfaces was immobilized by covalent coupling. Arrays were blocked with either succinic anhydride (SA), bovine serum albumin (BSA) or left unblocked prior to hybridization with labeled PCR product. Quality factors evaluated were surface affinity for cDNA versus oligonucleotides, spot and background intensity, spotting concentration and blocking chemistry. Contact angle measurements and atomic force microscopy were preformed to characterize surface wettability and morphology. The GPS surface exhibited the lowest background intensity regardless of blocking method. Blocking the arrays

did not affect raw spot intensity, but affected background intensity on amine surfaces, BSA blocking being the lowest. Oligonucleotides and cDNA on unblocked GPS-modified slides gave the best signal (spot-to-background intensity ratio). Under the conditions evaluated, the unblocked GPS surface along with amine covalent coupling was the most appropriate for both cDNA and ***oligonucleotide*** microarrays.

CONTROLLED TERM: Check Tags: Comparative Study

*DNA, Complementary: CH, chemistry DNA, Complementary: GE, genetics

Glyceraldehyde-3-Phosphate Dehydrogenases: GE, genetics

Microscopy, Atomic Force Molecular Structure

*Oligonucleotide Array Sequence Analysis: MT,

methods

Oligonucleotide Probes: CH, chemistry Oligonucleotide Probes: GE, genetics

Polyamines: CH, chemistry Polylysine: CH, chemistry Propylamines: CH, chemistry Reproducibility of Results Research Support, Non-U.S. Gov't

Silanes: CH, chemistry Surface Properties

13822-56-5 (3-aminopropyltrimethoxysilane); 25104-18-1 CAS REGISTRY NO.:

(Polylysine)

CHEMICAL NAME: 0 (3-glycidoxypropyltrimethoxysilane); 0 (DNA,

> Complementary); 0 (Oligonucleotide Probes); 0 (PAMAM Starburst); 0 (Polyamines); 0 (Propylamines); 0 (Silanes); EC 1.2.1.- (Glyceraldehyde-3-Phosphate

Dehydrogenases)

L16 ANSWER 22 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

DUPLICATE 4 on STN

ACCESSION NUMBER: 2005101911 EMBASE

Optimisation of dendrimer-mediated gene transfer by anionic TITLE:

oligomers.

Maksimenko A.V.; Mandrouquine V.; Gottikh M.B.; Bertrand AUTHOR:

J.-R.; Majoral J.-P.; Malvy C.

CORPORATE SOURCE: A.V. Maksimenko, CNRS UMR 8121, Institut Gustave Roussy, 39

rue Camille Desmoulins, 94805 Villejuif Cedex, France.

andremak@igr.fr

Journal of Gene Medicine, (2003) Vol. 5, No. 1, pp. 61-71. SOURCE:

Refs: 25

ISSN: 1099-498X CODEN: JGMEFG

COUNTRY: DOCUMENT TYPE: United Kingdom Journal; Article

FILE SEGMENT:

022 Human Genetics

037 Drug Literature Index

039 Pharmacy

LANGUAGE:

English

SUMMARY LANGUAGE:

English

ENTRY DATE:

Entered STN: 20050317

Last Updated on STN: 20050317

ABSTRACT: Background: The application of synthetic vectors for gene transfer has potential advantages over virus-based systems. Their use, however, is limited since they generally lack the efficiency of gene transfer achieved with recombinant viral vectors such as adenovirus. Polyamidoamine (PAMAM) and phosphorus-containing dendrimers (P-dendrimers) are specific polymers with a defined spherical structure. They bind to DNA through electrostatic interactions thus forming complexes that efficiently transfect cells in vitro. Methods and results: The influence of anionic oligomers (

oligonucleotides , dextran sulfate) on dendrimer-mediated polyfection of

cultured cells has been studied. Anionic oligomers have been found to increase significantly the capacity of the **PAMAM** and P-dendrimers for DNA delivery into cells when they were mixed with plasmid DNA before addition of dendrimers. The efficiency of the DNA/dendrimer penetration depends on the size, structure and charge of anionic oligomers. Conclusions: Our results represent an important step towards the optimisation of gene transfer mediated by two types of dendrimers. The use of anionic oligomers improves the efficiency of gene expression within cells. As a consequence, a very efficient cell polyfection can be achieved with a lower plasmid quantity for the ***PAMAM*** dendrimer greatly increasing the gene expression level for P-dendrimers. Copyright .COPYRGT. 2002 John Wiley & Sons, Ltd.

CONTROLLED TERM: Medical Descriptors:

*nonviral gene delivery system

process optimization
qenetic transfection

cell culture
penetrance
molecular size
chemical structure

electricity gene expression plasmid vector

human nonhuman mouse

controlled study

human cell animal cell article

priority journal
Drug Descriptors:

dendrimer oligomer

oligonucleotide
dextran sulfate
polyamide
plasmid DNA

beta galactosidase: PR, pharmaceutics

CAS REGISTRY NO.: (dextran sulfate) 9011-18-1, 9042-14-2; (polyamide)

63428-83-1

L16 ANSWER 23 OF 41 MEDLINE on STN

ACCESSION NUMBER: 2002064592 MEDLINE DOCUMENT NUMBER: PubMed ID: 11788736

TITLE: DNA microarrays with PAMAM dendritic linker

systems.

AUTHOR: Benters Rudiger; Niemeyer Christof M; Drutschmann Denja;

Blohm Dietmar; Wohrle Dieter

CORPORATE SOURCE: Chimera Biotec GmbH, Schwachhauser Heerstrasse 30A, 28209

Bremen, Germany.

SOURCE: Nucleic acids research, (2002 Jan 15) 30 (2) E10.

Journal code: 0411011. ISSN: 1362-4962.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200202

ENTRY DATE: Entered STN: 20020125

Last Updated on STN: 20020205 Entered Medline: 20020204

ABSTRACT:

The DNA microarray-based analysis of single nucleotide polymorphisms (SNPs) is important for the correlation of genetic variations and individual phenotypes, and for locating disease-causing genes. To facilitate the development of surfaces suitable for immobilization of oligonucleotides, we report here a novel method for the surface immobilization of DNA using pre-fabricated polyamidoamine (PAMAM) starburst dendrimers as mediator moieties. Dendrimers containing 64 primary amino groups in their outer sphere are covalently attached to silvlated glass supports and, subsequently, the dendritic macromolecules are modified with glutaric anhydride and activated with N-hydroxysuccinimide. As a result of the dendritic PAMAM linker system the surfaces reveal both a very high immobilization efficiency for amino-modified DNA-oligomers, and also a remarkable high stability during repeated regeneration and re-using cycles. The performance of dendrimer-based DNA microarrays in the discrimination of SNPs is demonstrated.

CONTROLLED TERM: Anhydrides: CH, chemistry

> Base Pair Mismatch: GE, genetics Conservation of Natural Resources

*DNA: GE, genetics DNA: ME, metabolism

DNA Mutational Analysis: MT, methods

DNA Probes: GE, genetics DNA Probes: ME, metabolism

Fluorescence

Glass: CH, chemistry Glutarates: CH, chemistry Nucleic Acid Hybridization

*Oligonucleotide Array Sequence Analysis: MT,

methods

*Polyamines: CH, chemistry Polyamines: ME, metabolism

*Polymorphism, Single Nucleotide: GE, genetics

Research Support, Non-U.S. Gov't Sensitivity and Specificity Succinimides: CH, chemistry

CAS REGISTRY NO.:

108-55-4 (glutaric anhydride); 6066-82-6 (N-hydroxysuccinimide); 9007-49-2 (DNA)

CHEMICAL NAME:

0 (Anhydrides); 0 (DNA Probes); 0 (Glass); 0 (Glutarates);

0 (PAMAM Starburst); 0 (Polyamines); 0

L16 ANSWER 24 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

(Succinimides)

STN

ACCESSION NUMBER: 2002:115377 SCISEARCH

THE GENUINE ARTICLE: 516JY

TITLE: DNA microarrays with PAMAM dendritic linker

Benters R; Niemeyer C M (Reprint); Drutschmann D; Blohm D; AUTHOR:

Wohrle D

CORPORATE SOURCE: Univ Bremen, FB UFT 2, POB 330440, D-28334 Bremen, Germany

(Reprint); Univ Bremen, FB UFT 2, D-28334 Bremen, Germany; Chimera Biotec GmbH, D-28209 Bremen, Germany; Univ Bremen,

Inst Organ & Macromol Chem, D-28334 Bremen, Germany

COUNTRY OF AUTHOR:

Germany

SOURCE:

NUCLEIC ACIDS RESEARCH, (15 JAN 2002) Vol. 30, No. 2, arn.

e10.

ISSN: 0305-1048.

OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP, PUBLISHER:

ENGLAND.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

ENTRY DATE:

Entered STN: 15 Feb 2002

Last Updated on STN: 15 Feb 2002

ABSTRACT:

The DNA microarray-based analysis of single nucleotide polymorphisms (SNPs) is Important for the correlation of genetic variations and individual phenotypes, and for locating disease-causing genes. To facilitate the development of surfaces suitable for immobilization of oligonucleotides , we report here a novel method for the surface Immobilization of DNA using pre-fabricated polyamidoamine (PAMAM) starburst dendrimers as mediator moieties. Dendrimers containing 64 primary amino groups In their outer sphere are covalently attached to silvlated. glass supports and, subsequently, the dendritic macromolecules are modified with glutaric anhydride and activated with N-hydroxysuccinimide. As a result of the dendritic ***PAMAM*** linker system the surfaces reveal both a very high Immobilization efficiency for amino-modified DNA-oligomers, and also a remarkable high stability during repeated regeneration and re-using cycles. The performance of dendrimer-based DNA microarrays in the discrimination of SNPs is demonstrated.

CATEGORY: BIOCHEMISTRY & MOLECULAR BIOLOGY

SUPPL. TERM PLUS: MASS-SPECTROMETRY; NUCLEIC-ACIDS; ARRAYS; HYBRIDIZATION

REFERENCE(S):

(RAU)	(RPY)	(RVL)	(RPG)	• • •
BOLDT L CHEUNG V G DIEHL F DRYSDALE C M	2001 1998 1999 2001 2000	2 21 29 97	686 15 E38 10483	CHEMBIOCHEM BIOS 98 5 WORLD C BI NAT GENET S NUCLEIC ACIDS RES P NATL ACAD SCI USA
FAN J B	2001 2000 2000	10	E36 853 19	NUCLEIC ACIDS RES GENOME RES GENE
GRIFFIN T J GUO B C	2000 1999	18 71	77 R333	TRENDS BIOTECHNOL ANAL CHEM
ISOLA N R	2001 2001 2000	73	1189 2126 1001	EXP GERONTOL ANAL CHEM NAT BIOTECHNOL
MASKOS U MCCARTHY J J	1992 2000	20 18	1679 505	NUCLEIC ACIDS RES NAT BIOTECHNOL
PIEHLER J	2000	115	527 473 471	J BIOMOL STRUCT DYN BIOSENS BIOELECTRON GENOME RES
SHCHEPINOV M S SOUTHERN E	1997 1999	25 21	1155 5	NUCLEIC ACIDS RES NAT GENET S
TOMALIA D A WANG D G	1990 1998	129	215 138 1077 1361	BBA-GENE STRUCT EXPR ANGEW CHEM INT EDIT SCIENCE AM J CARDIOL

L16 ANSWER 25 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:913942 SCISEARCH

THE GENUINE ARTICLE: 491JX

TITLE: Tumor targeting and imaging of intraperitoneal tumors by

use of antisense oligo-DNA complexed with

dendrimers and/or avidin in mice

AUTHOR: Sato N; Kobayashi H (Reprint); Saga T; Nakamoto Y;

Ishimori T; Togashi K; Fujibayashi Y; Konishi J; Brechbiel

M W

CORPORATE SOURCE: Kyoto Univ, Hitachi Med Co, Grad Sch Med, Dept Diagnost &

Intervent Imagiol, Sakyo Ku, 54 Kawaharacho, Kyoto

6068507, Japan (Reprint); Kyoto Univ, Hitachi Med Co, Grad

Sch Med, Dept Diagnost & Intervent Imagiol, Sakyo Ku,

Kyoto 6068507, Japan; Kyoto Univ, Dept Nucl Med & Diagnost Imaging, Kyoto 6068507, Japan; Fukui Med Univ, Biomed Imaging Res Ctr, Mol Imaging Div, Fukui 9101193, Japan; NCI, Chem Sect, Radiat Oncol Branch, NIH, Bethesda, MD

20892 USA

COUNTRY OF AUTHOR: J

Japan; USA

SOURCE:

CLINICAL CANCER RESEARCH, (NOV 2001) Vol. 7, No. 11, pp.

3606-3612.

ISSN: 1078-0432.

PUBLISHER:

AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL

35202 USA.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

41

ENTRY DATE:

Entered STN: 30 Nov 2001

Last Updated on STN: 30 Nov 2001

ABSTRACT:

To establish an effective nonviral gene delivery and a corresponding imaging method. for i.p.-disseminated tumors, various **oligonucleotide**-carrier complexes were synthesized, and their in vitro and in vivo properties were examined.

The 20-mer multiamino-linked oligonucleotide (oligo), synthesized antisense against the c-erbB-2 sequence, and the 3'-biotinylated form of the same oligonucleotide (oligo-Bt) were In-111 labeled In-111-oligo was mixed through a diethylenetriaminepentaacetic acid chelate. with generation 4 polyamidoamine dendrimer (G4) or with biotinylated G4 (G4-Bt), which are positively charged to form electrostatic complexes. In-111-oligo/G4-Bt and In-111-oligo-Bt were conjugated to avidin (In-111-oligo/G4-Av and In-111-oligo-Av, respectively). In-111-oligo/G4. In-111-oligo/G4-Av, In-111-oligo-Av, and carrier-free In-111-oligo (2.96 kBg/22.4-45.9 ng of oligo) were examined for internalization in vitro in human Biodistribution of In-111-oligo-carrier ovarian cancer cells (SHIN3). complexes or In-111-oligo was examined in normal (n = 4-7) or i.p. tumor-bearing (n = 6-10) mice 2-24 h after Lp. injection (74 kBq/125-300 ng). Scintigraphy of i.p. tumor-bearing and normal mice was performed at various times postinjection of In-111-oligo-carrier complex or In-111-oligo (1.85 MBq/2.2 nq).

In-111-oligo-carrier complexes bound to the tumor cells were internalized at a rate of 34-56% at 24 h. In vivo, G4, G4-Av, and Av significantly enhanced tumor delivery of In-111-oligo [9.1, 14.5, and 24.4% of injected dose per g of tissue (ID/g) at 24 h; P < 0.05, < 0.01, and < 0.0001, respectively] compared with delivery without carrier (0.8% ID/g). Scintigrams of In-111-oligo delivered to the i.p.-disseminated tumors by the carriers were successfully obtained.

In conclusion, G4, G4-Av, and Av can effectively deliver In-111-oligo to i.p.-dissenunated tumors. In-111-oligo-carrier complexes also have potential as tracers for imaging and monitoring of gene delivery.

CATEGORY:

ONCOLOGY

SUPPL. TERM PLUS:

STARBURST POLYAMIDOAMINE DENDRIMERS; SUICIDE GENE-THERAPY; MONOCLONAL-ANTIBODY; PLASMID DNA; CATIONIC LIPOSOMES;

EFFICIENT TRANSFER; **PAMAM** DENDRIMERS; NUDE-MOUSE; IN-VIVO; **OLIGONUCLEOTIDES**

Referenced Author (RAU)	(RPY) (RVL	(RPG)	ferenced Work (RWK)
ABDOU S	11997 142		H VIROL
ALAHARI S K	11996 50	•	PHARMACOL
BIELINSKA A U	1997 1353	180 BBA-	-GENE STRUCT EXPR
BIELINSKA A U	1999 10	843 BIO	CONJUGATE CHEM
BIELINSKA A	1996 24	2176 NUC	LEIC ACIDS RES
BOADO R J	1992 3	519 BIO	CONJUGATE CHEM

BOADO R J	1994	15	406	BIOCONJUGATE CHEM
CHALOIN L	1998	1243	601	BIOCHEM BIOPH RES CO
DELONG R	1997	186	762	J PHARM SCI
FUJIBAYASHI Y	1999	126	17	NUCL MED BIOL
GAO X	1995	12	710	GENE THER
HABERLAND A	2000		229	PHARMACEUT RES
HAENSLER J	1993	14	372	BIOCONJUGATE CHEM
HUDDE T	1999	16	939	GENE THER
KANG S H	1999	19	497	ANTISENSE NUCLEIC A
KIKUCHI A	1999	110	947	HUM GENE THER
KIM J	1999	16	172	CANCER GENE THER
KOBAYASHI H	1995	186	310	JPN J CANCER RES
KOBAYASHI H	2000	127	1334	EUR J NUCL MED
KOBAYASHI H	1999	110	103	BIOCONJUGATE CHEM
	1996		4897	P NATL ACAD SCI USA
LEONETTI J P	1990	11	149	BIOCONJUGATE CHEM
LEWIS J G	1996	193	3176	P NATL ACAD SCI USA
MARUYAMATABATA H	2000	17	53	GENE THER
PARDRIDGE W M	1991	1288	30	FEBS LETT
PIWNICAWORMS D	1994	135	1064	J NUCL MED
PRINCEN F	2000	18	79	J DRUG TARGET
QIN L H	1998	19	553	HUM GENE THER
RAJUR S B	1997	18	935	BIOCONJUGATE CHEM
SATO N	1999	140	685	J NUCL MED
STEIN C A	1993	1261	1004	SCIENCE
TANG M X	1997		823	GENE THER
THEDREZ P	1989	149	3081	CANCER RES
TOMALIA D A	1990	129	138	ANGEW CHEM INT EDIT
	12000		156	EUR J RADIOL
YAKUBOV L A	1989	86	6454	P NATL ACAD SCI USA
YAO Z S	1998	190	25	J NATL CANCER I
YAO Z S	11999	40	1479	J NUCL MED
YOO H	1999	16	1799	PHARMACEUT RES
ZELPHATI O		•	111493	P NATL ACAD SCI USA
ZHAO Q Y	1995	5	185	ANTISENSE RES DEV

L16 ANSWER 26 OF 41 MEDLINE on STN ACCESSION NUMBER: 2002098006 MEDLINE DOCUMENT NUMBER: PubMed ID: 11828505

TITLE: Dendrimer-activated solid supports for nucleic acid and

protein microarrays.

AUTHOR: Benters R; Niemeyer C M; Wohrle D

CORPORATE SOURCE: Institute of Organic and Macromolecular Chemistry,

University Bremen, FB2, P.O. Box 330440, 28334 Bremen,

Germany.

SOURCE: Chembiochem: a European journal of chemical biology, (2001

Sep 3) 2 (9) 686-94.

Journal code: 100937360. ISSN: 1439-4227. Germany: Germany, Federal Republic of Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200204

ENTRY DATE: Entered STN: 20020206

Last Updated on STN: 20020419 Entered Medline: 20020418

ABSTRACT:

PUB. COUNTRY:

DOCUMENT TYPE:

The generation of chemically activated glass surfaces is of increasing interest for the production of microarrays containing DNA, proteins, and low-molecular-weight components. We here report on a novel surface chemistry for highly efficient activation of glass slides. Our method is based on the initial modification of glass with primary amino groups using a protocol,

specifically optimized for high aminosilylation yields, and in particular, for homogeneous surface coverages. In a following step the surface amino groups are activated with a homobifunctional linker, such as disuccinimidylglutarate (DSG) or 1,4-phenylenediisothiocyanate (PDITC), and then allowed to react with a starburst dendrimer that contains 64 primary amino groups in its outer sphere. Subsequently, the dendritic monomers are activated and crosslinked with a homobifunctional spacer, either DSG or PDITC. This leads to the formation of a thin, chemically reactive polymer film, covalently affixed to the glass substrate, which can directly be used for the covalent attachment of amino-modified components, such as oligonucleotides. The resulting DNA microarrays were studied by means of nucleic acid hybridization experiments using fluorophor-labeled complementary oligonucleotide targets. The results indicate that the novel dendrimer-activated surfaces display a surface coverage with capture oligomers about twofold greater than that with conventional microarrays containing linear chemical linkers. In addition, the experiments suggest that the hybridization occurs with decreased steric hindrance, likely a consequence of the long, flexible linker chain between the surface and the DNA oligomer. The surfaces were found to be resistant against repeated alkaline regeneration procedures, which is likely a consequence of the crosslinked polymeric structure of the dendrimer film. The high stability allows multiple hybridization experiments without significant loss of signal intensity. The versatility of the dendrimer surfaces is also demonstrated by the covalent immobilization of streptavidin as a model protein.

CONTROLLED TERM:

Autoradiography

Cross-Linking Reagents

*Glass

Indicators and Reagents Nucleic Acid Hybridization *Nucleic Acids: CH, chemistry

*Oligonucleotide Array Sequence Analysis: MT,

Oligonucleotides: CH, chemistry

Photometry Polyamines

Research Support, Non-U.S. Gov't

Streptavidin: CH, chemistry

Surface Properties

Thiocyanates: CH, chemistry

CAS REGISTRY NO.:

4044-65-9 (bitoscanate); 9013-20-1 (Streptavidin)

CHEMICAL NAME: 0 (Cross-Linking Reagents); 0 (Glass); 0 (Indicators and

Reagents); 0 (Nucleic Acids); 0 (Oligonucleotides

); 0 (PAMAM Starburst); 0 (Polyamines); 0

(Thiocyanates)

L16 ANSWER 27 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2001:859784 SCISEARCH

THE GENUINE ARTICLE: 485ZJ

TITLE:

Transcytosis of nanoparticle and dendrimer delivery

systems: evolving vistas

AUTHOR: Florence A T (Reprint); Hussain N

Univ London, Sch Pharm, Ctr Drug Delivery Res, 29-39 CORPORATE SOURCE:

Brunswick Sq, London WC1N 1AX, England (Reprint); Univ London, Sch Pharm, Ctr Drug Delivery Res, London WC1N 1AX,

England

COUNTRY OF AUTHOR:

England

SOURCE:

ADVANCED DRUG DELIVERY REVIEWS, (1 OCT 2001) Vol. 50,

Supp. [1], pp. S69-S89.

ISSN: 0169-409X.

ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, PUBLISHER:

NETHERLANDS.

DOCUMENT TYPE:

Article; Journal

LANGUAGE: English

REFERENCE COUNT: 86

Entered STN: 9 Nov 2001

Last Updated on STN: 9 Nov 2001

ABSTRACT:

ENTRY DATE:

The translocation of particulate matter across the gastrointestinal tract is now a well documented phenomenon offering new potential for the delivery of drugs with poor dissolution profiles and labile chemistries via encapsulation in biodegradable nanoparticles. The last few years have seen an acceleration in the number of publications describing the varying facets of this approach and the multidisciplinary nature of this field. This review delineates data from this rather fragmented area and from cognate fields to provide a physicochemical viewpoint of the importance of surface chemistries of oral drug delivery vehicles and their interactions in and with gut contents prior to The role of lymphoid and non-lymphoid tissues is examined, and the role of bioadhesion is discussed. The exciting potential of molecular encapsulation of drugs via dendrimers and star branched molecules is discussed in the context of nanotechnological applications for the oral route. vistas include a better understanding of the plasticity of the intestinal epithelium and M-cell induction as well as the influence of disease states on to an understanding of the subject including (i) some background knowledge on particulate uptake (the subject of several reviews), (ii) factors affecting uptake such as diameter and surface charge and character, (iii) the dynamic nature of particle interactions in the gut, (iv) the dynamic nature of the processes of capture, adhesion, uptake, transcytosis and translocation, and (v) the influence of surface ligands. (C) 2001 Elsevier Science B.V. All rights reserved.

CATEGORY: PHARMACOLOGY & PHARMACY

SUPPLEMENTARY TERM: nanoparticle; dendrimer; translocation; Peyer's patch;

uptake; absorption; drug delivery; intestine;

transfection; gene therapy

SUPPL. TERM PLUS: GASTROINTESTINAL-TRACT; PARTICLE-SIZE; ORAL UPTAKE;

IN-VIVO; ANTISENSE OLIGONUCLEOTIDES;

POLYAMIDOAMINE DENDRIMERS; INTESTINAL-MUCOSA; DIGESTIVE

FLUIDS; PAMAM DENDRIMERS; SHEAR-FLOW

REFERENCE(5):				
Referenced Author	•	•	•	Referenced Work
(RAU)			(RPG)	•
========	•	+====	-	·
AKIYAMA Y	1999	1	477	BIOADHESIVE DRUG DEL
ALJAMAL K	2001			UNPUB SOLUBILIZATION
ALPAR H O	1989	41	194	J PHARM PHARMACOL
BERG R D	1999	473	11	ADV EXP MED BIOL
BESTETTI A	2000	41	1597	J NUCL MED
BLISS J M	1996	21	221	MOL MICROBIOL
CHRISTERSSON C E	1992	100	98	SCAND J DENT RES
CONACHER M	2001	19	2965	VACCINE
DAWSON G F	2000	17	1420	PHARMACEUT RES
DEJAEGHERE F	2000	18	143	J DRUG TARGET
DELIE F	2001	19	25	INT J PHARM
DEMANECHE S	2001	67	293	APPL ENVIRON MICROB
DENISMIZE K S	2000	17	2105	GENE THER
DEROSSI D	1998	18	84	TRENDS CELL BIOL
DESAI M P	1996	13	1838	PHARMACEUT RES
DICKERSON J B	2001	120	1500	BIOTECHNOL BIOENG
DURRER C	1999	19	437	STP PHARMA SCI
DURRER C	1994	11	1680	PHARMACEUT RES
DURRER C	1994	11	1674	PHARMACEUT RES
EASSON J H	1999	1	1409	BIOADHESIVE DRUG DEL
ELDRIDGE J H	1989	251	1191	ADV EXP MED BIOL
FLORENCE A T	1997	14	1259	PHARMACEUT RES

FLORENCE A T	2000	165	1253	J CONTROL RELEASE
	1995			J DRUG TARGET
	1981			INFECT IMMUN
	1995	122	585	1.T ODAT DEWARTT
GULLBERG E	2000	1279	1808	J ORAL REHABIL BIOCHEM BIOPH RES CO
	1995	12/3	157	J DRUG TARGET
HOICZYK E	2000			ARCH MICROBIOL
	1999		•	GENE THER
	2001	150	1107	INDU DDIC DELTUED DEV
HICCATN N	1998	115	1152	ADV DRUG DELIVER REV PHARMACEUT RES
	1996	112	11716	PHARMACEUT RES
	1987	150	1710 769	ICELI
	2001	1/18	1163	ACTA BIOCHIM POL
	1990	140	1821	I.I DHADM DHADMACOL
TANT D	1989	111	1800	J PHARM PHARMACOL J PHARM PHARMACOL
KVMBV W	2000	1308	161	INT J PHARM
NAMERO D				VIROLOGY
	1999			SEMIN IMMUNOL
KERNEIS S				SCIENCE
				MOL THER
	2001			BIOCONJUGATE CHEM
		126	1705	P CONTROL REL SOC
			1369	
LAMPRECHT A	12001	172	1225	LI CONTROL DELEASE
LANDRY F B	11001	16	1293	J CONTROL RELEASE J DRUG TARGET
LANDRY F B	11996	0 1 <i>7</i>	1715	BIOMATERIALS
				COLLOID POLYM SCI
				INFECT IMMUN
		1 Q	1547	I DHARMACEUT DES
	2000	151	1468	EUROPHYS LETT
	2000	118	1893	NAT BIOTECHNOL
	1998			J CONTROL RELEASE
	1999			ANTI-CANCER DRUG
		11535	1164	IBBA-MOL BASTS DIS
MATHIOWITZ E	11997	1386	1410	BBA-MOL BASIS DIS NATURE
	1983		1263	J RETICULOENDOTH SOC
				EUR J PHARM SCI
MELDAL M	11997	11	1552	CURR OPIN CHEM BIOL
MITCHELL J P	11999	19	12785	CURR OPIN CHEM BIOL BIOORG MED CHEM LETT DRUG DISCOV TODAY
PAGE D T	2001	16	192	DRUG DISCOV TODAY
PATIL V R S	2001	180	1733	BIOPHYS J
	2000			J AUTOIMMUN
	1986			BIOCHIM BIOPHYS ACTA
RENWICK L C	2001			TOXICOL APPL PHARM
	1999			NAT MED
•	1998			PHARMACEUT RES
SANDERS N N	2000	162	1905	AM J RESP CRIT CARE
SIEPMANN J	2001	148	229	ADV DRUG DELIVER REV
STOLL R G	1973	162	65	J PHARM SCI
STOLL B R	12000	164	217	J CONTROL RELEASE
TENG C L C	11987	16	133	J CONTROL RELEASE
TIROSH B	1998	87	453	J PHARM SCI
TOBIO M	2000	18	315	COLLOID SURFACE B
UCHIDA T	1994	17	1272	BIOL PHARM BULL
VANDEWEERT W M	2000	17	1159	PHARMACEUT RES
VANDERLUBBEN I M	2001	22	687	BIOMATERIALS
	1993	•	•	SCAND J DENT RES
WANG J	2000	17	237	DRUG DELIV
WATTENBARGER M R	11990	57	765	BIOPHYS J
WINNIPS C	2001	1	62	DRUG DISCOV WORLD
YOO H	1999	16	1799	PHARMACEUT RES
YOO H	12000	128	4225	NUCLEIC ACIDS RES

| J CONTROL RELEASE ZAUNER W |2001 |71 139

ZIMMERMAN S C |1996 |271 |1095 |SCIENCE

L16 ANSWER 28 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN DUPLICATE 5

ACCESSION NUMBER: 2000405498 EMBASE

TITLE:

Enhanced delivery of antisense

oligonucleotides with fluorophore-conjugated

PAMAM dendrimers.

AUTHOR:

Yoo H.; Juliano R.L.

CORPORATE SOURCE: R.L. Juliano, Department of Pharmacology, School of

Medicine, University of North Carolina, Chapel Hill, NC

27599-7365, United States. arjay@med.unc.edu

SOURCE:

Nucleic Acids Research, (1 Nov 2000) Vol. 28, No. 21, pp.

4225-4231.

Refs: 33

ISSN: 0305-1048 CODEN: NARHAD

COUNTRY:

United Kingdom Journal; Article

DOCUMENT TYPE: FILE SEGMENT:

022 Human Genetics

029

Clinical Biochemistry

LANGUAGE: SUMMARY LANGUAGE:

English English

ENTRY DATE:

Entered STN: 20001213

Last Updated on STN: 20001213

ABSTRACT: PAMAM dendrimers are cationic polymers that have been used for the delivery of genes and oligonucleotides to cells. However, little is known about the behavior of dendrimer-nucleic acid complexes once they reach the cell interior. To pursue this issue, we prepared dendrimers conjugated with the fluorescent dye Oregon green 488. These were used in conjunction with oligonucleotides labeled with a red (TAMRA) fluorophore in order to visualize the subcellular distribution of the dendrimer-oligonucleotide complex and of its components by two-color digital fluorescence microscopy. The 2'-O-methyl antisense ***oligonucleotide*** sequence used in these studies was designed to correct splicing at an aberrant intron inserted into a luciferase reporter gene; thus effective delivery of the antisense agent results in the expression of the reporter gene product. The dendrimer-oligonucleotide complex remained associated during the process of uptake into vesicular compartments and eventual entry into the nucleus. Since the pharmacological activity of the compound was manifest under these conditions, it suggests that the dendrimer-oligonucleotide complex is functionally active. A surprising result of these studies was that the Oregon green 488-conjugated dendrimer was a much better delivery agent for antisense compounds

CONTROLLED TERM:

Medical Descriptors:

gene targeting conjugation

chemical labeling cellular distribution fluorescence microscopy

than unmodified dendrimer. This suggests that coupling of relatively hydrophobic small molecules to **PAMAM** dendrimers may provide a useful

means of enhancing their capabilities as delivery agents for nucleic acids.

color

nucleotide sequence

intron

RNA splicing gene insertion reporter gene gene expression cell nucleus

human

controlled study

human cell article

priority journal
Drug Descriptors:

*antisense oligonucleotide

*dendrimer

*polyamine derivative

fluorescent dye

luciferase: EC, endogenous compound gene product: EC, endogenous compound nucleic acid: EC, endogenous compound (luciferase) 61970-00-1, 9014-00-0

CAS REGISTRY NO.: (luc.

L16 ANSWER 29 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 2000:188851 SCISEARCH

THE GENUINE ARTICLE: 275LZ

TITLE: Molecular modeling of polyamidoamine (PAMAM)

Starburst (TM) dendrimers

AUTHOR: Bhalgat M K; Roberts J C (Reprint)

CORPORATE SOURCE: Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA

(Reprint)

COUNTRY OF AUTHOR: USA

SOURCE: EU

EUROPEAN POLYMER JOURNAL, (MAR 2000) Vol. 36, No. 3, pp.

647-651.

ISSN: 0014-3057.

PUBLISHER: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD

LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English 23

REFERENCE COUNT: ENTRY DATE:

Entered STN: 2000

Last Updated on STN: 2000

ABSTRACT:

Highly organized polymeric structures known as Starburst(TM) dendrimers have been subjected to qualitative structural evaluation using molecular modeling tools. These molecules are becoming increasingly important in several different fields ranging from drug delivery to applications in selective adsorption and catalysis, and even as chromatographic materials and adsorbents. Our studies suggest that low generation dendrimers are somewhat asymmetric and that the modification of the dendrimers with molecules such as porphyrins, may lead to the reduced accessibility of other surface groups thus limiting further modification. (C) 2000 Elsevier Science Ltd. All rights reserved.

CATEGORY: POLYMER SCIENCE

SUPPL. TERM PLUS: CHEMICAL MODIFICATION STRATEGY; NEUTRON-CAPTURE THERAPY;

EFFICIENT TRANSFER; DELIVERY; OLIGONUCLEOTIDES;

AGGREGATION; EXPRESSION; COMPLEXES; CHEMISTRY; TUMORS

Referenced Author (RAU)	(RPY) (RVL)	(RPG)	
ALAHARI S K	1998 286	419	J PHARMACOL EXP THER
BARTH R F	1994 5	58	BIOCONJUGATE CHEM
BELCHEVA N	1998 9	1207	J BIOMAT SCI-POLYM E
BHALGAT M K	1997 4	1	DRUG DELIV
BHALGAT M K	1997 4 .	13	DRUG DELIV
BIELINSKA A	1996 24	2176	NUCLEIC ACIDS RES
DELONG R	1997 86	762	J PHARM SCI
KUKOWSKALATALLO J F	1996 93	4897	P NATL ACAD SCI USA
LESCANEC R L	1990 23	12280	MACROMOLECULES

MANSFIELD M L	1993 26	4262	MACROMOLECULES
NAYLOR A M	1989 111	2339	J AM CHEM SOC
PAGE D	1997 8	714	BIOCONJUGATE CHEM
QIN L H	1998 9	553	HUM GENE THER
ROBERTS J C	1996 30	53	J BIOMED MATER RES
ROBERTS J C	1990 1 /	305	BIOCONJUGATE CHEM
SINGH P	1998 9	154	BIOCONJUGATE CHEM
TANG M X .	1997 4	1823	GENE THER
TANG M X	1996 7	703	BIOCONJUGATE CHEM
THOMPSON J P	1997 14	1837	GLYCOCONJUGATE J
TOMALIA D A	1993 26	91	ALDRICHIM ACTA
TOMALIA D A	1990 29	138	ANGEW CHEM INT EDIT
WIENER E C	1997 32	1748	INVEST RADIOL
YANG W L	1997 57	4333	CANCER RES
			4 · · · · · · · · · · · · · · · · · · ·

L16 ANSWER 30 OF 41 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 6

ACCESSION NUMBER:

2000:302912 BIOSIS

DOCUMENT NUMBER:

PREV200000302912

TITLE:

Inhibition of transforming growth factor betal and beta2

expression in human and rat lung fibroblasts using

antisense oligonucleotides complexed with

starburst PAMAM dendrimers.

AUTHOR(S):

Gharaee-Kermani, M. [Reprint author]; Phan, S.; Baker, J.,

Jr.

CORPORATE SOURCE:

Department of Internal Medicine, University of Michigan

Medical School, Ann Arbor, MI, 48109, USA

SOURCE:

FASEB Journal, (March 15, 2000) Vol. 14, No. 4, pp. A555.

print.

Meeting Info.: Annual Meeting of Professional Research

Scientists: Experimental Biology 2000. San Diego,

California, USA. April 15-18, 2000. Federation of American

Societies for Experimental Biology.

CODEN: FAJOEC. ISSN: 0892-6638.

DOCUMENT TYPE:

Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE:

English

ENTRY DATE:

Entered STN: 12 Jul 2000

Last Updated on STN: 7 Jan 2002

CONCEPT CODE:

Respiratory system - General and methods 16001

Cytology - Animal 02506 Cytology - Human 02508

Biochemistry studies - General 10060

Biophysics - General 10502

General biology - Symposia, transactions and proceedings

00520

INDEX TERMS:

Major Concepts

Respiratory System (Respiration)

INDEX TERMS:

Parts, Structures, & Systems of Organisms fibroblasts; lung: respiratory system

INDEX TERMS:

Chemicals & Biochemicals

antisense oligonucleotides;

collagen; mRNA [messenger RNA]: expression; starburst

PAMAM dendrimers; transforming growth

factor-beta-1: expression; transforming growth

factor-beta-2: expression

INDEX TERMS:

Miscellaneous Descriptors

Meeting Abstract

ORGANISM:

Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

human Taxa Notes

Animals, Chordates, Humans, Mammals, Primates,

Vertebrates

ORGANISM:

Classifier

Muridae 86375

Super Taxa

Rodentia; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

rat

Taxa Notes

Animals, Chordates, Mammals, Nonhuman Vertebrates,

Nonhuman Mammals, Rodents, Vertebrates

L16 ANSWER 31 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

ACCESSION NUMBER:

2000254618 EMBASE

TITLE:

The use of PAMAM dendrimers in the efficient

transfer of genetic material into cells.

AUTHOR:

Eichman J.D.; Bielinska A.U.; Kukowska-Latallo J.F.; Baker

J.R. Jr.

CORPORATE SOURCE:

J.R. Baker, University of Michigan, Center for Biologic

Nanotechnology, Department of Internal Medicine, Ann Arbor,

MI 48109, United States. jbakerjr@umich.edu

SOURCE:

Pharmaceutical Science and Technology Today, (1 Jul 2000)

Vol. 3, No. 7, pp. 232-245.

Refs: 86

ISSN: 1461-5347 CODEN: PSTTF8

PUBLISHER IDENT.:

S 1461-5347(00)00273-X

COUNTRY:

United Kingdom

DOCUMENT TYPE:

Journal; General Review

FILE SEGMENT:

O15 Chest Diseases, Thoracic Surgery and Tuberculosis

022 Human Genetics

029 Clinical Biochemistry

030 Pharmacology

037 Drug Literature Index

LANGUAGE:

English English

SUMMARY LANGUAGE: ENTRY DATE:

Entered STN: 20000803

Last Updated on STN: 20000803

ABSTRACT: Polyamidoamine (PAMAM) dendrimers have steadily grown in popularity in the past decade in a variety of disciplines, ranging from materials science to biomedicine. This can be attributed in part to their use in applications that range from computer toners to medical diagnostics.

PAMAM dendrimers are safe and nonimmunogenic, and can function as highly efficient cationic polymer vectors for delivering genetic material into cells. They have been shown to be as efficient or more efficient than either cationic liposomes or other cationic polymers (e.g. polyethylenimine, polylysine) for in vitro gene transfer. This article will focus on the application of PAMAM dendrimers as a nonviral gene delivery vector from the initial discovery of this capacity to the most recent experimental findings. Copyright (C) 2000 Elsevier Science Ltd.

CONTROLLED TERM:

Medical Descriptors:

*gene transfer

*gene targeting

*lung fibrosis: DT, drug therapy

nonhuman mouse

animal experiment animal model

review

Drug Descriptors:

*dendrimer
*plasmid DNA

*antisense oligonucleotide: DT, drug therapy

liposome polymer

L16 ANSWER 32 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN DUPLICATE 7

ACCESSION NUMBER: 2000126495 EMBASE

TITLE: A lipid carrier with a membrane active component and a

small complex size are required for efficient cellular

delivery of anti-sense phosphorothioate

oligonucleotides.

AUTHOR: Jaaskelainen I.; Peltola S.; Honkakoski P.; Monkkonen J.;

Urtti A.

CORPORATE SOURCE: I. Jaaskelainen, Department of Pharmaceutics, University of

Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland.

ijaaskel@messi.uku.fi

SOURCE: European Journal of Pharmaceutical Sciences, (2000) Vol.

10, No. 3, pp. 187-193.

Refs: 25

ISSN: 0928-0987 CODEN: EPSCED

PUBLISHER IDENT.: S 0928-0987(00)00068-3

CONTROL IDENI: 5 0920-0907(00)000

COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 022 Human Genetics

030

027 Biophysics, Bioengineering and Medical

Instrumentation Pharmacology

037 Drug Literature Index

039 Pharmacy

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20000421

Last Updated on STN: 20000421

ABSTRACT: Anti-sense oligonucleotides are potential therapeutic agents that are used to block protein expression from mRNA. To assess the essential properties for an efficient cellular delivery system of phosphorothioate oligonucleotides (PS-ODNs), different cationic carriers were compared. The carriers were complexed with at various +/- charge ratios in MES-Hepes buffer. ***oligonucleotides*** Cationic polymers, polylysines (PLL, mean MWs 4000, 20 000, 200 000 kDa), polyethyleneimines (PEI, mean MWs 25 and 800 kDa) and fractured sixth-generation polyamidoamine dendrimer (PAMAM) were tested for ODN delivery into a D 407 cell line (human retinal pigment epithelial cells) with stably transfected luciferase gene. Anti-sense ODN was directed against the luciferase gene, and the anti-sense effect was determined using a luminometric method. Lipid-based vehicles included DOTAP, DOTAP/DOPE (1/1 by mol), DOTAP/Chol (1/1 by mol), DOTAP/DOPE/Chol (2/1/1 by mol), DOGS and Cytofectin GS/DOPE (2/1 by mol). Additionally a membrane-active peptide JTS-1 (NH2 -GLFEALLELLESLWELLLEA-COOH) was added to the complexes containing DOTAP, PEI or PLL. In D 407 and CV-1 cells, the anti-sense effect was seen only with lipid-based carriers with a membrane-active component (DOPE or JTS-1). The polymeric systems were ineffective. The effect of the complexation medium was further studied on CV-1 cells. Complexes were prepared in either water, MES-Hepes buffer or cell growth medium (DMEM). Complexes prepared in water were generally most effective and the greater activity is probably due to the smaller complex size. Complex sizes differed greatly in buffer and DMEM, especially in the case of DOPE containing complexes. In conclusion, lipid carrier with a membrane active component and small complex size are required

for an efficient cellular delivery of phosphorothioate oligonucleotides . Copyright (C) 2000 Elsevier Science B.V.

CONTROLLED TERM: Medical Descriptors: particle size complex formation drug delivery system protein expression electricity molecular weight pigment epithelium cell line genetic transfection photometry technique human nonhuman controlled study human cell animal cell article priority journal Drug Descriptors: *oligodeoxynucleotide phosphorothioate: PD, pharmacology *oligodeoxynucleotide phosphorothioate: PR, pharmaceutics *antisense oligonucleotide: PD, pharmacology *antisense oligonucleotide: PR, pharmaceutics drug carrier: PR, pharmaceutics lipid: PR, pharmaceutics messenger RNA: EC, endogenous compound cation: PR, pharmaceutics 4 (2 hydroxyethyl) 1 piperazineethanesulfonic acid polylysine: PR, pharmaceutics polymer: PR, pharmaceutics polyethyleneimine: PR, pharmaceutics dendrimer: PR, pharmaceutics polyamine: PR, pharmaceutics luciferase cholesterol: PR, pharmaceutics peptide water polyamidoamine: PR, pharmaceutics dotap: PR, pharmaceutics n [1 (2,3 dioleoyloxy)propyl] n,n,n trimethylammonium methylsulfate: PR, pharmaceutics 1,2 dioleoyl 3 phosphatidylethanolamine: PR, pharmaceutics dope: PR, pharmaceutics unclassified drug CAS REGISTRY NO.: (lipid) 66455-18-3; (4 (2 hydroxyethyl) 1 piperazineethanesulfonic acid) 7365-45-9; (polylysine) 25104-18-1, 25988-63-0, 33960-24-6, 38000-06-5, 73565-56-7; (polyethyleneimine) 74913-72-7; (luciferase) 61970-00-1, 9014-00-0; (cholesterol) 57-88-5; (water) 7732-18-5 Aldrich; Avanti (United States); Fluka; Sigma (United COMPANY NAME: States) L16 ANSWER 33 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER: 1999:272418 SCISEARCH

THE GENUINE ARTICLE: 184XD

An EPR study of the interactions between starburst TITLE:

dendrimers and polynucleotides

AUTHOR: Ottaviani M F (Reprint); Sacchi B; Turro N J; Chen W;

Jockusch S; Tomalia D A

CORPORATE SOURCE: Univ Florence, Dept Chem, Via G Capponi 9, I-50121

Florence, Italy (Reprint); Univ Florence, Dept Chem, I-50121 Florence, Italy; Columbia Univ, Dept Chem, New York, NY 10027 USA; Michigan Mol Inst, Midland, MI 48640

USA

COUNTRY OF AUTHOR:

Italy; USA

SOURCE:

MACROMOLECULES, (6 APR 1999) Vol. 32, No. 7, pp. 2275-2282

ISSN: 0024-9297.

PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036

USA.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English ·

REFERENCE COUNT:

40

ENTRY DATE:

Entered STN: 1999

Last Updated on STN: 1999

ABSTRACT:

Interactions of nitroxide-labeled polyamidoamine dendrimers of generations 2 and 6 (2SBD-T and 6SBD-T, respectively) with double-stranded polynucleotides-Calf Thymus DNA (C.T.DNA), poly(deoxyadenylic-deoxythymidylic acid) (termed Poly(AT)), poly(deoxyguanylic-deoxycytidylic acid) (termed Poly(GC)), and a double-stranded oligonucleotide of 12 base pairs (DNA-12mer)-were investigated by EPR. Computer-aided analysis of the EPR spectra provided information on the mobility of the nitroxide labels and their partition in different environments, which, in turn, gave information on the interactions between dendrimers and polynucleotides. After complexes were formed between DNA and SBD, the labels retained fast mobility at room On the basis of EPR analysis at 258 K, interaction of oligo- or temperature. polynucleotides with SBDs decreased in the following order: DNA-lamer > C.T.DNA > Poly(GC) > Poly(AT). Small dendrimers (2SBD-T) at low pH (5.5) showed significant interaction with the polynucleotides, which decreased with an increase in concentration due to self-aggregation of dendrimer molecules. Conversely, interaction between large dendrimers (6SBD-T) and polynucleotides increased with an increase in SBD concentration until saturation of the interacting sites occurred. Comparison with previous studies on nSBD-T-vesicle systems indicated that interaction of dendrimers with vesicles is stronger than dendrimer-polynucleotide interaction. This study provides some insights into dendrimer-DNA interactions of particular interest in understanding the mechanism of gene transfer to mammalian cells by SBDs.

CATEGORY: POLYMER SCIENCE

SUPPL. TERM PLUS: SPIN-ECHO MODULATION; POLYAMIDOAMINE DENDRIMERS;

PAMAM DENDRIMERS; ACID; CHEMISTRY; MICELLES;

POLYMERS; PROBE; DNA; ARCHITECTURE

Referenced Author (RAU)		(RVL)	(RPG)	
ALPER J AMATO I BAGLIONI P BEHR J P BERLINER L J BERLINER L J BERLINER L J BIELINSKA A BRIBER R M CHAIRES J B CHEN W	1991 1990 1987 1983 1989 1976 1979 1996 1992 1982	251 138 91 26 8 1 2 24 67 21	1562 298 1516 274 2176 430 3933	SCIENCE SCI NEWS J PHYS CHEM-US ACCOUNTS CHEM RES BIOL MAGNETIC RESONA SPIN LABELING THEORY SPIN LABELING THEORY NUCLEIC ACIDS RES POLYM MAT SCI ENG BIOCHEMISTRY-US
DVORNIC P R	1994	88	123	MACROMOL SYMP

```
FRECHET J M J
                     |1994 |263
                                 |1710 |SCIENCE
HAENSLER J
                     |1993 |4
                                 1372
                                       |BIOCONJUGATE CHEM
                    |1983 |105
                                 |5230 |J AM CHEM SOC
HASHIMOTO S
                                 |1287 |J CHEM SOC P1
HAWKER C J
                    |1993 |
                    |1995 |2
                                       |CHEM BIOL
HAYES J J
                                 |127
                                 |1572 |J PHYS CHEM-US
                     |1989 |93
HIFF T
                     |1962 |5
                                 |172 |J MOL BIOL
INMAN R B
                                 |2413 | ANGEW CHEM INT EDIT
ISSBERNER J
                   | 1994 | 133
                     |1990 |112 |4592 |J AM CHEM SOC
KIM Y H
KROHN K
                     |1991 |
                                 1378
                                       IORG SYNTH HIGHLIGHTS
                     |1996 | 193
                                 14897 | P NATL ACAD SCI USA
KUKOWSKALATALLO J F
                     |1992 |31
                                 |1571 | ANGEW CHEM INT EDIT
MAKELBURGER H B
                     |1981 |74
                                 |4200 |J CHEM PHYS
MILLAR D P
                     |1989 |111 |2341 |J AM CHEM SOC
NAYLOR A M
                     |1993 |
                                       ADV DENDRITIC MACROM
NEWKOME G R
                                 |1176 | ANGEW CHEM INT EDIT
                     |1991 |30
NEWKOME G R
                     |1997 |13
OTTAVIANI M F
                                 |347
                                       |APPL MAGN RESON
                     |1998 |102 |6029 |J PHYS CHEM B
OTTAVIANI M F
                     |1997 |101
OTTAVIANI M F
                                |158
                                       J PHYS CHEM B
                     |1996 |100 |11033 |J PHYS CHEM-US
OTTAVIANI M F
                     |1989 |72
PAULY G T
                                 |110
                                      | HELV CHIM ACTA
                    |1998 |31
                                 |1621 |MACROMOLECULES
RAMZI A
                    |1989 |8
                                 |1 |BIOL MAGN RESON
SCHNEIDER D J
                    |1996 |7
                                 |703 |BIOCONJUGATE CHEM
TANG M X
TOMALIA D A
                    |1990 |29
                                 |138 | ANGEW CHEM INT EDIT
TOMALIA D A
                    |1993 |165 |193 |TOP CURR CHEM
                    |1987 |109 |1601 |J AM CHEM SOC
TOMALIA D A
                     |1998 |31
                                 |4498 |MACROMOLECULES
UPPULURI S
```

L16 ANSWER 34 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN DUPLICATE 8

ACCESSION NUMBER: 2000027815 EMBASE

TITLE: **PAMAM** dendrimers as delivery agents for

antisense oligonucleotides.

AUTHOR: Yoo H.; Sazani P.; Juliano R.L.

CORPORATE SOURCE: R.L. Juliano, Department of Pharmacology, University of

North Carolina, Chapel Hill, NC 27599, United States.

arjay@med.unc.edu

SOURCE: Pharmaceutical Research, (1999) Vol. 16, No. 12, pp.

1799-1804. Refs: 40

ISSN: 0724-8741 CODEN: PHREEB

COUNTRY: United States
DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 027 Biophysics, Bioengineering and Medical

Instrumentation

037 Drug Literature Index

039 Pharmacy

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20000202

Last Updated on STN: 20000202

ABSTRACT: Purpose. To investigate the potential use of PAMAM

dendrimers for the delivery of antisense oligonucleotides
into cells under conditions that mimic the in vivo environment

into cells under conditions that mimic the in vivo environment. Methods. We used HeLa cells stably transfected with plasmid pLuc/705 which has a luciferase gene interrupted by a human β -globin intron mutated at nucleotide 705,

thus causing incorrect splicing. An antisense

oligonucleotide overlapping the 705 splice site, when delivered effectively, corrects splicing and allows luciferase expression. The ability of dendrimers to deliver oligonucleotides to HeLa Luc/705 cells was evaluated in the absence or presence of serum. Results. PAMAM

dendrimers formed stable complexes with oligonucleotides that had modest cytotoxicity and showed substantial delivery activity. The dose of the ***oligonucleotide*** , the charge ratio of oligonucleotide to dendrimer, and the size (generation) of the dendrimers were all critical variables for the antisense effect. The physical properties of dendrimer/oligonucleotide complexes were further investigated using sedimentation and gel electrophoresis methods. Effective ***oligonucleotide*** /generation 5 dendrimer complexes were macromolecular rather than particulate in nature, and were not sedimented at 100,000 RPM. Compared to other types of delivery agents, PAMAM dendrimers were more effective in delivering oligonucleotides into the nucleus of cells in the presence of serum proteins. Conclusions. Our results suggest that PAMAM dendrimers form nonparticulate delivery complexes that function in the presence of serum proteins and thus may be suited for in vivo therapeutic applications.

CONTROLLED TERM: Medical Descriptors:

*drug delivery system

HeLa cell
RNA splicing
drug cytotoxicity
dose response
physical chemistry

human

controlled study

human cell article

priority journal
Drug Descriptors:

*antisense oligonucleotide: PR, pharmaceutics
*antisense oligonucleotide: PK, pharmacokinetics

*dendrimer: PR, pharmaceutics
*dendrimer: PK, pharmacokinetics

*polyamidoamine dendrimer: PR, pharmaceutics *polyamidoamine dendrimer: PK, pharmacokinetics

L16 ANSWER 35 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN DUPLICATE 9

ACCESSION NUMBER:

1999270910 EMBASE

TITLE:

Uptake and intracellular distribution of oligonucleotides vectorized by a PAMAM

dendrimer.

AUTHOR:

Helin V.; Gottikh M.; Mishal Z.; Subra F.; Malvy C.;

Lavignon M.

CORPORATE SOURCE:

V. Helin, UMR 1772, Institut Gustave Roussy, 39 Rue Camille

Desmoulins, 94800 Villejuif, France

SOURCE:

Nucleosides and Nucleotides, (1999) Vol. 18, No. 6-7, pp.

1721-1722.

Refs: 4

ISSN: 0732-8311 CODEN: NUNUD5

COUNTRY:

United States

DOCUMENT TYPE: Journal; Conference

Journal; Conference Article

FILE SEGMENT:

016 Cancer

029 Clinical Biochemistry 037 Drug Literature Index

LANGUAGE:

English English

SUMMARY LANGUAGE: ENTRY DATE:

Entered STN: 19990819

Last Updated on STN: 19990819

ABSTRACT: We studied the uptake and intracellular distribution of an FITC labelled phosphodiester oligodeoxynucleotide (ODN) vectorized by a dendrimeric structure in cell culture.

CONTROLLED TERM: Medical Descriptors:

*protein structure *protein transport

cell culture

cellular distribution confocal microscopy

flow cytometry cancer cell fibroblast lymphocyte human nonhuman human cell animal cell conference paper Drug Descriptors:

*oligonucleotide

*fluorescein isothiocyanate

*phosphodiester oligodeoxynucleotide

complementary RNA

dendrimer

CAS REGISTRY NO.: (fluorescein isothiocyanate) 25168-13-2, 27072-45-3,

3326-32-7

L16 ANSWER 36 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN DUPLICATE 10

ACCESSION NUMBER: 1998242007 EMBASE

TITLE: Interaction of oligodeoxynucleotides with mycobacteria:

Implications for new therapeutic strategies.

AUTHOR: Attia S.A.; Shepherd V.E.; Rosenblatt M.N.; Davidson M.K.;

Hughes J.A.

CORPORATE SOURCE: J.A. Hughes, University of Florida, College of Pharmacy,

1600 SW Archer RD, Gainesville, FL 32610, United States

SOURCE: Antisense and Nucleic Acid Drug Development, (1998) Vol. 8,

No. 3, pp. 207-214.

Refs: 27

ISSN: 1087-2906 CODEN: ANADF5

COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology

037 Drug Literature Index

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 19980806

Last Updated on STN: 19980806

ABSTRACT: The use of synthetic oligonucleotides (ONs) to systematically address new pharmacologic targets in mycobacteria would enhance the introduction of new molecular targets for drug intervention.
Oligonucleotides ' mechanism of action allows researchers to pursue the importance of particular proteins without the requirement of having purified samples. For this approach to be effective, mycobacteria must be able to transport ONs to their cytoplasm, and if this is not the case, the agents must be otherwise delivered. In this report, we characterize the ability of phosphorothioate (PS) and phosphorodiester (PD) ONs to interact with both Mycobacterium smegmatis and Mycobacterium tuberculosis. In addition, the use of delivery enhancer compounds, ethambutol and PAMAM dendrimer, was evaluated on the ON-mycobacteria interaction. ON interaction was demonstrated to be concentration-dependent, suggesting a possibly active component of the ***oligonucleotide*** and bacteria interaction. ON interaction could be increased by the coincubation of the bacteria with the delivery adjuvants. Treatment with ethambutol or dendrimers (fourth generation) was demonstrated to increase ON interaction with both species of mycobacteria although not to the same extent. The results of these preliminary experiments indicate that through use of the proper delivery adjuvant, ON interactions with mycobacteria can be increased. These findings may have implications for probing future antimycobacterial therapeutic targets.

CONTROLLED TERM: Medical Descriptors:

*mycobacterium

nucleic acid transport

cytoplasm

drug delivery system

nonhuman

controlled .study

article

priority journal Drug Descriptors: *oligodeoxynucleotide phosphorothioic acid

ester ethambutol dendrimer

antimycobacterial agent

(phosphorothioic acid) 10101-88-9, 13598-51-1, 15181-41-6; CAS REGISTRY NO.:

(ethambutol) 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5

L16 ANSWER 37 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

97176859 EMBASE ACCESSION NUMBER:

DOCUMENT NUMBER: 1997176859

Characterization of complexes of oligonucleotides TITLE:

with polyamidoamine starburst dendrimers and effects on

intracellular delivery.

AUTHOR: DeLong R.; Stephenson K.; Loftus T.; Fisher M.; Alahari S.;

Nolting A.; Juliano R.L.

CORPORATE SOURCE: R. DeLong, Department of Pharmacology, School of Medicine,

University of North Carolina, Chapel Hill, NC 27599, United

DUPLICATE 11

Journal of Pharmaceutical Sciences, (1997) Vol. 86, No. 6, SOURCE:

pp. 762-764. Refs: 10

ISSN: 0022-3549 CODEN: JPMSAE

COUNTRY:

United States DOCUMENT TYPE: Journal; Article FILE SEGMENT: 030 Pharmacology

> 037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 970702

Last Updated on STN: 970702

the further evaluation of dendrimers for oligonucleotide delivery in

ABSTRACT: This study evaluates polyamidoamine PAMAM 'starburst' dendrimers (generation 3, M(r) 6909) as a potential delivery vehicle for ***oligonucleotides.*** Complexes between dendrimer and phosphorothicate ***oligonucleotides*** were observed by agarose gel electrophoresis and were positive, negative, or neutral in charge depending on stoichiometry. Complexes were stable in 50% serum to variations in pH (3, 5, and 10) and ionic strength (0-500 mM). Ultrafiltration and gel filtration characterization indicated that the dendrimer: oligonucleotide complexes were primarily <100 kD, although some larger complexes were formed at oligonucleotide excess. Use of dendrimers resulted in a 50-fold enhancement in cell uptake of ***oligonucleotide*** as determined by flow cytometry, and enhanced cytosolic and nuclear availability, as shown by confocal microscopy. These data support

cell culture and in vivo.

CONTROLLED TERM:

Medical Descriptors:
*complex formation

agar gel electrophoresis

analytic method

article

cell migration dna binding

drug bioavailability drug delivery system genetic transfection

ionic strength

nonhuman

ultrafiltration
Drug Descriptors:

*amine: PR, pharmaceutics

*oligonucleotide: PR, pharmaceutics

L16 ANSWER 38 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

DUPLICATE 12

ACCESSION NUMBER:

96179911 EMBASE 1996179911

DOCUMENT NUMBER: TITLE:

Regulation of in vitro gene expression using

antisense oligonucleotides or

antisense expression plasmids transfected using

starburst PAMAM dendrimers.

AUTHOR:

Bielinska A.; Kukowska-Latallo J.F.; Johnson J.; Tomalia

D.A.; Baker Jr. J.R.

CORPORATE SOURCE:

Department of Internal Medicine, 1150 West Medical Center

Drive, Ann Arbor, MI 48109-0666, United States

SOURCE:

Nucleic Acids Research, (1996) Vol. 24, No. 11, pp.

2176-2182.

ISSN: 0305-1048 CODEN: NARHAD

COUNTRY:

United Kingdom

DOCUMENT TYPE:

Journal; Article

FILE SEGMENT: 02
LANGUAGE: Er

022 Human Genetics

SUMMARY LANGUAGE:

English English

ENTRY DATE:

Entered STN: 960708

Last Updated on STN: 960708

ABSTRACT: Starburst polyamidoamine (PAMAM) dendrimers are a new type of synthetic polymer characterized by a branched spherical shape and a high density surface charge. We have investigated the ability of these dendrimers to function as an effective delivery system for antisense and 'antisense expression plasmids' for the ***oligonucleotides*** targeted modulation of gene expression. Dendrimers bind to various forms of nucleic acids on the basis of electrostatic interactions, and the ability of DNA-dendrimer complexes to transfer oligonucleotides and plasmid DNA to mediate antisense inhibition was assessed in an in vitro cell culture system. Cell lines that permanently express luciferase gene were developed using dendrimer mediated transfection. Transfections of ***antisense*** oligonucleotides or antisense cDNA plasmids into these cell lines using dendrimers resulted in a specific and dose dependent inhibition of luciferase expression. This inhibition caused .apprx. 25-50% reduction of baseline luciferase activity. Binding of the phosphodiester oligonucleotides to dendrimers also extended their intracellular survival. While dendrimers were not cytotoxic at the concentrations effective for DNA transfer, some non-specific suppression of luciferase expression was observed. Our results indicate that Starburst

dendrimers can be effective carriers for the introduction of regulatory nucleic

acids and facilitate the suppression of the specific gene expression.

CONTROLLED TERM:

Medical Descriptors:

*gene expression regulation

*plasmid animal cell article

expression vector

mouse nonhuman

priority journal

rat

genetic transfection Drug Descriptors:

*antisense oligonucleotide

*dendrimer

complementary dna

L16 ANSWER 39 OF 41 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN

ACCESSION NUMBER:

1996:308348 BIOSIS PREV199699030704

DOCUMENT NUMBER: TITLE:

Modulation of gene expression by antisense oligonucleotides and expression plasmids

transfected with Starburst-TM PAMAM dendrimers.

AUTHOR(S):

Bielinska, Anna; Kukowska-Latallo, Jolanta F.; Johnson,

Jennifer; Tomalia, Donald A.; Baker, James R., Jr.

CORPORATE SOURCE:

SOURCE:

Univ. Mich., Ann Arbor, MI 48109, USA

FASEB Journal, (1996) Vol. 10, No. 6, pp. A1152.

Meeting Info.: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists. New Orleans, Louisiana, USA. June 2-6, 1996.

CODEN: FAJOEC. ISSN: 0892-6638.

DOCUMENT TYPE:

Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE:

English

ENTRY DATE:

Entered STN: 2 Jul 1996

CONCEPT CODE:

Last Updated on STN: 2 Jul 1996 General biology - Symposia, transactions and proceedings

00520

Genetics - General 03502

Biochemistry studies - Nucleic acids, purines and

pyrimidines 10062

Replication, transcription, translation 10300

Metabolism - Nucleic acids, purines and pyrimidines 13014

INDEX TERMS:

Major Concepts

Biochemistry and Molecular Biophysics; Genetics; Metabolism; Molecular Genetics (Biochemistry and

Molecular Biophysics)
Miscellaneous Descriptors

INDEX TERMS:

ANTISENSE OLIGONUCLEOTIDES;

BIOCHEMISTRY AND MOLECULAR BIOPHYSICS/MOLECULAR

GENETICS; DNA TRANSFER METHOD; EXPRESSION PLASMIDS; GENE

EXPRESSION MODULATION; GENETIC ENGINEERING; MEETING

ABSTRACT; METHODS AND TECHNIQUES;

OLIGONUCLEOTIDE DELIVERY SYSTEM; REGULATORY
NUCLEIC ACID INTRODUCTION; STARBURST PAMAM
DENDRIMERS; STARBURST POLYAMIDOAMINE DENDRIMERS;

SYNTHETIC POLYMER

L16 ANSWER 40 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

1996:384885 SCISEARCH ACCESSION NUMBER:

THE GENUINE ARTICLE: UK861

Modulation of gene expression by antisense

oligonulcleotides and expression plasmids transfected with

starburst(TM) PAMAM dendrimers

Bielinska A (Reprint); KukowskaLatallo J F; Johnson J; AUTHOR:

Tomalia D A; Baker J R

CORPORATE SOURCE: UNIV MICHIGAN, ANN ARBOR, MI 48109; MICHIGAN MOLEC INST,

MIDLAND, MI 48640

COUNTRY OF AUTHOR:

SOURCE: FASEB JOURNAL, (30 APR 1996) Vol. 10, No. 6, pp. 884-884.

ISSN: 0892-6638.

FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, PUBLISHER:

BETHESDA, MD 20814-3998.

DOCUMENT TYPE:

Conference; Journal

FILE SEGMENT:

LIFE English

LANGUAGE:

REFERENCE COUNT: ENTRY DATE:

Entered STN: 1996

Last Updated on STN: 1996

CATEGORY: BIOLOGY; BIOCHEMISTRY & MOLECULAR BIOLOGY

L16 ANSWER 41 OF 41 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

ACCESSION NUMBER: 97028056 EMBASE

DOCUMENT NUMBER:

1997028056

TITLE:

Dendrimer delivery of oligonucleotides.

AUTHOR: Poxon S.W.; Mitchell P.M.; Liang E.; Hughes J.A.

Dr. J.A. Hughes, Department of Pharmaceutics, University of CORPORATE SOURCE:

Florida, P.O. Box 100494, Gainesville, FL 32610, United

States. hughes@cop.health.ufl.edu

SOURCE:

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, (1996) Vol. 3, No. 4, pp. 255-261.

Refs: 31

027

ISSN: 1071-7544 CODEN: DDELEB

COUNTRY:

United States

DOCUMENT TYPE:

Journal; Article

FILE SEGMENT:

Biophysics, Bioengineering and Medical

Instrumentation

029 Clinical Biochemistry

030 Pharmacology

037 Drug Literature Index

039 Pharmacy

LANGUAGE:

English

SUMMARY LANGUAGE:

English

ENTRY DATE:

Entered STN: 970224

Last Updated on STN: 970224

ABSTRACT: Factors limiting the pharmacological effectiveness of oligonucleotides include serum stability and the ***antisense*** fact that these agents are inefficiently transported to their sites of action in the cytoplasm and nucleus. Polyamidoamine (PAMAM) dendrimers are nonlinear polycationic cascade polymers composed of interconnected ethylenediamine molecules that are able to bind oligonucleotides electrostatically. This new complex potentially reduces metabolic degradation of phosphodiester oligonucleotides in the serum and in the lysosome. Dendrimers also have the potential to increase oligonucleotide cellular uptake, thus augmenting their pharmacological effectiveness. We studied various dendrimer generations and their ability to interact with

phosphodiester oligonucleotides. Alterations in pH and in ionic

strength were studied for their effects on the dendrimer-

oligonucleotide complex. A fluorescent-labeled oligonucleotide was utilized to study these interactions through a fluorescence anisotropy method. Oligonucleotides complexed to dendrimers were shown to have increased metabolic stability compared with free oligonucleotides. Using tissue culture models, fluorescent-labeled oligonucleotides complexed to dendrimers were studied for their transport properties. Flow cytometry was used to monitor cell-associated fluorescence of ***oligonucleotides*** and dendrimer systems. The electrostatic oligodeoxynucleotide (ODN)-dendrimer interaction was found to be sensitive to pH and to ionic strength, with the maximal interaction occurring at low pH and ionic strength. Using fluorescent-labeled ODN, we demonstrated that the ODN-DEN complex accumulated to a greater extent than free ***oligonucleotides.*** In summary, dendrimers have the potential to increase the effectiveness of oligonucleotides by forming an electrostatic complex that is conducive to increasing metabolic stability and cellular accumulation. In this report we describe the interactions between phosphodiester ODNs and dendrimers with regard to their electrostatic interactions and their cellular uptake.

CONTROLLED TERM: Medical Descriptors:

*complex formation

animal cell anisotropy article

cell strain 3t3

cho cell

controlled study
drug degradation
drug delivery system
drug metabolism
drug stability
drug uptake
electricity
fluorescence
ionic strength

lysosome mouse nonhuman

ph

priority journal

serum

tissue culture Drug Descriptors:

*dendrimer: PR, pharmaceutics

*oligonucleotide: PR, pharmaceutics
*oligonucleotide: PK, pharmacokinetics

antisense oligonucleotide: PK, pharmacokinetics antisense oligonucleotide: PR, pharmaceutics

fluorescein isothiocyanate

fluorescent dye

oligodeoxynucleotide: PR, pharmaceutics oligodeoxynucleotide: PK, pharmacokinetics

phosphodiester oligonucleotide: PK,

pharmacokinetics

phosphodiester oligonucleotide: PR, pharmaceutics

poly(amido amine): PR, pharmaceutics

polycation: PR, pharmaceutics polymer: PR, pharmaceutics

unclassified drug

CAS REGISTRY NO.:

(fluorescein isothiocyanate) 25168-13-2, 27072-45-3,

3326-32-7

COMPANY NAME:

Aldrich (United States); Polyscience (United States)